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A DISSERTATION SUBMITTED TO THE UNIVERSITY OF BRISTOL IN
ACCORDANCE WITH THE REQUIREMENTS FOR AWARD OF THE DEGREE OF
DOCTOR OF PHILOSOPHY IN THE FACULTY OF HEALTH SCIENCES




When a trialist is designing a trial, related work will often be used to inform several as-
pects. This information is often used informally, such as using a systematic review to indi-
cate whether a gap in the current evidence base justifies a new trial. External evidence can
be used more formally, by explicitly incorporating it in a Bayesian framework through a
prior distribution.
Funders often highlight the importance of taking into account existing evidence when
planning a new trial. Researchers and trialists acknowledge that existing evidence should
be used to inform new research to reduce research waste. However, the prevalence of
explicitly using external evidence through informative prior distributions is low and there
is still much controversy around its use in all stages of a trial.
In this thesis, we explore whether and how trialists could use a synthesis of external evi-
dence in the design and analysis of a clinical trial, through a Bayesian analysis. We begin
with a survey and qualitative study to capture the current use of evidence synthesis by tri-
alists and reasons why it might not be used in practice. In the remainder of the thesis, we
assess and extend methods in areas where external evidence could have the most benefit
to a trialist. We focus on the following three case studies:
 External evidence on likely bias in a trial, based on information from meta-analyses
within meta-epidemiological studies.
 External evidence on the likely effect size in a trial, based on information from similar
trials within meta-analyses.
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1 Introduction
1.1 Rationale of thesis
"I believe that the more you know about the past, the better you are prepared
for the future."
Theodore Roosevelt
Randomised controlled trials (RCTs) are considered the gold standard method to compare
the relative efficacy of competing interventions and represent a significant investment of
clinical research resources [1, 2]. Funders often highlight the importance of taking into
account existing evidence when planning a new trial [3, 4, 5] in order to reduce research
waste [6]. It is important that RCTs are designed and conducted in a way that allows the
research question to be addressed in the most efficient and cost-effective manner, given
what is already known from previous research [7]. It is fully ingrained into researchers,
and in particular trialists, that existing evidence should be used in some way to inform
new research [1, 8].
Existing evidence can be used to inform all stages of a clinical trial: planning of a trial
before it begins, monitoring of a trial in progress, and analysis and reporting of the results
of a new trial alongside other relevant research [7]. However, the amount to which existing
evidence can be used to inform the design and analysis of trials can vary greatly [8, 9, 10].
There are ‘traditional’ uses of previous evidence, for example, in sample size calculations,
to inform parameters about which we need to make assumptions. Similarly, in the early
design stage, existing evidence can be collated and summarised in a systematic review,
and subsequently used to inform whether a gap in the current evidence base justifies a
new trial [11]. In 2007, Clarke et al [12] made a plea for reports of clinical trials to begin
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and end with an updated systematic review. However, it is still unclear precisely how
trialists are using external evidence in the design and analysis of trials. Furthermore, the
formal explicit use of external information, such as from other trials, is largely omitted
from methodological guidelines.
A formal way of incorporating previous evidence is by use of informative prior distri-
butions, in a Bayesian framework [13]. A Bayesian approach combines the new trial data
with existing data, as represented by the prior distribution [14]. One advantage of this
approach is it allows the analyst to make use of all relevant data and put their work in
the context of existing research, and there have been numerous calls to do this [6, 12]. In a
Bayesian framework, informative prior distributions can, in theory, be assigned to any pa-
rameter during the design or analysis stage of a trial when there is existing data available.
However, there is still much controversy about the use of informative priors.
In this thesis, we focus on exploring the use of informative priors in trials. I use Bayesian
methodology to synthesise external trial data and subsequently assess how these data can
be used to inform parameters during the design and analysis stage of a trial, such as the
effect size or bias. Therefore, the aim of this thesis is to extend, develop and assess the
feasibility of methods to use external evidence, based on an existing body of data (such
as a collection of studies), to inform the design and analysis of an individual trial. This
thesis does not look at elicitation methods to form priors from expert opinion. Instead, we
will include consideration of how best to form suitable priors based on existing evidence
and how a trialist could use these priors in a clinical trial setting. An underlying theme
throughout the thesis is whether trialists would be happy to implement these methods in
practice, and a survey and extensive qualitative study is undertaken to evaluate this issue.
In this chapter we provide background about what a clinical trial is and how the results
of a clinical trial can be used to inform medical practice and policy. Section 1.2 explains
the different phases of a trial and how the majority of trials are analysed in a frequentist
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framework. We then describe the idea of analysing a trial in a Bayesian framework, to
allow the incorporation of external evidence to be combined with trial data. Section 1.3
introduces different types of evidence syntheses, including definitions, and focusses on
the role evidence synthesis has to inform policy. In Section 1.4, we return to the possible
opportunities of using external evidence in trials, highlighting the areas on which this
thesis focusses. Finally, a chapter synopsis outlining the structure of the thesis is given.
1.2 Clinical trials
In medical research, there are often competing interventions and the aim is to try and un-
derstand which intervention is better. An intervention can be a new drug, surgical tech-
nique, device, or treatment plan. There is usually a hypothesised ’superior’ intervention
which we want to compare to the standard intervention (or placebo). We use the term
"intervention" to refer to any intervention, placebo or other control. The best way to deter-
mine which intervention is better is to do a clinical trial [2]. In a standard parallel group
trial these are allocated to groups, which we refer to as experimental and control groups.
1.2.1 Phases of a clinical trial
The earliest phase of a clinical trial of a pharmaceutical product begins by trying to iden-
tify pathways of how a molecule (which will potentially be the new drug) interacts, i.e.
biological processes within cells [15]. This is very much at the heart of the transition from
basic science to translational medicine. These pathways are explored by scientists in a
laboratory who are looking for interactions between molecules and cells, that could have
some clinical relevance. When there is an interaction, this translates to potential clinical
relevance for a particular group of patients and generates a scientific hypothesis. In order
to test that hypothesis, a trial is designed which requires patients to be assigned to differ-
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ent treatment or control arms, to separate the impact of a treatment or therapy. Notably,
only a tiny number of these hypotheses go forward to be evaluated in an early phase trial.
This phase is known as first-in-human (FIH) or phase I trials and usually occurs in a small
number of healthy individuals. In some cases, this phase occurs in patients with the target
disease, often oncology trials.
The main aim of phase I trials is to check tolerability and establish safe doses of a new
drug, in order to move to phase II. Phase II trials often involve eligible patients with the
disease of interest, where the main aim is to find the correct dose and to establish dose
frequencies, administration routes, and endpoints, before moving to a phase III trial. A
phase III trial will again include even more patients, who are assigned to different treat-
ment or control arms, to enable the comparison of treatments and determine efficacy. If
efficacy is confirmed, the trial will then progress to the final stage, known as phase IV. In
phase IV, the intervention is rolled out to a broader population and any adverse events
are monitored over a longer period of time. In this thesis, we will consider case studies of
potential uses of external evidence syntheses to inform FIH studies and phase III trials.
Pilot and feasibility studies are often used to inform aspects of a phase III trial design,
such as predicting recruitment rates [16]. They are also used to see if it is feasible for the
main trial to go ahead [17], for example, whether the intervention can be delivered and
implemented as planned [18]. The primary aim of feasibility studies is to establish if a new
trial can be done: they do not analyse the outcome of interest. Instead, they are used to
estimate parameters which are needed in the design of the main study. In contrast, pilot
studies are closely related to what the main study plans to be but are smaller in size. The
primary aim of pilot studies is to see how all the components of the main study work
together. Pilot studies therefore emulate the main trial, but on a much smaller scale [19].
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1.2.2 Approaches to clinical trials
One of the simplest designs of a phase III clinical trial, compares the group of participants
who receive the experimental intervention to the other group of participants, who receive
either the control intervention or a placebo. Each group of participants is then followed
over (ideally) the same period of time. Information on a relevant outcome(s) is collected
at either one or multiple times. An ideal study would be designed such that at the end
of the study we could attribute any difference in the outcomes between the two groups,
to the difference in interventions. For this to be the case (unbiased estimate of the inter-
vention effect) we require the two groups to be similar in terms of all other characteristics
(e.g. similar age groups, similar proportions of males and females etc). After receiving the
intervention, we want the patients to behave in exactly the same way (except for any ef-
fect of the interventions) until we measure the difference between them. This is achievable
through the following steps:
 Randomisation to ensure each group has participants with the same characteristics.
If one group is systematically different to the other this can cause confounding.
 Adequate concealment of which intervention is next in the randomisation sequence.
A failure to adequately conceal which treatment will be received by the participant
may introduce confounding or selection bias [20]. It is important to conceal alloca-
tion from the people recruiting patients into the trial. This is called allocation con-
cealment.
 The participant, the person(s) providing or delivering the intervention and the per-
son(s) assessing the outcome should be blinded to the intervention delivered where
possible. Sometimes an individual has more than one of these roles: for example, if
the outcome is a questionnaire filled out by the patient, they will be both the par-
ticipant and the person assessing the outcome. Failure to blind those delivering the
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intervention (i.e. healthcare providers) can result in performance bias and failure to
blind the outcome assessor can result in detection bias [21].
 It is important that each participant has their outcome measured. Failure to do so
could cause incomplete outcome data and therefore attrition bias.
 If only some outcomes were reported (relative to those presented in the protocol
and planned to be reported) and selection depends on the results, this is known as
reporting bias.
If any of these steps either cannot be implemented or implementation fails, then each can
cause the results of a trial to become biased.
1.2.3 Analysis of a clinical trial
In statistical analysis, and thus when analysing a trial, there are two different underly-
ing philosophies: frequentist or Bayesian. In general, either approach can be used for any
data [22]. For example, if one type of analysis is in a frequentist framework, there will
usually be an equivalent within the Bayesian framework [23]. Bayesian approaches will
often identify themselves as such by use of the word Bayesian, whereas a frequentist ap-
proach is not usually explicitly stated, as it is considered most traditional and more widely
accepted as the default framework.
Suppose in a clinical trial we have a simple null hypothesis, that there is no difference
between the two interventions and the alternative hypothesis is that there is a difference.
The theory behind frequentist and Bayesian approaches to examining this hypothesis is
fundamentally different and therefore determines how trial results are interpreted; mainly
because of the way probability is viewed for each. A frequentist framework quantifies if a
clinical trial was repeated over and over again, how often would these results have been
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observed if the null hypothesis was false. In contrast, a Bayesian approach asks a direct
probability question: given the results observed in these data, what is the probability the
null hypothesis is false [24]? The focus of a Bayesian analysis is on how the trial should
change our belief about the treatment effect [14]. This forces us to state a reasonable belief
concerning the plausibility of different values of the treatment effect before a trial has
started as a ’prior distribution’. This has historically been considered controversial [14, 25].
Combined with the data for the trial, a revised belief about the treatment effect is produced
(known as the posterior distribution).
Seemingly, the most discussed area in Bayesian analysis is the selection of an appropriate
prior distribution [25, 26]. Priors can either be uninformative (intended to represent an
absence of any prior knowledge about the value of the treatment effect) or informative.
Informative priors may be further divided into: (i) those based on previous evidence in
a specific clinical area; (ii) those based on expert opinion from knowledge of the clinical
area; and (iii) default ‘sceptical’ or ‘enthusiastic’ priors, representing the idea that the treat-
ment effect in general is relatively unlikely or likely [13]. In this thesis, we focus on the
formulation and use of those prior distributions based on previous evidence in a specific
clinical area.
Many authors have shown there are no issues or there should at least be no controversy if
priors are uninformative [25, 27]. A pivotal study in the late 1980s looked at the practical
use of adopting Bayesian methods in the pharmaceutical industry [28], compared to the
classical or more widely known frequentist approach [29]. This study received much at-
tention and dismissed many negative theories of using non-informative priors in Bayesian
analysis of medical data. However, there is still much controversy about the use of infor-
mative priors [27]. Partly because of this, clinical trial data are usually analysed in isola-
tion, without explicit reference to the wider evidence base and are therefore conducted
in a frequentist framework [13]. However, there is often relevant external evidence avail-
25
able [6, 30]. For example, a meta-analysis of results of a set of similar previous trials could
provide information on the likely size of the intervention effect [6]. A meta-analysis is
a statistical method which combines intervention effects (or any other parameter) across
multiple studies to summarise all available evidence about the intervention effect [31]
(and is described in more detail in Section 1.3.2).
A meta-analysis which analytically summarises the existing studies can be used to formu-
late a sensible prior distribution of likely treatment effects. The process is represented by
Figure 1.1a: the prior information (from the meta-analysis) and the data from the new trial
are combined to form the posterior distribution. This is summarised by statistics such as
the mean and 95% intervals. The less precise the external information, the more the com-
bined (posterior) results will be driven by the new trial. For example, in Figure 1.1b the
horizontal line represents a lack of any relevant prior information (i.e. an ’uninformative’
or ’vague’ prior), such that any value of the intervention effect is felt to be equally likely.
In this case, the posterior distribution is driven entirely by the data. The results obtained
are then the same as if we had followed a classical (non-Bayesian) approach.
The computation of the posterior distribution in Bayesian analyses are often carried out
using Markov chain Monte Carlo (MCMC) simulation methods. One of the most common
ways to do this is to use Gibbs Sampling, which generates samples from the posterior
distribution. In this thesis, Bayesian software WinBUGS, version 1.4.3 (MRC Biostatistics
Unit, Cambridge, UK) [32] and Stan (via RStan) are used. To fit these models, the user
has to specify the statistical distribution (likelihood) for each piece of data, the prior dis-
tribution for the parameters, the function of parameter that each data source provides
an estimate of, and how these relate to each other, i.e. the model. MCMC is equivalent
to integrating over one or more density functions and is achieved by simulating random
variables from known statistical distributions. A Markov Chain is a random process which
has the specific property that the future depends only on the current state of the process
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(a) Prior information (from the meta-
analysis) and the data from the new trial
are combined to form what is known as the
‘posterior distribution’.
(b) Prior information (representing any value
of the intervention effect being equally likely)
and the data from the new trial are combined
to form what is known as the ‘posterior dis-
tribution’.
Figure 1.1: Prior and trial data regarding a treatment effect in a clinical trial combined to
make a posterior distribution in two scenarios.
and not the past. Thus, initial values for the chain need to be specified. Once the chain
has converged the posterior distribution of the parameter of interest is summarised using
general summary statistics. The median and 2.5th and 97.5th percentiles are often used,
especially when the posterior distribution is skewed. The 95% credible interval (CrI) is
defined as the interval between the 2.5th and 97.5th percentiles.
Rather than incorporating prior information on the treatment effect, Bayesian approaches
can also incorporate external evidence on other parameters, examples of these are given
in Section 1.4.
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1.3 Evidence synthesis methods
1.3.1 Introduction to evidence synthesis methods
The results of clinical trials offer one of the best sources of evidence to help determine
whether an intervention is effective or not, clinically, economically, or both. However, the
result of one clinical trial often has little impact. Instead, it often takes the synthesis of
multiple trials to determine if an intervention should be adopted in practice [30].
Evidence synthesis is the collation and combination of multiple sources of evidence in or-
der to answer a specific research question. This includes conducting a literature review
(systematic or otherwise) and providing a narrative summary of the results. More for-
mally, a systematic review may be undertaken to collate all evidence that fits pre-specified
eligibility criteria in order to address a specific research question [33]. To provide a numer-
ical summary of a body of evidence, a meta-analysis is often performed. This statistically
combines results from two or more studies addressing the same research question. In the
following section, the background and explicit formulae of a meta-analysis are given, as
we make use of these in Chapters 4 to 6.
1.3.2 Meta-analyses
Most meta-analyses use either a fixed effect or a random effects statistical model which are
based on differing assumptions [34, 35, 36]. They can also be performed in a frequentist or





A fixed effect meta-analysis is usually interpreted as assuming all studies are estimating
the same (fixed) underlying intervention effect [37], i.e. differences amongst studies are
due to chance or random error. The type of effect estimate will be related to the outcome
variable of interest. For binary outcomes, usually odds ratios or risk ratios including its
standard error) are synthesised. For these ratio measures, meta-analysis is performed on
the log scale. For continuous outcomes, we usually seek a mean difference and its standard
error from each study or the mean, standard deviation, and number of participants in each
group [38]. These effect estimates are usually extracted from articles [39].
Suppose we have studies i = 1, 2, ..., n. We define Yi to be the effect estimate in study i
and s2i its variance (assumed known). For each of the studies, we apply a weight wi to the





One of the most common methods in the frequentist framework is the inverse-variance
method. The pooled estimate from the inverse-variance (fixed-effect) method can be found














The maximum likelihood estimate is used because it is asymptotically unbiased, efficient,
and normally distributed. If we assume that θ̂ is approximately normally distributed, then
an approximate 95% confidence interval for the pooled estimate can be obtained from the




There is debate about combining studies in to a single summary estimate through a fixed
effect meta-analysis when some studies could be very context specific [40]. There is a
strong assumption in a fixed effect meta-analysis that particular characteristics across
studies will not influence the size of the treatment effect (such as the conduct of the trial)
[41, 42, 43]. All meta-analyses are susceptible to heterogeneity. This is likely due to dif-
ferences in trial conduct, which vary across studies and as such will likely impact upon
the underlying treatment effect across studies [44]. When there is more variation in the
treatment effect estimates observed across studies than is expected by chance alone, this
is defined as statistical heterogeneity [45]. A random effects meta-analysis allows for this
heterogeneity. The I2 statistic can be used to describe the percentage of the total variation
across studies that is estimated to be due to between-study heterogeneity [41, 44].
A random effects meta-analysis assumes the underlying treatment effect varies across
studies with mean θ and between-study variance, denoted by τ 2. We now account for
both the within-study variation and between-study variation when estimating the new
pooled effect θ̂. To compute θ̂ we must first estimate the between-study variance τ̂ 2. This
is often estimated by the DerSimonian and Laird (1986) method of moments [31] where
the weights are from the fixed effect meta-analysis. If τ̂ 2 is > 0 this indicates that hetero-
























In contrast to a fixed effect meta-analysis, a random effects meta-analysis assumes a distri-
bution of intervention effects across studies [41]. The pooled estimate is then interpreted as
the average intervention effect across studies. Therefore, in a random effects meta-analysis
individual studies could have an intervention effect that varies considerably away from
the average value.
In addition to summarising the average intervention effect of the studies in a random
effects meta-analysis, it is also possible to derive a predictive distribution [42]. The pre-
dictive distribution summarises the true intervention effect in a new study that is like
those already in the meta-analysis, allowing for the additional variability between the
studies [46]. An approximate 95% prediction interval for the underlying effect is θ̂ ±
(1.96
√
τ̂ 2 + V (θ̂)).
Bayesian approaches
The majority of this thesis is conducted within a Bayesian framework and in Chapters 4
and 5, we make specific reference to Bayesian meta-analysis models for binary data. In
Chapter 6, we also use the Bayesian model for normal data. These are briefly introduced
below.
Bayesian random effects meta-analysis model for normal data
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The estimates Yi come from the following random effects distributions:
Yi|θi ∼ N(δi, si2) (1.7)
The unknown random effects δi are assumed to come from a common distribution:
δi|θ, τ ∼ N(θ, τ 2) (1.8)
This model is in fact the basis for the frequentist random effects inverse variance approach
(equation (1.4)). In a fixed effect model, δi would be assumed to be the same for all studies
and therefore equal to θ. In a Bayesian framework, the parameters, θ and τ which are es-
timated by the model and assumed unknown, need to be given prior distributions. These
can be either non-informative or informative. The random effects mean, θ, is usually given
a very vague prior such as θ ∼ N(0, 105). One of several options for a vague prior for the
between study SD is τ ∼ Unif(0, 5). However, informative empirical priors for the be-
tween study variance have been suggested by Turner et al [47].
Most meta-analyses are based on normal approximations to the distribution of Yi. How-
ever, in a Bayesian framework it is straightforward to model data exactly rather than using
approximations.
Bayesian random effects meta-analysis model for binary data
For binary data Smith et al [48] suggest the following model:
rt,i ∼ Binomial(pt,i, nt,i) (1.9)
rc,i ∼ Binomial(pc,i, nc,i) (1.10)
logit(pc,i) = µi (1.11)
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logit(pt,i) = µi + δi (1.12)
δi ∼ N(θ, τ 2) (1.13)
where rt,i, rc,i, nt,i, nc,i are the number of events and patients in the treatment and control
arm, respectively. In the ith study in the treatment arm, the probability of an event is pt,i
and in the control arm is pc,i. The logit of the event probability in the control arm is µi.
As with the normal random effects model, the treatment effect in study i is δi, the mean
value of all treatment effects across all studies is θ, and τ 2 is the heterogeneity (variance)
between the study estimates. The additional parameters µi are usually given N(0, 105)
prior distributions.
1.3.3 Other types of evidence synthesis methods
An extension of any of the above meta-analysis models in the context of healthcare inter-
ventions is a network meta-analysis (NMA), which allows the simultaneous comparison
of the effectiveness of multiple interventions through the use of direct and indirect evi-
dence [49, 50]. An economic decision model can be used to evaluate intervention effects
formally in the context of other factors such as costs and potential harms and make de-
cisions on use of interventions in practice [51]. Sometimes, a value of information (VoI)
analysis is used to assess whether there is value in conducting a new study, and to iden-
tify the optimal design for such a study within an analytical modelling framework (based
on a decision model) [52, 53]. Expected value of sample information (EVSI) is a specific
type of VoI analysis used to assess the ability of a new trial to inform a cost-effectiveness
assessment of the intervention to determine the optimal sample size [54].
Large-scale empirical ("meta-epidemiological") studies of randomised trials allow us to
learn about biases, by comparing results of trials suffering from specific limitations with
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results of trials that are free of these limitations. Bayesian hierarchical models for meta-
epidemiological research developed by Welton et al [55] estimate the average amount of
bias expected in high risk of bias (RoB) studies, the average variability in this bias within
meta-analyses, and variability in average bias between meta-analyses. In future chapters,
we analyse and develop meta-epidemiological models.
1.4 Current uses of external evidence in trials
Evidence synthesis methods play an important role in identifying and summarising infor-
mation in the current evidence base. There are different levels of external data which may
be synthesised, for example, individual participant data (IPD) from trials, whilst sum-
mary level data may be combined in a meta-analysis. In this thesis, we explore how a
trialist can use information from such syntheses to inform the design and analysis of their
clinical trial, with particular reference to the impact on the current evidence base. Build-
ing upon the overview of how external evidence is used to inform trials in Section 1.1,
we now describe this in more detail. A summary of the application of evidence synthesis
methods, using different levels of evidence, is provided in Table 1.1, with consideration of
each stage of a trial.
Before design
Before the design stage of a trial, funders, such as the National Institute for Health Re-
search (NIHR), often request a systematic review and, where possible, a meta-analysis, to
justify a gap in the evidence base [5, 56]. If there are no relevant previous trials, a search strat-
egy might be requested by funders to support this. Relevant systematic reviews might
include existing clinical trials, early phase trials, non-randomised comparisons, animal
studies, or qualitative research studies [57]. If a meta-analysis exists, this will provide
34
information on effect sizes from ’similar’ trials. Burke et al show how an existing meta-
analysis of similar phase II trials can be used to inform whether a phase III trial should be
conducted [58]. This is conducted within a Bayesian framework and the authors strongly
suggest documenting sensitivity to the choice of meta-analysis model.
Design
In the design stage, a systematic review or meta-analysis may highlight the population and
particular subgroups that warrant further investigation [59]. For example, the population
in the Lung ART trial [59] was defined by subgroup results from an IPD meta-analysis of
postoperative radiotherapy vs none. Similarly, results from evidence syntheses, including
network meta-analyses, decision models, and VoI analyses, can be used to choose which
interventions and comparators to trial [60] and characteristics of these, e.g. dose or duration
of treatment [11, 59]. For example, an IPD meta-analysis comparing prophylactic cranial
irradiation vs. none in patients with small-cell lung cancer informed the choice of com-
parators in the trial [59].
A systematic review can help inform the choice of outcomes [11, 57] in a new trial and
how they should be defined and, if relevant, the duration of follow-up [59]. For example,
a systematic review may highlight adverse events that should be monitored, in particu-
lar events that are expected and related. A systematic review and/or meta-analysis may
also provide information on the parameters needed for sample size calculations [11, 59],
such as the standard deviation, control group outcome rates, plausible effect sizes, loss to
follow-up, and correlation coefficients [57]. For example, an IPD meta-analysis comparing
chemotherapy vs standard radiotherapy informed the control group survival rate used as
the basis for the sample size calculation in the OUTBACK trial [59]. Alternatively, EVSI
calculations can be used to assess the ability of a new trial to inform cost-effectiveness
assessment of the intervention to determine sample size and reduce decision uncertainty
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[54].
Information from meta-analyses can be used to inform parameters within a trial. External
evidence might be used to improve the estimation of secondary or ‘nuisance’ parameters in-
volved in trial analysis which are often poorly estimated. An example of a secondary or
nuisance parameter is the intra-class correlation coefficient (ICC) in cluster randomised
trials [61] and between-centre variability in multi-centre trials. When calculating the sam-
ple size for cluster randomised trials, an estimate of the variability between clusters, the
ICC, is required. It was common practice to look back at previous studies to informally
estimate the ICC value, however, sample size calculations can be sensitive to the choice of
this value. Turner et al suggest a Bayesian approach to allow for the uncertainty around
pooled ICC values from multiple studies. The authors describe how priors for the ICC,
based on a meta-analysis of existing studies, can be used to inform sample size calcula-
tions for cluster randomised trials.
Monitoring (conduct)
During the monitoring stage of the trial, external evidence on recruitment rates can be used
to inform rates in new hospitals or centres. Observed adverse event rates can be compared
with predictions from a synthesis of historic data to see if they are higher than expected
by chance [62]. For example, the incidence of cancer was calculated in an interim analysis
in patients taking ezetimibe and this was then compared to the expected incidence from
two larger ongoing trials [62]. The incidence was not higher than expected and so the
trial continued. Emerging trial results considered in the context of results from previous
studies might be used to make the decision to stop a trial early [59]. For example, subgroup
results from a meta-analysis of IPD (of postoperative platinum-based chemotherapy vs.
none for non-small-cell lung carcinoma (NSCLC)) were used to stop the trial and cancel
the planned phase III component due to clear discrepancies [59].
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Analysis and reporting
Factors such as measures of effects (event rates, mean difference etc.) from previous tri-
als might influence the choice of statistical model. Prognostic or predictive factors identified
through evidence synthesis may be used to stratify or adjust trial analyses [59]. For ex-
ample, an IPD meta-analysis validated predictive risk factors which were then used to
inform the basic statistical analysis of the new trial by adjusting for them in the model
[59]. Choice of the most important covariates to be recorded for imputation modelling
might be informed by patterns of missing data in previous trials.
A well designed RCT is considered the highest level of evidence and often referred to as
the gold standard study design to compare treatments [2]. However, RCTs are susceptible
to bias throughout [21, 63]. External evidence about typical biases associated with undesir-
able study characteristics, e.g. inadequate blinding, might come from ‘meta-epidemiological’
studies [55, 64, 65] or from opinions elicited from experts [66].
Individual patient data from previous trials can inform patient level parameters. In an in-
dividual trial setting, Pocock et al make use of previous information on historical control
outcomes, not only in the design stage to randomise fewer patients but also in the analysis
stage [67]. An informative prior is used on the mean outcome in the control arm based on
a weighted average of the means of the new and historical controls. This can be advanta-
geous as it more precisely estimates the treatment effect comparisons based on both types
of control.
An updated systematic review [12] or meta-analysis including the new trial results [46]
should be reported to put the results in the context of the wider evidence base [59]. For
example, EORTC 62931 trial report uses results of meta-analysis and subsequent trials to
place trial results in the context of other results from similar studies [59]. An existing meta-
analysis might be used to form a prior distribution for the treatment effect in a new study.
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This can then be updated using the trial data in a Bayesian statistical analysis.
Table 1.1: Summary of opportunities for evidence synthesis to inform design, conduct and
analysis of a clinical trial.
Stages of a
clinical trial
Opportunities in which previous evidence might be used
Before design To justify the need for a new trial in light of the existing evidence base.
A systematic literature review and, where appropriate, quantitative synthe-
sis, could be used to assess the need for the new trial [5, 9, 56].
Design Choice of population.
A systematic review may highlight the population and particular subgroups
that warrant further investigation [59].
Choice of interventions and comparators.
Results from evidence syntheses, including NMA, decision models, and VoI
analyses can be used to choose which interventions and comparators to trial
[60] and characteristics of these, e.g. dose or duration of treatment [11, 59].
Choice of outcomes and length of follow up.
A systematic review may help inform the choice of outcomes [11, 57] in a
new trial and how they should be defined and, if relevant, the duration of
follow-up [59].
Sample size calculations.
A systematic review and/or meta-analysis may provide information on the
parameters needed for sample size calculations [11, 57, 59]. Alternatively,
EVSI calculations can be used to assess the ability of a new trial to inform
cost-effectiveness assessment of the intervention and reduce decision uncer-
tainty [54].
To inform secondary parameters.
Continued on next page
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Table 1.1 – continued from previous page
Stages of a
clinical trial
Opportunities in which previous evidence might be used
External evidence might be used to improve the estimation of ‘nuisance’ pa-
rameters involved in trial analysis which are often poorly estimated, such
as the intra-class correlation coefficient in cluster randomised trials [61] and
between-centre variability in multi-centre trials.
Monitoring Recruitment and consent.
(conduct)
For example, good or poor recruitment rates in previous relevant trials can
inform site selection in a new multi-centre trial [11].
To deal with adverse events.
Observed adverse event rates can be compared with predictions from a syn-
thesis of historic data to see if they are higher than expected by chance [62].
To decide whether to stop an ongoing trial.
Emerging trial results considered in the context of results from previous stud-
ies might be used to make the decision to stop a trial early [59].
Analysis To inform the statistical analysis plan.
Factors such as measures of effects (event rates, mean difference etc.) from
previous trials might influence the choice of statistical model. Prognostic or
predictive factors identified though evidence synthesis may be used to strat-
ify or adjust trial analyses [59].
To adjust for potential biases.
External evidence about typical biases associated with undesirable
study characteristics, e.g. inadequate blinding, might come from ‘meta-
epidemiological’ studies [64], allowing the analyst to assess the sensitivity
of the findings to alternative model assumptions.
To assess the trial treatment effect in the context of existing evidence.
Continued on next page
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Table 1.1 – continued from previous page
Stages of a
clinical trial
Opportunities in which previous evidence might be used
An existing meta-analysis might be used to form a prior distribution for the
treatment effect in a new study, which can then be updated using the trial
data in a Bayesian statistical analysis.
Reporting To report the new trial results in the context of the wider evidence base.
An updated systematic review [12] or meta-analysis including the new trial
results [46] should be reported to put the results in the context of the wider
evidence base [59].
Most of these uses do not involve informative priors, which is what we focus on in this
thesis. Despite these suggestions and examples in the methodological literature, informa-
tive priors are not routinely used within the clinical trials community and instead only
applied in specific areas [14, 68, 69, 70]. Spiegelhalter [13] describe how informative priors
are rarely used even within Bayesian analyses. Possible barriers to use of Bayesian meth-
ods across clinical trials include concerns about misspecification and subjectivity of the
prior distribution [24] and the perspective of wanting to look at data of the clinical trial in
isolation [71]. Deaton et al allude to this and continue the “lumpers and splitters” debate
about meta-analysis, illustrating lots of issues about combining studies and firmly define
everything as heterogeneous and context specific [40]. Davey-Smith and Egger discuss
this issue at great length and construct arguments from both sides [72], arguing a poten-
tial reason why results of clinical trials and meta-analyses, and thus the proper account
of previous evidence, are under used in clinical trials. However, it is less clear why infor-
mative priors are not used to (i) improve the estimation of key parameters and/or (ii) put
trial results in the context of the existing evidence base.
In this thesis we consider three case studies of potential uses of external evidence syn-
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theses in the design or analysis of a clinical trial, each relating to a different level of a
hierarchy of sources of external evidence.
 (i) External evidence on bias from meta-analyses within meta-epidemiological
studies. First, when there are potential unavoidable limitations in the methodology
of the new trial, the analyst could attempt to account for these via incorporation of
an informative prior distribution for the likely amount of bias. An example of an
unavoidable limitation is the allocated treatment being unblinded to the patient or
personnel, which can cause bias in the treatment effect estimate. The Bayesian anal-
ysis would then provide a treatment effect estimate from the new study that has
been adjusted for the likely bias, allowing the analyst to assess the sensitivity of the
findings.
 (ii) External evidence on effect sizes from trials within meta-analyses. Second,
there are methods in the literature [13, 73, 74] which enable trialists to use infor-
mation from an existing meta-analysis to inform sample size calculations, but it is
unclear which of these (if any) to use in practice. We compare methods, when the
focus of inference is the new trial or the updated random effects mean to see ex-
actly what size a trial needs to be in order to have an impact on the current evidence
base. This can potentially reduce the sample size needed for a new trial and give an
indication to trialists of whether their new trial will have any impact to update an
existing meta-analysis and therefore to change future policy. We also compare our
results when using EVSI, based on the ability of the new trial to change the decision
based on a cost-effectiveness model.
 (iii) External evidence on outcomes from patients within trials. Third, a synthe-
sis of ’similar’ studies might be used to inform other parameters in the analysis
which may be poorly estimated, such as when an analyst compares adverse events
between two interventions. Therefore, external evidence synthesis could be used to
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inform the control group event rate when the event is rare and adverse outcomes are
underpowered.
Qualitative work can explore people’s views, attitudes, and previous experiences to al-
low an in-depth understanding on topics which may be multi-faceted [75, 76, 77]. In this
thesis, we perform a questionnaire and qualitative study to explore current attitudes and
experiences of trialists using informative priors, in the form of real trial data, to inform
the design and analysis stage of a trial.
1.4.1 Aims of the thesis
There are several key aims to this thesis:
 To explore the current use of evidence synthesis in trials and the potential barriers
to such use through a questionnaire and qualitative study.
 To extend and develop Bayesian methodology to synthesise relevant external data
for each of the three case studies.
 To assess how this data can be used to inform the design and analysis stages of a
trial. This will include considering how best to form suitable priors based on existing
evidence and how a trialist would use these priors in a clinical trial setting.
1.4.2 Structure for the thesis
In Chapter 2 we explore the current use of and opinions about use of evidence synthe-
sis methods in trial design and analysis. A survey was undertaken at the International
Clinical Trials Methodology Conference (ICTMC) 2015 [78]. A subset of questions focused
on the use of previous evidence in the analysis stage of a trial and specifically identifies
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the views on use of informative prior distributions in a Bayesian statistical framework, for
each of: (i) the treatment effect, (ii) potential biases and (iii) secondary parameters. We also
explore the potential barriers to the use of external evidence. The findings of the ’INVEST’
(INVestigating the use of Evidence Synthesis in the design of clinical Trials) survey inform
the rationale for the remainder of the thesis.
Chapter 3 describes a qualitative study that builds upon the findings of the INVEST sur-
vey. The aim of the study is to explore in more detail trialists’ perspectives and experiences
of analysing clinical trials in the context of external evidence, conducted through in-depth
semi-structured interviews. The study targets key people within the clinical trials commu-
nity, such as methods leads, those writing grant applications, and chief investigators. In
the interviews we elicited views on the three case studies. We also explore the barriers to
the use of informative priors across these settings and contrast the results to our INVEST
survey.
In Chapters 4 and 5 we consider our first case study of (i), using external evidence on the
likely amount of bias from meta-analyses within meta-epidemiological studies. Previous
meta-epidemiological studies of blinding have generally compared intervention effect es-
timates from trials described as “double-blind” with those from trials not described as
“double-blind”. However, “double blind” is an ambiguous term as it is unclear precisely
which parties were blinded [79]. In Chapter 4 we describe the first meta-epidemiological
study to disentangle the impact of different types of blinding to enable the clear separation
of the two main types of blinding-related bias: “performance bias” (systematic differences
in the care provided to the participants in the comparison groups other than the interven-
tion under investigation, which can be addressed by blinding the participants and care
providers), and “detection bias” (systematic differences between comparison groups in
how outcomes are ascertained, addressed by blinding outcome assessors), first described
in 1.2.2. We examine, separately, the impact of blinding participants, care providers, and
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outcome assessors, and explore how this might vary by type of outcome. This chapter also
extends current methodology to develop models which: combine binary and continuous
outcomes; and stratify the average bias.
Although it seems reasonable to adjust for trials at a high RoB in meta-analyses, the re-
sults of such meta-epidemiological studies are still rarely used in this way [80]. Further-
more, meta-epidemiological studies have never, to our knowledge, been used, to inform
bias adjustment within an individual trial setting. Instead, limitations of the trial, such
as non-blinding, are often written descriptively in an end of study report or publication.
There is usually no quantification about the likely amount of bias or how it may affect the
interpretability of the findings. Therefore, in this thesis, we address some of the limita-
tions of previous meta-epidemiological models [55] and extend them to try and improve
their potential for implementation in practice. Chapter 5 explores statistical considerations
of modelling meta-epidemiological data [55] with an application of these methods using
published data from a recent meta-epidemiological study [81]. We extend current method-
ology to model associations between treatment effect estimates and categorical and nu-
merical study characteristics. This includes jointly modelling unclear and high RoB trials
in relation to the common reference group of low RoB trials; and modelling continuous
bias predictors. Finally, we estimate the probability an unclear RoB trial is at a high RoB
[82]. We also discuss the use of meta-epidemiological evidence to adjust for a potentially
biased treatment effect in an individual trial.
It can be assumed any previous trials of the same intervention should inform the decision
as to whether to conduct a further trial [3, 10]. However, it is less clear how the results of
such a synthesis should be used by trialists, when designing their trial and by funders,
when deciding whether to invest in the proposed new trial. Chapter 6 explores the use
of existing evidence to inform the design stage of a trial, more precisely, the use of an
existing meta-analysis to inform sample size calculations [73, 74]. An example looking at
44
the effect of cortisterioids after traumatic brain injury is used for illustration [83, 84]. This
chapter compares methods for explicitly incorporating information on the intervention
effect from a previous meta-analysis for use in sample size calculation. We describe and
compare the following methods: (1) standard power calculations; (2) calculations based
on the power of a Bayesian analysis of the new trial with an informative prior distribution
based on a meta-analysis [13]; (3) calculations based on the power of an updated meta-
analysis [73, 74] and (4) EVSI calculations, based on the ability of the new trial to change
the decision in a cost-effectiveness model. We discuss the advantages and disadvantages
of each for their use in practice.
Chapter 7 presents an application of Bayesian mixed modelling to a collection of placebo
arm data in FIH studies to estimate the incidence of safety events. In this chapter we in-
vestigate how to use this existing data to make predictions and inform the analysis of FIH
studies [85]. The results are used to assess whether a safety event observed of the investi-
gational drug is likely to be due to chance or caused by the compound under investigation.
An example of placebo data from seventy-seven FIH studies is used for illustration.
Finally, Chapter 8 summarises the key findings from the thesis and discusses areas for
further research.
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2 Current practice and attitudes: the INVEST survey
The work presented in this chapter was performed in collaboration with the MRC Evi-
dence Synthesis Working Group which included Isabelle Smith, Julian Higgins, Borislava
Mihaylova, Benjamin Thorpe, Robert Cicero, Kusal Lokuge, Julia Forman, Jayne Tierney,
Ian White, Linda Sharples, and Hayley Jones.
2.1 Introduction and aims
One of the overarching aims of this thesis is to develop methodological approaches that
use existing evidence syntheses to inform the design and analysis stage of an individual
trial. Despite the promotion of reducing research waste [6], it is still currently unclear
whether and how trialists are using existing evidence syntheses to inform the design and
analysis of a trial in practice.
In a survey of 24 investigators whose trials were included in an update of a Cochrane re-
view, only 8 (33%) indicated that a previous review had influenced trial design, and only 2
(8%) had used the previous Cochrane review [10]. More recently, reviews of trials funded
by the NIHR Health Technology Assessment (HTA) programme found that the majority
(77% of those funded between 2006 and 2008 [11], and 100% of those funded in 2013 [57])
referenced a systematic review in the funding application. When a systematic review was
not referenced, there were valid reasons for this, such as there being no relevant system-
atic review addressing the proposed research question [57]. Arguably of more interest is
whether and how a cited review was used to inform trial design. Jones et al [11] found
only 54% (20/37) of trials that referenced a systematic review used the review in some
way. The recent review of Bhurke et al [57] found that 94% (32/34) of the trials examined
used the referenced systematic review to justify the treatment comparison in the new trial,
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but that other uses were relatively infrequent. The other most common uses were in selec-
tion of a definition or outcome (16%), to inform the standard deviation (9%) or to inform
duration of follow up (6%). Tierney et al describe examples of how meta-analyses of IPD
have informed trial design, conduct and analysis in practice [59].
To our knowledge, there are no recent studies investigating the extent of use of evidence
synthesis in the design of trials funded through streams other than the NIHR HTA pro-
gramme or in trial analyses. Therefore, the aim of this chapter is to explore the current
use of and opinions about use of evidence synthesis methods in trial design and analysis.
To do this, a survey ‘INVEST’ was undertaken at the ICTMC, 2015. The purpose of this
survey was to (i) summarise current evidence synthesis use in trial design and analysis
across clinical trials teams, (ii) capture current opinions of trialists and methodologists on
such use, and (iii) understand any barriers to use in practice.
The survey will therefore provide a snapshot of the current views of trialists of how and
what evidence synthesis methods are being used to inform both trial design and analysis,
and also help determine appropriate areas for the consideration of such methods in the
remaining chapters of this thesis.
2.1.1 Aims
The following aims are:
Aim 1: Evidence synthesis methods in trial design
 To summarise respondent’s views and opinions on the use of evidence synthesis
methods to inform trial design.
This will identify if respondents are using evidence synthesis methods to justify or inform
(i) whether a trial is needed; (ii) the choice of population; (iii) the choice of interventions;
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(iv) the choice of outcomes and follow-up time; (v) sample size calculations. We also ex-
plore how these methods are implemented, whether they are conducted by the trials team
or based on previously published evidence syntheses, such as an existing systematic re-
view and/or meta-analysis.
Aim 2: Evidence synthesis methods in trial analysis
 To summarise respondent’s views and opinions on the use of evidence synthesis
methods to inform trial analysis in the following three areas:
 Treatment effect, such as using information from a previous meta-analysis;
 Potential biases arising from trial conduct, for example, evidence on the likely
amount of bias from methodological limitations;
 Other quantities that need to be estimated in the analysis such as correlations
and baseline event rates.
Aim 3: Barriers to the use of evidence synthesis methods in trial design and analysis
 To understand the barriers to the use of evidence synthesis methods in both trial
design and analysis.
This will identify the most important barriers to such use and help identify areas for future
research.
A supplementary aim is to characterise the sampling frame:
 To summarise the characteristics of delegates who attended the conference and those
who responded;
 To infer potential differences between respondents, whether there are differences be-




The sampling frame consisted of all delegates at the two-day ICTMC on 16-17th Novem-
ber 2015. The conference was open to both those involved and those who have an in-
terest in clinical trials methodology. Approximately 638 people registered to attend the
conference across a range of disciplines including trialists, clinicians, statisticians, health
economists, information specialists and qualitative researchers. 95% of the registered del-
egates were from the UK and the Republic of Ireland, with the remaining 5% from Aus-
tralia, Canada, Denmark, France, Germany, Holland and the United States. The main UK
research centres represented were Aberdeen, Birmingham, Bristol, Cambridge, Cardiff,
Coventry, Glasgow, Leeds, London, Liverpool, Manchester, Oxford and Southampton.
Conference delegates were first invited to take part in the survey during the opening ple-
nary session, then by researchers from the INVEST team during breaks. The survey could
be completed either on paper or online, with a closing date of 18th December 2015. The
survey is available in full in the Appendix, Figure A.1.
The survey will be presented in two parts: first, descriptively summarising all participants
in the survey and second, describing only the subset of participants involved in trial de-
sign and trial analysis. All participants will be characterised using their job role, setting
and which aspects of clinical trials they are involved in.
2.2.1 All participants
Following details about their job role, job setting and the length of time they had spent
working in clinical trials, respondents who indicated that they had been involved in trial
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design (and/or analysis) were further asked questions about whether and how they have
used evidence synthesis (i.e. in practice). All respondents were then asked about their
views on the use of evidence synthesis in trial design and analysis. They were also asked
to rank what they considered to be the three greatest barriers to such use. There were eight
potential barriers listed, and an ‘other’ category allowing free text. The subsets of respon-
dents who indicated that they had been involved in trial design (and/or analysis) were
used to contrast views on whether evidence synthesis methods should be used versus
current use in practice.
2.2.2 Use of evidence synthesis to inform trial design
Respondents who indicated they had personally been involved in trial design were asked
to consider any trials in which they had been involved over the last 10 years and to specify,
if applicable, how evidence synthesis had been used in practice. A matrix style layout was
chosen to allow multiple responses, with rows for each area of trial design and columns
for types of evidence synthesis method. In addition to (i) a description of previous evi-
dence, (ii) a systematic review and (iii) a meta-analysis, we listed three evidence synthesis
methods that extend meta-analysis: (iv) NMA; (v) an economic decision model; (vi) a VoI
analysis [86]. A final option of ‘none of these methods’ was included. Respondents were
provided with a brief definition of these evidence synthesis methods to reduce ambiguity.
The areas of trial design listed were: (i) whether a trial is needed; (ii) the choice of popu-
lation; (iii) the choice of interventions; (iv) the choice of outcomes and follow-up time; (v)
sample size calculations. Respondents were also asked to indicate whether any evidence
synthesis used had been performed by the trial team or previously published by others.
We also asked all respondents which of the listed evidence synthesis methods they thought
should be used to inform aspects of trial design. This question was formatted to match the
earlier question about how those involved in trial design were using evidence synthesis
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methods, facilitating comparison between ideal and current practices.
2.2.3 Use of evidence synthesis to inform trial analysis
Respondents who indicated they had personally been involved in trial analysis were
asked which (if any) of three types of external evidence they had used in practice, dur-
ing the last 10 years: (i) external information about the treatment effect (including a meta-
analysis); (ii) evidence around the likely size of potential biases arising from trial conduct
(e.g. blinding infeasible); and (iii) other quantities involved in the analysis (e.g. correla-
tions or baseline event rates).
We asked all survey respondents whether each of these three types of external evidence
should be used to inform trial analysis. For each of these, the options were ‘yes’, ‘no’,
and ‘don’t know’. An additional ‘don’t understand’ response was also included since we
anticipated that some of these uses of evidence synthesis might be new concepts to some
respondents [87, 88].
2.2.4 Analysis of survey responses
Our main analysis is descriptive, as sample sizes were not sufficient for a robust assess-
ment of associations or subgroup comparisons. Missing responses were excluded from
denominators and are indicated in footnotes in the tables that follow.
For the subsets of respondents involved in trial design or analysis, we compared their
responses for desirability versus actual use of evidence synthesis. For each of the five aspects
of trial design, we categorised each respondent who indicated they had been involved in
trial design into one of the following: ’used and think desirable’, ‘used but don’t think
desirable’, ‘not used and don’t think desirable’ and ‘not used but think desirable’. For each
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of the three aspects of trial analysis, we added three categories to these options: ‘used and
don’t know whether desirable’, ‘not used and don’t know whether desirable’, and ‘don’t
understand’.
To summarise responses about the three greatest barriers to use of evidence synthesis, we
assigned three points to the first (greatest perceived) barrier, two to the second and one to
the third for each respondent. If a respondent had ticked three barriers but not indicated a
ranking, each was assigned two points. No points were allocated for respondents who did
not answer the question. For each potential barrier, the scores were then summed across
respondents, so that higher overall scores indicated greater perceived barriers.
Although highly exploratory in nature because of small numbers, we examined answers
to specific questions for two subgroups: the perceived barriers to use of evidence synthe-
sis in practice by statisticians specifically, statisticians’ use versus perceived desirability
of using evidence synthesis in trial analysis, and the views of health economists on VoI
analyses.
2.3 Results
There were 106 respondents, of whom 54 (51%) were statisticians, 8 (8%) were health
economists and 18 (17%) worked in trial management. These are overlapping categories,
i.e. respondents were asked to select all roles that applied to them. All respondents had
spent some time working in the area of trials: 86 (81%) for at least 3 years and 32 (30%)
for more than 10 years. 96 (91%) respondents indicated that they had been involved in
the design, setting up or running of trials (77 (80%) in a clinical trials unit, and 9 (9%) in
industry). 85 (80%) indicated that they had been involved in trial design, 71 (67%) in trial
conduct, 73 (69%) in statistical analysis, and 52 (49%) had been involved in undertaking
a systematic review of trials. Only 3 (3%) respondents indicated that they had not been
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involved in any of these. Full details are shown in Table 2.1.




Clinical co-ordinator 1 0.9
Data management 5 4.7
Epidemiologist 5 4.7
Health economist 8 7.5
Information specialist 2 1.9
Programmer 1 0.9







Statistician and data manager 1/10
Unspecified 2/10




Director of trials unit/CEO 2/15
Continued on next page
1 This question was ‘tick all that apply’ so respondents could have selected more than 1 and therefore the
percentages do not add up to 100% 2 Student disciplines will have already been counted if they ticked
one of the available options
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Involved in design, setting up or running trials in your job/role
None at all 10 9.4
Clinical trials unit only 59 55.7
Industry only 1 0.9
Clinical trials unit and Industry 6 5.7
Clinical trials unit and other setting: 12 11.3
CTU & Academia 10/12
CTU & NHS/Hospital 2/12






Involved in a trials unit at some point 77 72.6
Time spent working in the area of clinical trials
Not at all 0 0
0-2 years 20 18.9
3-5 years 30 28.3
6-10 years 14 13.2
11-20 years 26 24.5
Continued on next page
3 Could also have ticked any of the available options
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Table 2.1 – continued from previous page
N=106 n %
Over 20 years 16 15.1
Aspects of clinical trials have you been involved in
Trial design 85 80.2
Trial conduct 71 67.0
Statistical analysis 73 68.9
Undertaking a systematic review of trials 52 49.1
None of these 3 2.8
2.3.1 Use of evidence synthesis to inform trial design
Figure 2.1 summarises the views of respondents on the desirability of using evidence syn-
thesis in trial design. Support for using a description of previous evidence or a systematic
review to inform each aspect listed was high. For most aspects of design, support was
slightly higher for a simple description of previous evidence than a systematic review. In
contrast, there was slightly more support for a systematic review to inform whether a trial
is needed (92/104 or 89% systematic review versus 75/104 or 72% description of previous
evidence) and the choice of interventions (78/103, 76% versus 74/103, 72% respectively).
Over 50% of respondents also felt that a meta-analysis should be used to inform whether
a trial is needed, the choice of interventions and the sample size.
Fewer respondents indicated support for use of more complex analyses (NMA, deci-
sion models and VoI analyses). For example, only 19% (20/101 respondents) indicated
that VoI analyses should be used to inform sample size calculations. Of these respon-
dents, 55% (11/20 respondents) were statisticians and 20% (4/20 respondents) were health
economists, including one person who identified themselves in both roles. However, six
of the eight health economists (75%) supported such use of VoI calculations across at least
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Figure 2.1: Views of respondents on whether evidence synthesis methods should be
used to inform trial design. The type of evidence synthesis method is summarised across
five aspects of trial design: whether a trial is needed (n=104), choice of population (n=103),
choice of interventions (n=103), choice of outcomes and follow-up time (n=101), sample
size (n=103).
one aspect of design.
All respondents indicated support for using some form of evidence synthesis in at least
three of the five aspects of trial design that were listed. Seven respondents, all of whom
had experience in trial design, suggested that no form of evidence synthesis was required
for one or two specific aspects, most commonly ‘choice of outcomes and follow-up time’
(3/101 or 3% of respondents). Full results are shown in Table 2.2.
Of the 85 respondents who indicated involvement in trial design, Figure 2.2 contrasts their
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n % n % n % n % n % n % n %
Whether a trial
is needed1 75 72.1 92 88.5 79 76 33 31.7 14 13.5 24 23.1 1 1
Choice of
population2 79 76.7 64 62.1 43 41.7 17 16.5 14 13.6 12 11.7 2 1.9
Choice of
interventions3 74 71.8 78 75.7 62 60.2 27 26.2 13 12.6 21 20.4 1 1
Choice of outcomes
and follow-up time4 79 78.2 73 72.3 45 44.6 14 13.9 16 15.8 17 16.8 3 3
Sample
size5 67 65 59 57.3 61 59.2 23 22.3 15 14.6 20 19.4 2 1.9
Any design
aspect6 88 87.1 93 92.1 87 86.1 38 37.6 28 27.7 35 34.7 7 6.9
1 2 respondents with missing data. 2 3 respondents with missing data.
3 3 respondents with missing data. 4 5 respondents with missing data.
5 3 respondents with missing data. 6 5 respondents with missing data.
views on how evidence synthesis methods should be used versus their own use during
the last 10 years. Full results are shown in Table 2.3.
Slightly more respondents indicated they had used a description of previous evidence to
inform aspects of trial design than had indicated that such use was desirable. For exam-
ple, 82% (69/84) had used a description of previous evidence to decide whether a trial is
needed, compared with 71% (60/84) indicating support for such use. Of the 69 respon-
dents who had used a description of previous evidence in this way, 14 (20%) did not
indicate that such use was desirable. In contrast, our results suggested that trial design
practitioners would like to be using each of the other five types of evidence synthesis
more than they currently do in practice. This pattern was consistent across all aspects of
trial design. For example, only 50% (42/84) of respondents had used a meta-analysis to in-
form whether a trial is needed, whereas 74% (62/84) thought it was desirable. 93% (39/42)
of those who had used a meta-analysis to inform whether a trial is needed felt that such
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Table 2.3: Actual uses of evidence synthesis in trial design during the last 10 years, com-














Whether a trial is needed1
Description of
previous evidence 55 65.5 5 6 10 11.9 14 16.7 69 82.2 60 71.4
Systematic review 58 69 17 20.2 6 7.1 3 3.6 61 72.6 75 89.2
Meta-analysis 39 46.4 23 27.4 19 22.6 3 3.6 42 50 62 73.8
NMA 2 2.4 25 29.8 57 67.9 0 0 2 2.4 27 32.2
Decision model 4 4.8 7 8.3 71 84.5 2 2.4 6 7.2 11 13.1
VoI analysis 5 6 16 19 63 75 0 0 5 6 21 25
Choice of population2
Description of
previous evidence 51 62.2 8 9.8 11 13.4 12 14.6 63 76.8 59 72
Systematic review 29 35.4 26 31.7 19 23.2 8 9.8 37 45.2 55 67.1
Meta-analysis 15 18.3 21 25.6 43 52.4 3 3.7 18 22 36 43.9
NMA 0 0 13 15.9 69 84.1 0 0 0 0 13 15.9
Decision model 2 2.4 9 11 71 86.6 0 0 2 2.4 11 13.4
VoI analysis 0 0 11 13.4 71 86.6 0 0 0 0 11 13.4
Choice of intervention3
Description of
previous evidence 51 62.2 7 8.5 15 18.3 9 11 60 73.2 58 70.7
Systematic review 51 62.2 13 15.9 12 14.6 6 7.3 57 69.5 64 78.1
Meta-analysis 31 37.8 20 24.4 27 32.9 4 4.9 35 42.7 51 62.2
NMA 4 4.9 17 20.7 61 74.4 0 0 4 4.9 21 25.6
Decision model 2 2.4 8 9.8 71 86.6 1 1.2 3 3.6 10 12.2
VoI analysis 2 2.4 17 20.7 63 76.8 0 0 2 2.4 19 23.1
Choice of outcomes and follow-up time4
Description of
previous evidence 54 66.7 8 9.9 8 9.9 11 13.6 65 80.3 62 76.6
Systematic review 47 58 12 14.8 14 17.3 8 9.9 55 67.9 59 72.8
Meta-analysis 16 19.8 20 24.7 42 51.9 3 3.7 19 23.5 36 44.5
NMA 0 0 9 11.1 72 88.9 0 0 0 0 9 11.1
Decision model 3 3.7 9 11.1 68 84 1 1.2 4 4.9 12 14.8
VoI analysis 0 0 14 17.3 67 82.7 0 0 0 0 14 17.3
Sample size5
Description of
previous evidence 50 61.7 2 2.5 17 21 12 14.8 62 76.5 52 64.2
Systematic review 34 42 17 21 23 28.4 7 8.6 41 50.6 51 63
Meta-analysis 31 38.3 18 22.2 30 37 2 2.5 33 40.8 49 60.5
NMA 1 1.2 17 21 62 76.5 1 1.2 2 2.4 18 22.2
Decision model 4 4.9 7 8.6 69 85.2 1 1.2 5 6.1 11 13.5
VoI analysis 5 6.2 13 16 63 77.8 0 0 5 6.2 18 22.2
1 1 respondent with missing data. 2 3 respondents with missing data. 3 3 respondents with missing data.
4 4 respondents with missing data. 5 4 respondents with missing data.
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n % n % n % n % n % n %
Previously published evidence
syntheses (such as a systematic
review or meta-analysis)
62 72.9 59 69.4 46 54.1 5 5.9 7 8.2 1 1.2
Conducted by the
clinical trial team 59 69.4 55 64.7 31 36.5 2 2.4 7 8.2 6 7.1
Figure 2.2: Comparisons between desirable and current practice in use of evidence syn-
thesis methods in trial design. This is summarised by type of evidence synthesis method,
among survey respondents involved in trial design to inform five aspects of trial de-
sign: whether a trial is needed (n=84), choice of population (n=82), choice of interven-




Some 96% (78/81) of respondents claimed to have used some form of evidence synthesis
to inform sample size calculations in the last 10 years, close to the 99% (80/81) who indi-
cated support for such use (data not shown). Making the same comparison but excluding
the less formal ‘description of previous evidence’, we found a larger discrepancy: 62%
(50/81) had used evidence synthesis methods to inform sample size calculations, com-
pared with 84% (68/81) indicating that this is desirable (data not shown). Only 6% (5/81)
of respondents had used a VoI analysis to inform sample size calculations, compared with
22% (18/81) indicating that VoI analysis should be used for this. All five respondents who
had used VoI in this way were in support of its use. For all types of evidence synthesis
methods except VoI analyses, which was mostly conducted by the clinical trials team, use
of previously published evidence syntheses was most common, although only marginally
(See Table 2.4).
2.3.2 Use of evidence synthesis to inform trial analysis
Of the 106 participants who were asked all questions on the survey, only 100 (94%) an-
swered questions on trial analysis. 79% (79/100) of respondents indicated that external
information about the treatment effect should be used to inform aspects of the analysis
(See Figure 2.3; Table 2.5). Similarly, 69% (69/100) expressed support for using external
information related to potential biases in trial analysis, and 67% (67/100) for use of ex-
ternal evidence on other quantities which are usually poorly estimated. While only a few
respondents (5% or less) indicated that external evidence should not be used in these
ways, between 15 and 30% selected the ‘don’t know’ or ‘don’t understand’ options.
73/106 (69%) respondents indicated they were involved in trial analysis. Figure 2.4 con-
trasts the views of this subsample on how evidence synthesis methods should be used to
60
Figure 2.3: Views of respondents on whether evidence synthesis should be used to in-
form trial analysis. This is summarised across three aspects of trial analysis: the treatment
effect, potential biases arising from trial conduct and other quantities (of n=100 people
who answered this question).







n % n % n % n %
External information about the treatment effect
(including a meta-analysis) 79 79 5 5 12 12 4 4
External information related to potential biases
arising from trial conduct (e.g. blinding infeasible) 69 69 4 4 20 20 7 7
External information about other quantities involved
in the analysis (e.g. correlations or baseline event rates) 67 67 5 5 20 20 8 8
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inform aspects of analysis versus their own use in practice. 52% (35/68) indicated that,
during the past ten years, they had used external information about the treatment effect
to inform trial analysis, compared with 79% (54/68) indicating support for such use. 97%
(34/35) of those who had used external information in this way felt that such use was de-
sirable. Whilst 63% (20/32) of respondents who had not used external information about
the treatment effect in trial analysis also felt such use was desirable, 22% (7/32) were not
sure. Similar patterns were seen for using external evidence on potential biases and other
quantities. Full results are shown in Table 2.6. A sensitivity analysis including only statisti-
cians suggested slightly less use of external evidence in each of the three areas (See Figure
2.5).
Table 2.6: Actual uses of evidence synthesis in trial analysis during the last 10 years, com-

















effect1 34 50 20 29.4 5 7.4 1 1.5 0 0 7 10.3 1 1.5
Potential
biases2 28 40.6 19 27.5 4 5.8 2 2.9 0 0 12 17.4 4 5.8
Other
quantities3 33 48.5 16 23.5 5 7.4 2 2.9 0 0 10 14.7 2 2.9
1 5 respondents with missing data. 2 4 respondents with missing data. 3 5 respondents with missing data.
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Figure 2.4: Comparisons between desirable and current practice in use of evidence syn-
thesis methods in trial analysis. This is summarised among survey respondents involved
in trial analysis to inform three aspects of trial analysis: the treatment effect (n=68), poten-
tial biases arising from trial conduct (n=69) and other quantities (n=68). Numbers dis-
played as percentages.
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Figure 2.5: Comparisons between ideals and current practice of evidence synthesis meth-
ods amongst statisticians only in use of evidence synthesis methods to inform three different
aspects of trial analysis: the treatment effect (n=54), potential biases arising from trial con-
duct (n=54) and other quantities (n=54).
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2.3.3 Barriers to the use of evidence synthesis methods
Figure 2.6 shows the barriers to using evidence synthesis, ordered by their perceived im-
portance. The bars show the total number of points awarded to each barrier, split by the
number of points it acquired by being ranked the first, second and third greatest barrier.
Of the 106 participants who were asked all questions on the survey, only 103 (97%) an-
swered questions on barriers to the use of evidence synthesis methods. 87% (90/103) of
respondents answered this question fully. By far the greatest perceived barrier was time
constraints. This was followed by a belief the trial was the first in the area, and a belief
that previous trials were different from the current trial. Of those selecting ‘Other’, rea-
sons included complexity of the trials and the “Chief Investigator had more evidence than
previously published information.” ‘Objections to using evidence syntheses (from you or
colleagues)’ was the lowest scoring barrier of those listed. The conclusions remained un-
changed when the analysis was restricted to statisticians only (data not shown).
2.4 Discussion
This survey had three aims: first, to summarise and contrast the use of evidence synthesis
methods to inform aspects of trial design; second, to summarise and contrast the use of
evidence synthesis methods to inform aspects of trial analysis and third, to understand
potential barriers to such use of evidence synthesis in both design and analysis. The key
findings and limitations are displayed in Figure 2.7 and now discussed.
2.4.1 Overview of key findings
Our INVEST survey indicates a high level of support for use of evidence synthesis to
inform aspects of trial design and analysis. Support was generally high for using a de-
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Figure 2.6: Barriers to the use of evidence synthesis (higher scores indicate greatest per-
ceived barriers). 3 points were assigned to the greatest barrier, 2 points to the second and
1 to the third. For example, 38 respondents ranked time constraints as the greatest barrier
(3 x 38 = 114 points), 21 ranked it second (2 x 21 = 42) and 11 third (1 x 11=11).
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scription of previous evidence, a systematic review or a meta-analysis when designing
a trial. Fewer respondents indicated support for use of NMA, decision models and VoI
analyses. Only a few respondents (approximately 5%) felt that external evidence about
particular parameters should not be used in the analysis of a trial, however many (up to
20%) did not know if such evidence should be used in practice. Our results indicate some
discrepancies between the evidence synthesis methods people think should be used and
what they are using in current practice. In particular, respondents did not appear to be us-
ing systematic reviews, meta-analyses, NMAs, decision models and VoI analyses as much
as they wanted across all aspects of trial design.
The greatest perceived barrier to using evidence synthesis methods in trial design or anal-
ysis was time constraints, followed by a belief the new trial was the first in the area. The
second biggest barrier of, ‘the first trial in this area’ seems a reasonable one, although, it
could still be possible to use evidence synthesis for some unknowns that go into design
considerations. One of the barriers to evidence synthesis methods in practice was “Chief
Investigator had more evidence than previously published information”. Arguably, this
may be true in some settings, in that pooling over a disparate set of studies may obscure
the key uncertainties.
2.4.2 Limitations
Of approximately 638 attendees of the conference, 106 (17%) completed the survey, half of
whom were statisticians. Some 95% of our sampling frame were from the UK and Republic
of Ireland, so the results may not be generalisable to the international clinical trials com-
munity. Although the support of evidence synthesis methods is more promising than we
may have initially thought it is likely that we sampled more methodologists than trialists.
Our sampling frame consisted of conference delegates closely involved in trial design and
analysis, who are likely to have a strong interest in promoting good practice. As such, we
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Figure 2.7: Key findings from the INVEST survey
Characteristics of the sampling frame
 Of approximately 638 attendees of the conference, 106 (17%) completed the sur-
vey, half of whom were statisticians.
 It is likely we sampled more methodologists than applied trialists, given the fo-
cus of the conference on trial methodology. Methodologists are likely to be more
supportive of more advanced methods, but their views could be quite different
from other trialists.
Aim 1: Evidence synthesis methods in trial design
 Support was generally high for using a description of previous evidence, a sys-
tematic review or a meta-analysis in trial design.
 Generally, respondents did not seem to be using evidence syntheses as often as
they felt they should. For example, only 50% (42/84 of relevant respondents) had
used a meta-analysis to inform whether a trial is needed compared with 74%
(62/84) indicating that this is desirable.
 Only 6% (5/81 relevant respondents) had used a VoI analysis to inform sample
size calculations versus 22% (18/81) indicating support for this.
Aim 2: Evidence synthesis methods in trial analysis
 Surprisingly large numbers of participants indicated support for and previous
use of evidence syntheses in trial analysis. For example, 79% (79/100) respon-
dents indicated that external information about the treatment effect should be
used to inform aspects of the analysis.
Aim 3: Barriers to the use of evidence synthesis methods in trial design and analysis
 The greatest perceived barrier to using evidence synthesis methods in trial design
or analysis was time constraints, followed by a belief the new trial was the first
in the area.
 Evidence syntheses can be resource-intensive, but their use in informing the de-
sign, conduct and analysis of clinical trials is widely considered desirable.
 We advocate additional research, training and investment in resources dedicated
to ways in which evidence syntheses can be undertaken more efficiently, offering
the potential for cost savings in the long term.
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might expect our sample to answer some of the questions more favourably than the wider
population of people involved in clinical trials. In particular, half of respondents were
statisticians (51%), who may be expected to be more open to advanced statistical methods
(such as using evidence syntheses to improve precision in estimates of some parameters)
compared with other contributors to the design, conduct, or delivery of trials. Statisticians
are also influential members of the multi-disciplinary teams that are involved in trial de-
sign and may be useful advocates for increased use of available evidence in trial design.
Although it would have been interesting to explore differences across research centres
and countries, we chose not to collect such geographical data to protect anonymity and
minimise the burden of survey completion.
The large proportions of respondents who indicated that they had either used evidence
synthesis to inform trial analysis or that they believed evidence synthesis should be used
in this way were surprising. Even more surprisingly, a sensitivity analysis including only
statisticians provided slightly lower estimates of these proportions, although the small
sample size precludes strong assertions. It is unlikely that these relatively advanced meth-
ods are being used so frequently in practice, we feel that it is likely the questions related
to trial analysis were misunderstood to mean the general use of previous evidence whilst
the intention had instead been to elicit views on the use of informative prior distribu-
tions in a Bayesian statistical framework. This explanation appears to be supported by the
result that fewer statisticians than non-statisticians claim to be using external evidence
in this way, i.e. it is likely that confusion about these questions was higher among non-
statisticians although there is no direct evidence of this. For example, respondents might
have interpreted the incorporation of ‘external information about the treatment effect (in-
cluding a meta-analysis)’ in trial analysis as meaning including the new trial results in
an updated meta-analysis. In order to gain feedback on the questions, the early versions
of the survey were piloted to colleagues known to the study team who had some in-
volvement in clinical trials. Although the survey was piloted, it is still possible there was
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ambiguity about how the questions regarding the use of external evidence to inform the
analysis stage of a trial were interpreted. Instead, examples of such uses may have been
more useful and helped to clarify that it was the more formal use of evidence synthesis
that we were interested in.
Since this was a paper and online survey, we ensured paper and online versions were
identical. In doing so, we allowed for missing data in the online survey to exactly match
the paper survey, rather than including missing data queries. It was also anonymous in
order to get participants to answer truthfully. As such, it was not possible to go back to ask
respondents how they had interpreted some questions. In the question regarding the use
of existing evidence to inform parameters in trial analysis, it was also not stated whether
the intention was as a primary or secondary analysis.
The question regarding the use of a systematic review or meta-analysis to inform a sam-
ple size calculation could instead indicate a variety of uses. For example, if a respondent
had ticked yes, it is not known how external evidence is being used. Informally, this may
include, justification for the choice of the effect size and standard deviation estimates,
or more, formally, translated external evidence into a prior distribution and used either
conditional or simulated power.
The use of decision models was low. A possible reason for this includes the way in which
the question was phrased. Decision models can only be used in trial design through VoI
analyses and have no other use. Therefore, having this as a separate option for decision
model and VoI analyses could have confused respondents.
To summarise the barriers to use of evidence synthesis, we assigned scores based on an
arbitrary assumption of linearity, i.e. such that an individual’s highest ranked barrier is 3
times as important as his/her third barrier. These scores, although helpful for summaris-
ing data, might not reflect respondents’ true views. We intended all listed barriers to be
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interpreted as reasons why a trial team might not seek or carry out evidence synthesis.
However, it is possible that some respondents who chose ‘Believed to be the first trial in
the area’ could have been thinking of the situation where a literature search or systematic
review reveals no previous trials. The extent of this barrier would then be over-estimated.
2.4.3 Comparison to recent reviews of evidence synthesis methods in trial design
The INVEST survey provides generally higher estimates of use of systematic reviews in
trial design than the recent review of Bhurke et al [57], with the exception of ‘justification
of the trial’ (Bhurke et al 94%, versus INVEST 73%). For example, 68% of our respon-
dents indicated that they had used a systematic review to inform choice of outcomes and
follow up time, whereas only 16% and 6% of trials reviewed by Bhurke et al had used a re-
view to inform these two aspects respectively. Similarly, 51% of our respondents said they
had used a systematic review to inform sample size calculations, seemingly in contrast to
Bhurke et al’s findings that only 9% of trials had used a review to inform the standard de-
viation and 3% to ‘estimate the difference to detect or margin of equivalence’. It is possible
that other trials in the Bhurke et al review relied on pilot trials to inform these parameters
[16, 17], while the INVEST results seem to suggest that relevant information will often
be available from evidence syntheses. However, the results are not directly comparable
since we asked respondents to consider all trials they had been involved in during the last
10 years whereas Bhurke et al investigated whether evidence synthesis had been used in
specific individual trials. On the other hand, Bhurke et al reviewed only publicly funded
(NIHR HTA) trials, while trialists attending ICTMC are likely to also participate in com-
pany funded trials, for which less justification is required and there is possibly a stronger
expectation for independently clear results.
In agreement with Bhurke et al we found that important barriers to the use of evidence
synthesis in practice include a new trial being the first in its area or being different from
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trials included in a previous review. However, by directly asking trialists instead of rely-
ing on documentation, we were able to see that the greatest barrier is time constraints.
In attempt to overcome the issue of time constraints when synthesising evidence, many
methods for rapid reviews have been proposed over recent years [89, 90]. Khangura et
al [90] developed their own eight step approach of conducting a rapid review having re-
viewed the current literature. Implementation of their approach in HTA trials has been
successful and can be applied to other types of trials [91]. However, more training on ap-
proximate methods and rapid reviews is needed to support their wider use in practice.
Investment in adequate resources and training at this stage could lead to cost savings in
the longer term, by reducing waste in research.
We found less support for the use of NMAs, decision models and VoI analyses in trial
design, which may be because they are more complex to conduct and require a higher
investment of time and expertise. These methods could further help inform decisions but
also require additional assumptions and ’a priori’ parameter estimates such as the cost-
effectiveness threshold and parameters related to structural uncertainties in the case of
VoI, which may not be available. A policy framework on when and how to perform such
analyses and how they are used could be a useful next step [53].
We also note that most individual trials investigate a specific research question for one
particular treatment: for example, in 2014, 80% of trials were still two arm trials [92]. In
contrast, NMAs, decision models and VoI analyses are commonly used to make decisions
and inform policy when there is a choice between a number of concurrent treatment op-
tions [93]. These methods could be considered less relevant in the design and analysis of
an individual two-armed trial. VoI analyses, in particular, are usually commissioned in
high value trials, often in situations with many treatments and uncertainty as to which is
best. However, a NMA could be more relevant to inform the interventions of a two arm
trial if used at the earlier part of the design process [49].
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Trial-based economic analyses are sometimes secondary to the clinical aspect rather than
being fully integrated within a trial design [54], meaning that the use of decision models
and VoI analyses to inform trial design can be limited. Only 6% (5/84) of our respondents
had used a VoI analysis to inform whether a trial is needed, although all of those who had
used a VoI analysis were in favour of its use more generally. Models in health economic
analyses are a strongly simplified representation of disease history and treatment effects
and are framed around a particular decision setting (e.g. UK) using setting-specific values
for healthcare use, costs and health benefits. These values may change over time and are
likely to be different in other settings. Streamlining of decision modelling and VoI analyses
would therefore be particularly challenging. Despite the assumptions and limitations of
a VoI analysis, its potential to guide the need for and the design of new studies warrant
its wider consideration and further development [94]. We explore a specific case of this in
Chapter 6 on the use of EVSI for sample size calculations.
We did not explore the views of funders or reviewers specifically, but this could be another
valuable avenue for future research, given the critical role they could play in minimising
research wastage.
2.5 Conclusions and rationale for remainder of thesis
The results of the survey highlighted that trial teams responding to the INVEST survey
at the ICTMC generally reported they are using evidence synthesis in trial design and
analysis more than we might have expected, but less than they might like to. This moti-
vates the need for methods development and guidance. Time constraints was identified
as the greatest barrier to more widespread use, so we discuss the practical implications of
implementing such methods throughout the remainder of this thesis.
In trial design, for both whether a trial was needed and for choosing an intervention,
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more respondents said that a systematic review, rather than a less formal description of
previous evidence, should be used. It therefore seems that respondents felt the need for
a thorough, systematic approach in order to show convincingly whether there is a gap in
the evidence base that merits a new trial. For the other aspects of trial design, there may
not be sufficient available evidence to warrant a systematic review, so that a less formal
description of previous evidence might be felt to be adequate.
It is likely that we sampled more methodologists than trialists, given the focus of the con-
ference. Methodologists are likely to be more supportive of such methods but unrepresen-
tative of trialists in general. Furthermore, it is likely the questions related to trial analysis
were not fully understood by respondents from this brief written survey. To address this,
a qualitative study is conducted in the next chapter to investigate more thoroughly how
trialists are currently using evidence synthesis to inform both design and analysis, and
the potential barriers to an increased amount of such use.
The survey also highlighted specific areas where trialists would like to be using more ev-
idence synthesis methods such as sample size calculations. This motivates Chapter 6 to
compare current methods of using the results of a meta-analysis to inform sample size
calculations. Together with further work in the following chapters, we will explore the
consideration of all relevant prior information, including the statistical and clinical rele-
vance.
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3 Eliciting current views and exploring barriers: a qualita-
tive study
This study was a collaboration with Daisy Elliott (DE), a qualitative researcher, and my
supervisors Hayley Jones (HJ) and Julian Higgins (JH). I was the lead investigator of the
study, forming the idea with HJ and JH and conducting all interviews and analyses.
3.1 Introduction
3.1.1 Context and objective
The results of the survey in the previous chapter indicated that approximately 50% of
those involved in trial analysis reported they had used evidence synthesis to inform at least
one area of the analysis [78]. However, we suspect the true proportion may be much lower.
Respondents may have either (i) answered the question more favourably because most
were methodologists rather than trialists or (ii) misinterpreted the question as referring to
the variety of different uses of evidence synthesis in a more informal manner (rather than
the use of informative priors, of which, the prevalence is low (see Section 1.4)), or both.
For example, respondents may have interpreted this as including the new trial results in
an updated meta-analysis rather than the more formal use of synthesising existing trials
in a Bayesian analysis.
Our aim in the survey had been to elicit views on how a synthesis of existing evidence
could be incorporated, for each of: (i) the treatment effect, (ii) potential biases, and (iii)
nuisance parameters. Interestingly, only about 5% of responders (n=5) felt that external
evidence should not be used in the analysis of a trial, however about 20% did not know
if such evidence should be used. In this chapter, we therefore undertake a qualitative
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study to explore the attitudes and experiences of trialists towards incorporating external
evidence, through the Bayesian design or analysis of a trial. Since there is less in the litera-
ture exploring the use of informative priors to inform the analysis stage [13], we focus more
on this than the design stage. This study builds upon our initial findings in the INVEST
survey, exploring the barriers to the use of informative priors, through semi-structured
interviews. Qualitative work can explore individuals’ views, attitudes and previous ex-
periences to allow an in-depth understanding on multi-faceted topics [75, 95, 96, 97, 98],
which may not be picked up in quantitative study designs, such as surveys.
We explore how external evidence could be useful to trialists; which types of external evi-
dence might be considered most relevant and what level of such use might be acceptable
in practice. A secondary aim of our study is to improve our understanding of how current
methodology is chosen; specifically, what kind of information informs this choice, and by
whom. We want to find the areas where external information could have the most benefit
over a frequentist analysis to minimise future research waste. We hope this will enable
recommendations to be made regarding the use of external evidence syntheses during the
design and analysis of clinical trials. We also hope to identify the research and/or training
needs to facilitate the incorporation of external evidence.
3.1.2 Background to qualitative research
In this section, a short overview of qualitative research is given. Two of the most com-
mon approaches to qualitative research are grounded theory (Glaser & Strauss [99]) and
thematic analysis [76]. A grounded theory approach is used when you have no precon-
ceptions about the data and a literature review is conducted after the data analysis. Con-
versely, in a thematic analysis a literature review is often conducted before any data collec-
tion.
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Within qualitative research, there are two different approaches which can be broadly cat-
egorised into an ’inductive’ and ’deductive’ approach. In an inductive approach patterns
are developed from the content of the data, whereas in a deductive approach patterns
from the data are driven by existing ideas. An inductive approach is usually preferred
as it shows findings have emerged analytically, thus reducing potential bias [76]. An in-
ductive approach is inherent in a grounded theory framework whilst a thematic analysis
can use either approach. Since we had some idea of the literature regarding the use of
evidence synthesis methods (Chapter 2) and the use of informative priors (or lack of) in
trial design and analysis (Section 1.4), a thematic analysis with an inductive approach was
conducted in the study and is described in more detail later on.
Prior to the analysis, eligible participants are sampled. Sampling in qualitative research
can be viewed as more flexible than in a quantitative framework. Some of the most com-
mon sampling methods in qualitative research are purposeful and snowball sampling.
Purposeful sampling is a sampling strategy which intends to recruit participants based on
particular characteristics of the eligibility criteria, in order to achieve variation between
respondents [100, 101]. Snowball sampling is a type of convenience sampling; often used
to improve recruitment by asking participants to suggest other people in similar job roles
[102]. It can therefore aid comparisons of similar or disparate views between such groups
of participants.
There are several data collection methods in qualitative research such as interviews, fo-
cus groups, observations etc. Each have their strengths and weaknesses and very much
dependent on the research question. For example, focus groups can be particularly use-
ful for gathering general opinions or beliefs and generating discussion amongst people,
whilst a disadvantage can be if there are particularly dominant or controversial views
others in the group could follow their opinions [103]. On the other hand, interviews are
advantageous when looking at the experiences and views of particular respondents. The
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interview process is usually ‘semi-structured’ meaning the interviewer has a list of topics
which they would like to be discussed with the participant [104]. These topics are usually
phrased as open-ended questions to allow a broad discussion of such topics and facilitate
and inductive approach. Conducting a semi-structured interview allows each participant
to be asked similar questions and aid comparison between individuals, whilst allowing
sufficient flexibility for discussion. A ’topic guide’ describing these questions/topics is
often used. It is common for the topic guide to be modified, with some questions added
or replaced as the study progresses. This may occur when relevant topics not originally
listed in the topic guide are raised in interviews and the researcher may want to raise the
topic in future interviews.
Braun and Clarke [76] describe a six-step approach to a thematic analysis. The first step
involves getting to know the data (i.e. interview transcripts) by reading and re-reading it
to get familiar with all aspects. Second, the researcher labels parts of the data which are
interesting and form part of an answer to the research question. These are known as codes.
Codes are generally short with an analytical meaning. As the analysis is often an iterative
process, these steps may taken for the first two to three interviews, and then the topic
guide modified if applicable and so on. Within this stage, specific codes can be refined
to support the same meaning, i.e. labelling relevant codes the same if the meaning is the
same across interviews. This can involve a process of ’constant comparison’ whereby the
researcher explores similarities and differences between interviewees [105].
The third step involves putting all the codes together from multiple interviews to see if
there are any emerging patterns, i.e. potential themes. Deviant cases can also emerge here,
whereby most interviewees or a subset of interviewees are broadly emerging to create a
theme whilst a minority of views seem to diverge from this.
The fourth step is a process in which potential themes are checked against the raw data.
This is an important step in which themes are often modified, merged or separated to tell
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the true story of the data [104]. The fifth step builds upon step four by defining and nam-
ing themes, ensuring each theme tells a story. This is generally where potential subthemes
emerge; subthemes can be more specific to some groups (or more general) but help to tell
the story of the overall theme. When no new key findings are emerging from new inter-
views, this is known as ’data saturation’ and determines the end of further data collection
[106]. Although this may be viewed as a subjective decision, data saturation is usually de-
termined when in the final two to three interviews no new concepts are added to the key
findings [107]. The final stage involves telling the overall story of the findings and putting
the findings in the context of other research.
Due to the subjective nature of qualitative research, it is likely the researcher brings their
own views and implicitly informs the research [77]. A reflexivity stance is often required
when discussing results to highlight the implications and impact the researcher’s views
can have on the results.
These qualitative approaches have previously been used to explore issues in evidence
synthesis methods. For example, a qualitative study by Lorenc et al explored the process
of how researchers dealt with issues relating to complex data in systematic reviews and
meta-analyses [108]. These authors used purposeful sampling to ensure a range of partic-
ipants’ views were explored amongst different fields. In general, the results consistently
highlighted a lack of consensus on which methods researchers felt they should be using to
deal with heterogeneity. Interestingly, many researchers were using their own judgement
to deal with this. Methods were therefore chosen based on their own experience, rather
than any methodological guidance. As such, the justification of these methods was often
not explicitly written in the end of study report.
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3.2 Methods
3.2.1 Recruitment and sampling (eligibility criteria)
We aimed to sample and interview a number of individuals working in clinical trials units
in England. Individuals were eligible for inclusion in this study if they were at least a
certain position but also had at least certain responsibilities. We aimed to sample a range of
individuals, across multiple locations, from the following positions: methods leads, lead
trial statisticians, trialists writing grant applications and leads of NIHR funded trials. Both
clinicians and statisticians were eligible to take part. We also selected participants whose
responsibilities broadly fell into one or more of the following categories: (i) conducting the
analysis of trials in practice (ii) planning such analysis and/or (iii) responsible for people
doing these things.
Individuals involved in developing evidence synthesis methods were excluded, for exam-
ple members of the evidence synthesis working group with the Medical Research Coun-
cil. Since we were recruiting individuals across various locations including some academic
ones, ethical approval was obtained by the University of Bristol on 27/04/2017 (Reference
number 48101). The consent form is shown in Figure A.2.
An initial list of potential participants was drawn up, based on connections members of
the study team had with colleagues working in trials. The lead researcher (GC) contacted
potential participants, via email, to explain the purpose of the study and ask whether
they were willing to take part in an interview. A participant information sheet was also
included to provide more detail about the study. This is shown in Figure A.3. Following
the initial list of participants drawn up, a combination of snowball [102] and purposeful
sampling [95] was used. Purposeful sampling was used to achieve maximum variation
between respondents, in which participants were sampled based on their position and
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responsibilities. Whilst snowball sampling was used to help aid recruitment. We asked
participants at the end of their interview if they could suggest anyone who they thought
may be suitable to take part in the study. The sampling strategy intended to recruit indi-
viduals who were at different stages of their career and also had differing roles within a
trials unit.
We did not specifically refer to Bayesian analysis in the participant information sheet, or
state that participants should have experience with Bayesian analysis, thus encouraging
a more diverse range of views from participants with different experiences and views.
Instead, the participant information sheet (Figure A.3) talked about exploring ’trialists’
views and experiences of analysing trials in the context of the wider evidence base.’ Re-
cruitment was driven by data saturation (whereby data collection continues until no new
themes emerged).
3.2.2 Data collection
Interviews were semi-structured. Topic guides were used to ensure similar areas were
covered in each interview, with sufficient flexibility to allow new issues of importance to
emerge [109]. The topic guide was initially developed with suggestions from all members
of the study team. An example topic guide is given in Figure A.4. There were two versions
of the topic guide; one for clinicians and the other for statisticians. These topic guides were
very similar, with some questions rephrased for clinicians to focus more on the conceptual
ideas of using previous evidence in different scenarios. For these differences, see Table A.1.
The topic guide was iteratively modified in light of previous interviews. This included
adding and rephrasing questions. For example, access to data and the issues surrounding
this became an emerging theme when discussing how these methods could be imple-
mented in practice. The following question was therefore added to both versions of the
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topic guide: “How would you access data needed [prompt: would such data need to be
collated by you or another colleague?]”. Each time the topic guide was modified, it was
saved as a new version. A log was kept of all amendments (Table A.2).
To meet our aim of understanding how analysis methods were chosen, we began the in-
terviews by trying to elicit which methods trialists were currently using and have used
throughout their career to analyse trials. We then explored the process of how previous
evidence was considered, when designing and analysing a trial. This included how ex-
ternal evidence was collected and synthesised. We then explored participants’ views and
experiences on the formal incorporation of existing data via a Bayesian analysis. As we
did not require participants to have any knowledge of Bayesian analysis, the essentials of
a Bayesian approach were explained to participants who did not have such understand-
ing. For example, I explained how a meta-analysis of results of a set of similar previous
trials could provide information on the likely size of the intervention effect in a new trial
and be explicitly incorporated with the data from the new trial. We also wanted to know
if participants knew of any colleagues using Bayesian analyses.
The latter part of the interview was used to examine hypothetical scenarios of how ex-
ternal evidence syntheses could be incorporated into a trial. This included our three case
study scenarios, external evidence on: bias from meta-analyses within meta-epidemiological
studies; effect sizes from trials within meta-analyses in sample size calculations and out-
comes from patients within trials to help inform adverse events. We also explored potential
barriers to implementing these methods in practice. At the end of the interview informa-
tion was collected regarding the participant’s demography: years in profession, type of
trials involved in, type of unit, affiliation, and university and their highest degree. Inter-




Interview recordings were transcribed verbatim whole to conduct a comprehensive anal-
ysis. Transcripts were analysed thematically and inductively by GC, using techniques of
constant comparison. The first three transcripts were analysed separately by GC to avoid
making any assumptions about potentially emerging themes. Following the first three in-
terviews, GC met with an experienced qualitative researcher (DE) and consolidated sev-
eral codes which captured the same idea into one.
Codes within transcripts were analytically summarised such that each code could be in-
terpreted on its own [76]. This involved detailed coding. For example, emerging themes
were compared with other codes across the dataset, to see if there were any shared or
disparate views amongst particular subgroups [110]. These subgroups included methods
leads, lead statisticians, trialists writing grant applications and NIHR leads and/or de-
pendent on their role responsibilities. As some trialists came from the same trials unit,
similarities and differences were also compared within trials units. If applicable, emerg-
ing themes were further sub-divided by type of characteristics [111]. Where applicable,
deviant cases were described at the end of the main theme [96]. The coding was conducted
using the qualitative data analysis software, NVivo (Version 11).
The initial coding was cross-checked by the qualitative researcher (DE) and discussed
with GC, with inconsistencies resolved by discussion. GC met with another member of
the study team (HJ) who is an expert in her field of evidence synthesis and trials, to double
code the first transcript. This involved HJ highlighting the key parts of the transcript, mak-
ing notes of any interesting points and summarising her key impressions of the data, with
four to six points of the key findings. Although it was expected that different labels/codes
would be assigned to parts of the transcript by GC and HJ, the overall meaning of the
code should be the same, i.e. this is a check of the reliability of coding. The overall mean-
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ing and interpretation of codes were similar, and any minor disparity was discussed until
there was consensus. For example, HJ analytically interpreted ‘Strong impression that it
would be hard to change practice – particularly to persuade people that using informative
priors at the analysis stage would be beneficial.” And GC had described this as “Would
have to convince a lot people to use previous information, formulated as a prior to inform
the current trial.” Although the meaning is the same, we discussed how best to articulate
this to ensure it was interpretable to someone with no previous knowledge in the field.
The final code was "Felt it would be hard to change practice and show it was beneficial to
use informative priors". In that time, we were happy that consistency in the interpretation
of the coding was reached.
The iterative process of identifying emerging themes was continued until saturation was
reached, i.e. until no new themes were emerging so that maximum variation within the
sample had been achieved. The first 13 interviews were coded in full; with each inter-
view analysed soon after it had taken place. After analysing the first 13 interviews, we
hypothesised that maximum variation had been reached [110]. Therefore, the last three
interviews were conducted to check that no new codes emerged which directly related to
the key findings. We report our study according to the consolidated criteria for reporting
qualitative research (COREQ) [112] and a summary table can be found in Table A.3.
3.3 Results
3.3.1 Participants
Among the 16 interviewees, three had a clinical background (two of which were Chief
Investigators) and 13 had a statistics background. 25% (4/16) had greater than 10 years’
experience working in trials. All had experience of working on RCTs. Most participants
had experience of working on observational studies, whilst only some had experience
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of working on feasibility studies (including pilot studies). Interviews lasted an average
of 54 minutes (range = 37 - 79 minutes). Table 3.1 provides participant and job-related
characteristics.
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P1 Trial statistician Conducting analysis of trials in practice 3.5 RCTs, feasibility studies,
primary & secondary care
MSc Statistics
P2 Senior statistician - Applied
Health Research
Lead trial statistician & writing grant applications 6 RCTs, observational stud-
ies, surgery
MSc Statistics
P3 Professor of Haematology Responsible for people planning/conducting the anal-
ysis of a clinical trial & lead of NIHR funded trials
>10 RCTs, FIH, translational
studies
PhD, Clinical
P4 Associate Professor (Reader)
of Population and Public
Health Sciences
Responsible for people planning/conducting the anal-
ysis of a clinical trial & lead of NIHR funded trials
>10 RCTs, feasibility studies PhD, Statistics
P5 Professor of Cardiac Surgery Responsible for people planning/conducting the anal-
ysis of a clinical trial & lead of NIHR funded trials
>10 RCTs, FIH, translational
studies
MD, Clinical
P6 Clinical PhD student Conducting analysis of trials in practice 5 RCTs PhD, Clinical
P7 Trial statistician Conducting analysis of trials in practice 5 RCTs, feasibility studies MSc Statistics
P8 Trial statistician Planning & conducting the analysis of a clinical trial 3.5 RCTs, feasibility studies PhD, Statistics
P9 Trial statistician Conducting analysis of trials in practice 3.5 RCTs, feasibility studies,
primary & secondary care
MSc Statistics
P10 Principle statistician Responsible for people planning/conducting the anal-
ysis of a clinical trial
>10 RCTs, feasibility studies MSc Statistics
P11 Senior statistician Planning & conducting the analysis of a clinical trial 7 RCTs, feasibility studies MSc Statistics
P12 Senior statistician Conducting analysis of trials in practice 4 RCTs, feasibility studies MSc Statistics
P13 NIHR Research Fellow Conducting analysis of trials in practice 0.5 RCTs, feasibility studies,
surgery
MSc Statistics
P14 Senior statistician Planning & conducting the analysis of a clinical trial &
writing grant applications









P16 Senior statistician, PhD stu-
dent
Conducting analysis of trials in practice 5 RCTs, feasibility studies MSc Statistics
RCT=Randomised Controlled Trial; NIHR=National Institute for Health Research; FIH=First-in-human. Locations were omitted to ensure anonymity.
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3.3.2 Key findings
We first describe the overall current practice of evidence synthesis methods in trials. We
then report the findings in four themes, displayed in Table 3.2. Each of the themes have
their own subthemes, supported by quotations.
Current practice of evidence synthesis methods
Consistent with the findings of our INVEST survey, we found participants, across all trials
units, were using existing evidence synthesis informally in a number of ways to inform
the design of a new trial. Uses of evidence included the justification of the new trial, the
choice of outcomes and parameters in sample size calculations.
The sourcing of previous evidence was often instigated by the clinician, who may for-
ward or share an existing systematic review with the study team. The evidence, usually
a systematic review, was typically being used to support the need for the trial and to
demonstrate equipoise in order to get funding for a trial, rather than to inform the design.
Ch inv, P5: “Obviously, there’s the evidence of equipoise. There’s the evidence
of the knowledge gap.”
Ch inv, P3: “And unless you can convince a funder or ethics committee of
equipoise to two treatment arms then you won’t get, you can’t do the study.
There’s got to be some sort of uncertainty.”
Many participants followed previous statistical analysis plans (SAPs) within their unit,
which were usually based on standard operating procedures (SOPs).
Senior stat, P12: “We all tend to work quite collaboratively so I think we quite
informally just run ideas past other people. I’m writing the SAP for [Study
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name omitted] which I know I should have my final version done already, but
completely I was looking at other people’s analysis”
We commonly found the statistical section in the protocol was written vaguely by the
senior statistician or methods lead, rather than the trial statistician or chief investigator.
The chief investigators’ then had some input into the analysis plan, often with the trial
statistician and the senior statistician, articulating the specifics of the research question.
Ch inv, P3: “And I’ve already had input into the statistical analysis plan. . .to the
extent that I’ve sat in front of the [senior statistician] and [trial statistician] I’ve
tried to articulate what the research question is. And the [senior statistician]
has translated into statistical language to explain to the [trial statistician].“
However, there was disparity between the two chief investigators’ in our sample in terms
of where responsibility ultimately lies, regarding which methods were used in the analy-
sis. Specifically, in relation to the statistics section in the protocol and the SAP.
Ch inv, P5: “. . . but I think it has to be set up by a statistician in terms of what
would be my qualifications to sign it off as it were.”
Ch inv, P3: “The ultimate responsibility has to be with the chief investigator for
all aspects of the study, that includes the analysis but obviously I’d be mad to
argue with the statistics team!”
Themes
We now describe our findings in four themes.
88
Table 3.2: Table summarising themes (and subthemes), supported by a quote
Themes/Subthemes Supporting quotes
Theme 1: Personal feelings
1a: Favour simplicity and stan-
dard statistical methods
Princ stat, P10: “It’s generally in a way just the simplest technique that
will get the job done and not overcomplicating it. Calculations get con-
fused enough as it is!“
1b: Lack of confidence in
Bayesian methods
Trial stat, P9: “It was a black-box moment of it went into the system
and came out and I didn’t really know what had gone on in between
[laughs]. Very bad statistician!”
1c: Relevance of prior data Trial stat, P9:”If you’ve got a few bad pennies in there that’s going to
make everything a bit skewed.”
1d: Lack of concern regarding
bias adjustment
Methods lead, P4: “If you’ve got a significant result the last thing you
want to do is talk it away!”
Theme 2: Perceived practical challenges of use
2a: Access to data Trial Stat, P8: “I suppose if there was, if there was consistency in the
way the studies were reported and there was a way, a simple way of
collecting all of the high-quality evidence together very quickly, then
that would obviously be a big help but yes, I suppose that’s a bit of a
pipe dream really.”
2b: Lack of roles/expertise
within the team to identify and
conduct a systematic review
Ch inv, P5: “One of the problems is there’s probably a shortage of
systematic review capacity. So, finding systematic reviewers is really
tough actually.”
2c: Aversion to software Methods lead, P4: “I think a lot of it is accessibility of the software
because Stata it’s just very straightforward, WinBUGS it’s not. So, I
think that’s a massive hurdle. If you could do it in Stata people would
probably do it.”
2d: Time and financial con-
straints
Ch inv, P3: “I’m trying to get funding for a study now to do this
comparison, I can’t easily spend loads of money having a statistician
spending ages trying to make a brilliantly efficient trial design...”
2e: No methodological guide-
lines
Trial stat, P8: “So, I think that would be a helpful if there was, I mean
certainly if there was some sort of guidance that had been produced
elsewhere.”
Theme 3: Concerns regarding acceptance of Bayesian methods in practice
3a: Concerned trials team would
not understand
Senior stat, P11: “I think actually clinicians and things are more famil-
iar with the frequentist approach rather than Bayesian and actually it
can be more difficult when you say, ‘I’ve used Bayesian methods’ and
they think ‘Oh, what have you done?’”
3b: Harder to publish Methods lead, P4: “Reviewers could be like ‘what on earth have you
done? I’ve worked in trials all my life and I’ve never done this.”
Theme 4: Perceived impact of making use of existing evidence
4a: Safety signals could be
picked up faster
Ch inv, P3: “So, we do you make use of it but obviously in a suboptimal
way and I can imagine that doing this kind of approach for adverse
events for example would offer greater safety and allow safety signal
to become obvious in my study earlier maybe so therefore better.”
4b: Powering a trial based on a
meta-analysis could be more ef-
ficient
Senior stat, P1: “You’re not gonna sort of waste time and money show-
ing an effect size in a single trial when you might be able to do it in
a combination with existing studies. I think that’s quite sensible, but I
guess it’s a case by case basis.”
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Theme 1: Personal feelings
This theme summarises how trialists chose which methods to analyse their trials with, in-
cluding their perceptions on using external evidence syntheses to inform these choices. We
found trialists were using standard statistical models (such as linear, logistic regression),
which they have always used. We also found they favoured simpler methods, rather than
methods they perceived to be more complicated. Some felt they were happy with how
they analysed trials in general. As such, participants felt that, if they were to bring in ex-
ternal information, they would need to know it was worthwhile. Many statisticians did
not feel confident in using Bayesian methods. External evidence, by definition, belongs to
someone else; a common finding with all participants was it can be difficult to trust such
evidence, with additional concerns it could bias their own trial results. Surprisingly, trial-
ists did not feel that their own trials were likely to be biased, even if some elements of the
trial design could not be implemented (such as blinding the outcome assessor). Instead,
they were happy to describe such trial design features as a limitation in the discussion,
rather than using any formal bias adjustment.
Subtheme 1a: Favour simplicity and standard statistical methods
We found relatively standard statistical models were used to analyse trials. For example,
logistic regression was used for binary outcomes, linear regression for continuous out-
comes and Cox regression for survival outcomes. When trials had repeated outcomes or
were part of a multicentre trial, many statisticians used mixed effect models to account for
the hierarchical nature of the data.
Senior stat, P2: “So, like logistic regression, linear regression. Erm mixed mod-
elling, survival analysis, usually just Cox regression.”
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Participants felt they wanted to analyse their trials using the simplest methods, and addi-
tionally using methods they had always used.
Princ stat, P10: “It’s generally in a way just the simplest technique that will get
the job done and not overcomplicating it. Calculations get confused enough as
it is! “
Some participants also believed there was nothing wrong with current methods and would
need to see a big enough motivating example to suggest otherwise.
Clinical PhD student, P6: “I guess you’ve got to start off with what’s the prob-
lem with the current methods and is there a problem with the current statistical
methods we’re using and what is the problem and how big is that problem and
do we need to change our methods because of that problem. The current meth-
ods, analysis methods, seem to be pretty robust.”
Subtheme 1b: Lack of confidence in Bayesian methods
We found that statisticians (across all years of experience) had a negative perception of
Bayesian methods. We found this was commonly a combination of generally not liking
Bayesian methods and not feeling comfortable conducting such analyses. The latter of
which could be attributed to a lack of confidence but also a lack of expertise if they have
not been taught Bayesian methods.
Senior stat, P11: “I personally don’t go anywhere near them. I think I did do
a course in Bayesian stuff, but I just don’t think I work that way and I don’t
feel comfortable using Bayesian methodology, so I personally would shy away
from it.”
Possible reasons for not feeling confident in Bayesian methods could be not having the
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understanding or skill set through a lack of education or experience.
Trial stat, P9: “It was a black-box moment of it went into the system and came
out and I didn’t really know what had gone on in between [laughs]. Very bad
statistician!”
Participants later in their career and more senior tended to have stronger opinions on the
use of Bayesian methods, which were mainly negative when initially asked.
Methods lead, P4: “I guess it’s not the standard thing to do and not what I’ve
been taught - or still teach my students to do [laughter] – and generally don’t
. . . unless I’m doing a mixed-treatment comparison I try, and steer clear of
Bayesian methods [laughs] at all costs!”
BRI007, Senior stat, P12: “I don’t know anything about Bayesian methods.”
Clinicians were equally rather hesitant to the use such statistics.
Ch Inv, P5: “Are you creating some sort of Bayesian statistic? ... Yeah, so I don’t
understand about that.”
Ch Inv, P3: “I have to be honest with you. . . virtually zero.”
We therefore found trials were not analysed in a Bayesian framework and subsequently
external information was not incorporated through informative priors. Most participants
were not aware of colleagues using Bayesian methods either.
In relation to one of our three case studies: many participants did not want to do any
formal bias adjustment (described in Subtheme 1d). A potential reason for this stemmed
from a lack of confidence and understanding in meta-epidemiological methods.
Trial stat, P8: “I’d need to have a much deeper understanding I think of how
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those adjustments work in order to do it.”
However, one statistician (a deviant case) was in favour of using bias adjustment, provid-
ing they were able to understand the method more. We found a lack of understanding
in meta-epidemiological methods for bias adjustment amongst those who were more in
favour of bias adjustment, and interpreting trial results in light of potential limitations.
Trial stat, P9: “If I was confident in the methods... as you’re saying it right
now, my head is blown by the idea, but if I knew the methods well enough,
definitely, because it sounds like something that would... I’d somehow be able
to take into account that impact.”
Subtheme 1c: Relevance of prior data
A lot of the concerns about formal use of existing evidence in a Bayesian framework sur-
rounded trust in the data; from how different the population of the external data was to
the trial population and whether such evidence would introduce bias into their trial. Many
mentioned they were not sure how relevant external data are to their trial population.
Senior stat, P11: “I am always a bit uncertain with meta-analysis about how
you can group together different trials because they are different trials. They
don’t use the same patient groups and there are different intricacies in there.”
Trial stat, P9: ”If you’ve got a few bad pennies in there that’s going to make
everything a bit skewed.”
Others felt this would also mean making extra assumptions above those made by the
standard methods, particularly around how external data was collated, assessed for bias
and its applicability to their trial.
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Methods lead, P4: “I think it opens a big can of worms that isn’t open if you
just do a frequentist analysis like you’ve always done.”
Some participants also felt that a new trial should be analysed in isolation rather than
being combined or mixed with existing data.
Senior stat, P12: “I think I’m not by nature a Bayesian, so I would tend to be
more on the no, let’s just go in fresh and see, especially if you’re doing a big
trial and you can kind of say but yeah, all sorts of things have changed.”
There were also major concerns about how relevant the existing data in meta-epidemiological
studies, or any study, is to tell them how biased their result could be. There were specific
concerns expressed about how use of such studies would affect the interpretation of the
trial results.
Trial stat, P8: “I don’t know but whether it would plague the interpretation of
the results making it more difficult for people reading it to understand what
was actually going on. Yes, I’d be a bit cautious I think about that”
Subtheme 1d: Lack of concern regarding bias adjustment
We found that trials being at RoB from lack of blinding or inadequate allocation conceal-
ment was not a concern to most trialists. In general, most statisticians did not worry about
whether a trial was biased.
GC: “Yeah, so do you think if the patients are aware of the treatment that
they’re receiving, do you think that could potentially bias the treatment ef-
fect?”
Senior stat, P1: “Yes, I suppose it can do but I’ve never been particularly wor-
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ried about it.”
Senior stat, P12: “I think nobody in a trial is trying to be unblinded or is trying
to cheat. I think you have to work from that but there’s unconscious bias.”
If a trialist thought their trial was at a potentially high RoB or there were potential design
limitations, they often reported this as a limitation in the discussion with no quantification
of how this may affect the results.
Ch Inv, P3: “So it’s absolutely critical to report that as a potential source of
bias. And as far as I know all you can say is, is this potential source of bias
means...well sometimes you can predict the potential direction of bias I guess
but not always.”
Senior stat, P1: “I haven’t done it, not thought about it or even something we
discuss as being potentially biased, just see it as a limitation.”
Many participants (including both chief investigators) believed they would not get fund-
ing for a trial unless they either ran a trial with all aspects of methodological components
fulfilled, such as adequate allocation concealment etc, or they had a very good reason why
it was not possible.
Ch Inv, P3: “You have to have a compelling case and if it’s pretty obvious that
in your design when someone reviews your funding application that implicit
in your trial there’s going to be a significant chance of bias then they’ll just say,
‘sorry there’s got to be a better way of doing it’.”
Senior stat, P2: “I guess in more recent, I guess quite often in trials I feel like
they might not actually get accepted by funding bodies if they aren’t able to
blind people or they don’t have an objective outcome and aren’t blinded.”
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The aim of ‘meta-epidemiology’ is to learn about average bias across many trials and the
amount of variability in that bias. However, this was something many participants had not
heard of before, and many did not think it that bias adjustment of results was something
they would do in practice. Even in a scenario where a trialist has got a significant result
in their analysis which was subject to methodological limitations, bias adjustment is not a
consideration.
Methods lead, P4: “If you’ve got a significant result the last thing you want to
do is talk it away!”
Theme 2: Perceived practical challenges of uses
Following on from theme 1, which looked more at an individual’s perception, theme 2
summarises the practical challenges participants felt they (and/or the wider trials unit)
would face if they wanted to formally incorporate external evidence, in practice. One of
the most common issues surrounded the logistics of accessing external data and the corre-
sponding consideration of anonymisation. A systematic review was seen as one the most
obvious ways to access multiple data sources. However, almost all of the trials units in this
study did not have direct access to a systematic review team. Many participants viewed
systematic reviewers as having a different skill set to most trialists. Many felt even if they
had access to the data, they would then have to learn Bayesian software and therefore
worried about the extra time and financial pressures this could have. It was frequently
brought up that, in order for these methods to be used in practice, there would need to be
guidelines and/or requirements to use such methods by funders.
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Subtheme 2a: Access to data
The majority of participants mentioned there was no single repository whereby individual
patient data is accessible. However, there is a shift in terms of trying to get individual
patient data shared across institutions [113, 114].
Trial stat, P8: “I suppose if there was, if there was consistency in the way the
studies were reported and there was a way, a simple way of collecting all of
the high-quality evidence together very quickly, then that would obviously be
a big help but yes, I suppose that’s a bit of a pipe dream really.”
Senior stat, P11: “I think I’ve heard it talked about the trial in a certain area you
always collect certain variables and then those variables could be uploaded
to a dataset and then it actually creates a big one. Everyone’s trial data gets
compiled together and then you do have a big database that you could then
use to inform sample size calculations and other things like that.”
Furthermore, more senior members recognised that access to a pooled repository of mul-
tiple data sources can bring its own challenges such as making sure data are anonymised.
Princ stat, P10: “If it’s publicly funded you need to make the data available
and that seems reasonable but there’s still always an administrative exercise
in getting through approvals and getting that and for somebody to create a
dataset that can be shared without risking identifiable data and stuff.”
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Subtheme 2b: Lack of roles/expertise within the team to identify and conduct a system-
atic review
One of the main sources of existing evidence is a systematic review. However, the majority
of trials units were not integrated with a systematic reviews team. As such, there was typ-
ically no individual responsible for identifying or performing systematic reviews within
the clinical trials team.
Ch Inv, P5: “One of the problems is there’s probably a shortage of systematic
review capacity. So, finding systematic reviewers is really tough actually.”
In situations where systematic reviews were identified, they often came from the chief
investigator to support the case for funding. Less senior members of trials units (such as
trial statisticians) often relied on the clinician having used previous evidence to inform
the design stage, rather than look for evidence themselves.
Trial Stat, P8: “Yes so this is kind of. . . my only experience of using sort of raw
data to inform the design of the study and on one case. . . in one case it was –
there was a lot of quite, you know, high quality, detailed data that was sourced
from one centre so it happened to be the one that the clinician was. . . where
they were based and so then that was used in order to try and inform the
parameters of the sample size calculations that we were doing and that was an
example.”
Subtheme 2c: Aversion to software
One of the most common issues that prevented trialists from analysing their trial in a
Bayesian framework was Bayesian software. Although there are some Bayesian packages
in Stata and SAS, most participants seemed unaware of this.
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Methods lead, P4: “I think a lot of it is accessibility of the software because Stata
it’s just very straightforward, WinBUGS it’s not. So, I think that’s a massive
hurdle. If you could do it in Stata people would probably do it.”
Princ stat, P10: "It’s also about software and knowing how to implement it even
if you wanted to.”
Some participants who had experience of using a wholly Bayesian software package, Win-
BUGS, were unsatisfied with its interface.
Research fellow, P13: “Not a fan and not a fan of their messages. So many
pitfalls because you could have those issues of non-convergence. . . WinBUGS,
first of all it’s been developed by academics so they’re not really looking for
profit, so you don’t have the same amount of time. You can see in the result of
Bugs; the user interface is really poor.”
Subtheme 2d: Time and financial constraints
Several participants discussed how external pressures can impact the time they have to
spend assessing the quality of external evidence and its relevance to their trial. Even when
not explicitly incorporating external data, the majority did not find it easy to access it,
summarise and justify its use in current practice.
Methods lead, P4: “If we’re designing a trial that’s using something else, I can
spend a long time thinking about how we justify and looking for papers to try
and justify the sample size.”
More senior trial members, such as the chief investigator and methods leads, identified
concerns regarding how much extra time would be needed to implement Bayesian meth-
ods, and the implicit costs associated with this.
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Ch Inv, P3: “I’m trying to get funding for a study now to do this comparison, I
can’t easily spend loads of money having a statistician spending ages trying to
make a brilliantly efficient trial design. That will obviously make my applica-
tion better but it’s having some resource to do that first. Finding a trial where
it works and then one that does – oh yes, we’ll use that – already spent tens of
thousands of pounds on salaries and time of a statistician”
Trial statisticians also felt the pressures of not having enough time to think about using
new methods and implementing them.
Senior stat, P12: “I think the truth is as well I’m so busy at work and under
such time pressures there’s times when I’ve not felt like what I’ve done has
been wrong, but I’ve thought, do you know what, I haven’t got the time. I don’t
feel I’ve got the time and it’s usually you’re forced to do it because somebody’s
kicked up a fuss.”
Subtheme 2e: Lack of methodological guidelines
Traditionally, trialists use the Consolidated Standards of Reporting Trials (CONSORT)
guidelines to determine what should and should not be reported. As more assumptions
are made in a Bayesian analysis about the external evidence and model assumptions, some
felt they would not know how to report such an analysis.
Methods lead, P4: “Yeah, and I guess when you’re putting a trial together,
you’d follow the CONSORT guidelines whereas there might be additional stuff
that really should be in the paper that maybe you wouldn’t know to put. I don’t
know. I wouldn’t be as clear what to include and what not to include”
To increase the uptake of these methods in practice, (in particular using external evidence
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to inform adverse event rates and sample size calculations) trialists felt methodological
guidelines were needed with clear case studies.
Trial stat, P8: “So, I think that would be a helpful if there was, I mean certainly
if there was some sort of guidance that had been produced elsewhere.”
Research fellow, P13: “So one thing I can say about Bayesian is you do find
some material, but you don’t find a lot of ways to apply it really hands on”.
Theme 3: Concerns regarding acceptance of Bayesian methods in practice
The use of Bayesian methods, with its inherent summarising of prior information and
combining this information with the results of the current trial, has long been debated
in the literature. Theme 3 summarises concerns about such methods being accepted in
practice. Many trialists think chief investigators, who ultimately sign off the analysis plan,
would not understand Bayesian methods, and moreover, would not encourage their use.
Since Bayesian analyses of trials are rarely seen in journals, some also thought publishing
a Bayesian analysis could be problematic.
Subtheme 3a: Concern that trials team would not understand
Most statisticians were concerned about whether the trial team, and in particular the chief
investigators and clinicians, would understand these methods.
Senior stat, P11: “I think actually clinicians and things are more familiar with
the frequentist approach rather than Bayesian and actually it can be more dif-
ficult when you say, ‘I’ve used Bayesian methods’ and they think ‘Oh, what
have you done?’”
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Senior stat, P1: “They don’t understand it [chief investigator] I think we’re get-
ting to the point where people generally understand a treatment effect and a
confidence interval and that’s fine. If we start adding all these other things in,
they’re going to be like okay, too much variability, why is there so much vari-
ability?”
When the clinicians were asked about Bayesian methods, their initial response did match
the statisticians’ perceptions.
Ch Inv, P3: “This is kind of universes apart from what most clinicians would
understand. It’s totally different and I’ve got colleagues who do RCTs and com-
pare treatment A vs B and don’t give this a second thought.”
Ch Inv, P5: “Are you creating some sort of Bayesian statistic? ... Yeah, so I don’t
understand about that.”
Subtheme 3b: Harder to publish
Some senior statisticians (and in particular methods leads) were concerned that if Bayesian
methods were used, it would make it much harder to publish their trials.
Methods lead, P4: “Whether it would be accepted by decision makers. I guess
if you’re doing anything that’s not the norm, you’d just be a bit scared, even
getting it published. Reviewers could be like ‘what on earth have you done?
I’ve worked in trials all my life and I’ve never done this.”
Some also thought there could be an issue with ethics, which could be a potential barrier
to these methods being used in practice.
Trial stat, P9: “I think it’s an interesting idea. I don’t know how you’d get the, I
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guess the approval for doing such a thing, like ethics, I can imagine you might
have an issue with.”
Theme 4: Perceived impact of making use of existing evidence
We have seen the potential barriers in themes 1-3, but there were also lots of enthusiasm
about making more use of existing data from many trialists. Many participants felt they
could make much more use of existing data, in particular aspects of trials. These aspects
included making more use of existing safety data, so that rare events could be picked up
faster, and powering a trial to update the existing evidence base to have a bigger impact
on changes to practice/policy.
Other participants, who were initially hesitant, could also appreciate the value that a
Bayesian framework allows for the incorporation of previous evidence. They also saw
a possible ethical impact of evidence by potentially influencing the initiation of new trials.
Senior stat, P12: “Well it’s the whole ethical thing isn’t it of doing further trials
when you already know the answer or it’s just putting it in the wider context
isn’t it so yeah, it’s sort of downgrading or upgrading whatever you’ve found
in the wider context.”
Furthermore, many participants, acknowledged they were already using existing evi-
dence, but not in a Bayesian framework.
Senior stat, P12: “I suppose it’s something that people do informally but not in
a structured Bayesian [way]. I think that’s what’s true.”
Many thought that making more use of existing data was advantageous, as a lot of time
and money is invested in trials, for the information collected not to be used again.
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Senior stat, P1: “We don’t want to do a trial that wastes a) time and b) money
so if we had existing evidence which would cut down time and money then I
think we should do it to start with.”
Subtheme 4a: Safety signals could be picked up faster
Participants from all trials units remarked that adverse events were typically summarised
descriptively because the control arm did not have an adequate response rate i.e. events
were rare. This meant, due to low event rates, the response rate in the experimental arm
could not be statistically compared to the response rate in the control arm. Most trials
units were therefore led by the clinician or chief investigator to list the adverse events
and then rely on their experience to identify a potential safety concern. There was also no
mention of using specific expected rates from external evidence to inform trialists of the
population adverse event rate if there have been lots of other studies looking at the same
control intervention.
This generally involved listing the expected and unexpected events, based on a chief in-
vestigator’s personal experience, with no mention to specific expected rates based on any
external evidence, such as similar studies.
Senior stat, P2: “So, I think you always have the rule that if there was less than
10 events, then we just present them as counts, so present how many occurred
in each group and not do any formal analysis.”
Trial stat, P9: “Me personally, I only get given a list... I hope that when I create
the table of expected events and then I say, ‘Oh, five people experienced this,’
that the clinicians within the trial team would then say, ‘Ooh, that’s a bit high.’”
Most participants acknowledged that describing adverse events and relying on the clin-
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ician or data monitoring committee (DMC) to identify anything unexpected, may not be
the best way of doing it.
Princ stat, P10: “I rely on the DMC quite a lot basically. I don’t think we’ve got
good methods for looking at adverse event rates really. It’s often just listings
or tabulations.”
When asked about their views on using existing data in a similar population to predict
what the expected adverse event rate would be in the control arm, many thought this was
a good idea. Clinicians and senior statisticians thought this would allow safety signals to
be picked up faster.
Ch Inv, P3: “So, we do make use of it but obviously in a suboptimal way and
I can imagine that doing this kind of approach for adverse events for example
would offer greater safety would allow safety signal to become obvious in my
study earlier maybe so therefore better.”
Trial stat, P9: “No, I never have, but now you’ve said it, it seems like such an
obvious tool, it should exist [laughs].”
Senior stat, P12: “I think if I’m totally honest I don’t think it had occurred to me
to think about doing it and now I can completely see the motivation for doing
it. It’s finding the time and prioritising as well”
Subtheme 4b: Powering a trial based on a meta-analysis could be more efficient
The concept of using an existing meta-analysis to power a new trial, based on its ability
to impact an existing meta-analysis, was unfamiliar to all participants. Traditionally, the
sample size for a new trial is calculated without explicitly incorporating existing evidence.
In current practice existing evidence from the literature might instead be used to provide
105
information on the likely event rate in the control group or the between-person standard
deviation in outcome measurements. The key assumption here is they are not based on
the idea that the trial will be analysed or interpreted together with others. However, the
evidence base in its entirety is commonly what impacts on policy and/or clinical prac-
tice. Therefore, the meta-analysis rather than the trial might be considered to be what is of
most interest. Multiple researchers, primarily methodologists [6, 73, 74] have suggested it
may be beneficial to conduct a meta-analysis of previous evidence and work out what a
new trial would need to show in order to demonstrate an intervention is effective. Hav-
ing briefly explained to participants that it is possible to power a new trial based on an
existing meta-analysis, the majority saw this as an advantage. Many thought it was a very
attractive idea and could make the trial more efficient. Many also recognised that they did
have some idea about the potential effect from a previous meta-analysis.
Senior stat, P1: “You’re not gonna sort of waste time and money showing an
effect size in a single trial when you might be able to do it in a combination
with existing studies. I think that’s quite sensible, but I guess it’s a case by case
basis.”
Methods lead, P4: “The body of evidence [meta-analysis] is going to change
practice. I guess then I can see that taking into account prior evidence might
be a good thing to do.”
There were, however, reservations about powering trials based on an existing meta-analysis.
Some participants felt they would only do this as part of a sensitivity analysis to see how
much the sample size would differ.
Methods lead, P4: “Equally I’m not sure. Still I think I’d prefer just to do a
meta-analysis afterwards I think.”
Princ stat, P10: “As I say, I think I’d be a bit reluctant that that was my main
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analysis or that that was the only analysis, but I think as part of a sensitivity
analysis or something that’s probably a good way of looking at it.”
Others thought an integral part of the trial results was to publish them in isolation, with-
out any form of Bayesian analysis or statistical incorporation of existing evidence.
Ch Inv, P6: “I think it will still, at least for the participants and all the staff
involved, we still deserve to have the results published in isolation as that in-
dividual trial”.
Others thought there could be potential to recruit fewer patients, which would also make
the trial cheaper.
Ch Inv, P3: “. . . because that means you can deliver a much bigger study or a
more cheaper study of more patients faster and that’s better for everyone.”
Trial stat, P8: “I think it’s quite sensible probably to power it based on you
know making a change to that if it means that you, you know, you’re gonna
recruit less participants.”
3.4 Discussion
3.4.1 Overview of key findings
A key finding of this qualitative study was that Bayesian methods, and therefore infor-
mative priors, were not used in practice by the interviewees. Most were not aware of
colleagues using them either. Many barriers to explicitly using external data in trials were
practical, but there was also an important concern that these methods would not be ac-
cepted by researchers in the field, or ethics boards.
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One of the key practical concerns was the lack of infrastructure most trials units have to
access external sources of data. In particular, many of the trials units in this study did not
have an integrated systematic review team. Participants also raised the practical issue that
it is not easy to use Bayesian software. Inherently, there could be a steep learning curve in
implementing these methods in practice. This may include the extra work it would take
to synthesise external prior data and subsequently model it; which intrinsically has time
and financial burdens.
The concerns about the lack of acceptance of Bayesian methods in trials arose from its
negative perceptions amongst researchers and the wider trials community such as edi-
tors and ethics boards. There was an additional fear that it would be harder to publish
these methods within the clinical trials community. Because of these perceived issues, we
found trialists had an internal discomfort about formally incorporating external data with
their own trial data. This included a lack of confidence to implement Bayesian methods,
concerns over relevance of the prior data and favouring simpler, standard methods.
Although there were many concerns, participants still thought they could be making more
use of existing data. Participants felt there could be positive clinical implications for in-
forming safety decisions. Rather than relying on what the clinicians says (which is often
based on their personal experience), the adverse event rate would be informed by previ-
ous studies and ideally an evidence based synthesis. Although explicitly using an existing
meta-analysis to inform a new trial by actually powering the trial based on its ability to
impact on the meta-analysis was unfamiliar to all participants, many thought it was a
good idea. A potential advantage was that it could be possible to recruit fewer patients,
making the trial cheaper. For some, this raised concerns about ethics, but others thought
the possibility to recruit fewer people was an advantage. Many also said it was multiple
trials, rather than an individual trial, that changes policies. If these methods were to be
used routinely in practice, there were calls for methodological guidelines [115].
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3.4.2 Reflexivity
In qualitative research, the results are inherently and indirectly influenced by the views of
the researcher who conducts the study [96]. In this study, part of the sample we targeted
were trial statisticians. Having worked as a trial statistician for two years before start-
ing my PhD, it is possible my own views could have influenced the results. In the first
two interviews of statisticians, I felt they did not elaborate on some statistical methods,
potentially knowing that I realised what they meant. For this reason, I tried to keep the
questions as open ended as possible and used probing questions to ask what they meant
by certain things to gain a deeper understanding. When meeting participants, one of the
first questions they would ask was about my PhD (closely related to the aims of the study)
which could force my views onto them. I therefore decided not to tell participants about
my PhD at the start, so that their views (positive or negative) were completely their own.
Interviewing people for the first time was strange in the beginning as I wanted to agree
with what they were saying and/or give my opinion. I had tried to prepare myself for this,
but it was a lot more difficult in reality. After the first few interviews, I tried to speak less
and appear that I was listening without giving any encouragement. Although, initially
I found silences daunting, I learnt these periods meant participants were thinking and
they often then gave more elaborate responses. Feeling more comfortable with silences
and asking statisticians to elaborate on methods, allowed the data to be richer and for
participants to elaborate on points without prompts.
3.4.3 Methodological strengths
Interviews were inductive rather than deductive; this was achieved by keeping the ques-
tions open ended. The topic guide was adapted when new themes were emerging in order
to explore potential new areas which we had not thought of. Therefore, the flexibility in
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the topic guide allowed new themes to develop.
We did not use the term ’Bayesian’ in the information sheet, instead referring to ‘existing
evidence’ (see Section 3.2 for more detail). By not using ’Bayesian’ at any point prior to
the interview, this meant participants did not have any preconceived ideas before the
interview. It also helped ensure a range of participants were in the sample, making it as
diverse as possible.
3.4.4 Limitations
In any qualitative study, it is possible that maximum variation within the sample was not
reached [76]. In our sample, only three clinicians were included. This was in part due to
the individuals who we wanted to recruit, as methods leads and NIHR leads were more
likely to have a statistical background rather than a clinical background.
Snowball sampling was used to identify new participants after initial key contacts in each
group were sampled from colleagues known to the study team. This has the potential to
bias the final sample by affecting how diverse the participants are in general and across
potential subgroups. However, following snowball and purposeful sampling, we sampled
from each group of our intended population. There was also only one person who said
they would like to take part but then could not find time. Furthermore, no one dropped
out, which reduces potential bias in the final sample of participants.
As the term ‘Bayesian’ was not used in the participant information sheet, it is possible
that we missed people who had a potentially strong view on such methods. However,
this term was purposely avoided as we were trying to get a range of participants without
any preconceived views. It is also a finding in itself that there were numerous trialists,
in multiple locations, who were not using Bayesian methods in trials units. Furthermore,
the potential barriers to these methods were explored in further detail and, again, form a
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major part of the findings.
3.4.5 Relevance of this study in relation to other studies
Unsurprisingly, one of the key findings of the study related to the ‘relevance of prior in-
formation’ which is one of the most discussed areas of Bayesian analysis [116]. This key
finding is also consistent with our INVEST survey [78] which found two of the top three
barriers were ‘First trial in area’ and ‘Previous trials different’. In the INVEST survey, we
also found ‘time constraints’ was the biggest barrier to the use of existing evidence across
both the design and analysis of trials. Although we did not identify time constraints as
an overarching theme in this study, this issue was implied as one of the practical chal-
lenges to using external evidence in trials in Theme 2. A more detailed exploration in our
study revealed the extra time needed to conduct a systematic review (given that system-
atic review teams are often not integrated into clinical trial teams) was a concern. We also
found trialists found it difficult to access and collate other external data, either aggregate
or IPD. Our study found there was an additional time aspect for statisticians to learn new
methods and software, such as WinBUGS.
Lilford [117] argues the assumption of equipoise in RCTs is misleading to the patients be-
ing invited to participate in a new trial. This is particularly so because, more often than
not, some evidence exists before an RCT either on similar treatments in the same disease
area or the same treatments in other disease areas. Lilford therefore contends that the
wording of equipoise in patient leaflets, as suggested by Donovan et al [118], is mislead-
ing, because it is quite likely that we do know something about different subgroups from
previous ‘similar’ studies. The finding of our qualitative study is consistent with this: tri-
alists recognised that they did have some idea about the potential effect from a previous
meta-analysis and it is the accumulation of evidence that is likely to change practice:
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Methods lead, P4: “The body of evidence [meta-analysis] is going to change
practice. I guess then I can see that taking into account prior evidence might
be a good thing to do.”
However, they did not explicitly incorporate this information into the trial design or anal-
ysis.
Brocklehurst et al [30] describe their experience of stopping a large trial because of emerg-
ing external evidence. The authors concluded that it remains unclear how trial investiga-
tors should consider external evidence during a trial and subsequently make decisions
regarding whether future recruitment should continue, stop, or be reduced. Our study
appears consistent with Brocklehurst et al [30] in the overarching finding that it remains
unclear to trialists (including investigators) the process by which external evidence should
be considered, and at precisely which stages of a trial. For example, when given the hypo-
thetical scenario of using external evidence to inform adverse event rates, it was unclear
to our participants where the data would come from, how it would be synthesised, how
to determine its relevance to their trial, and how to incorporate it statistically.
3.4.6 Implications for future research
The main implications based on the key findings are displayed in Figure 3.1.
Our study showed that trialists favour simplicity in their analyses. We therefore need real
world examples or case studies to convince trialists these methods are worth the extra
time to invest in learning and implementing them in potentially new software. Many is-
sues were related to the fact that WinBUGS is the main tool for Bayesian analysis whereas
most trials units use Stata or SAS. This is a problem, but more Bayesian techniques are be-
ing implemented in Stata. Furthermore, most funders and the Medicines and Healthcare
products Regulatory Agency require software to be validated, which calls for recommen-
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Figure 3.1: Implications for further research based on key findings
Implication 1: Real world examples or case studies are needed to motivate scenarios
in which external data might be used in trial analyses: specifically, for (i) safety signals
and (ii) powering a trial based on an existing meta-analysis.
Implication 2: Analyses that incorporate external evidence need it to be implemented
in software that is commonly used and validated.
Implication 3: Methodological guidelines are needed in order to guide statisticians as
to the necessary steps one should take and consider in incorporating external evidence
into trial analyses.
Implication 4: There is a need to improve access to existing data that might inform trial
analyses; and for further encouragement to trials units to make their data available in
databases or data platforms.
dations to build upon existing Bayesian software in Stata. Ultimately, real word examples
and case studies showing potential gains over current methods in a more user-friendly
software should be developed.
The use of informative priors in sample size calculations and using evidence synthesis
methods for rare events was perceived as attractive. It was these aspects of a trial where
most trialists thought improvements could be made to current methods. One of the poten-
tial reasons external evidence has not been used to inform adverse event rates routinely
is that there is less of a concern about safety in phase III trials, as opposed to early phase
trials. In cases where event rates are low in the control arm is inadequate, it may be useful
to use evidence-based models rather than relying on clinicians for these rates.
In relation to sample size calculations, it may not always be appropriate or possible to
power a trial based on an existing meta-analysis, but the option could be explored during
the design stage. If it is not possible, for example because the intervention is sufficiently
different, or the research question is different, then this should be made clear. This may
call for transparency on how evidence synthesis has been used.
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We found that statisticians across all levels do not feel confident applying Bayesian meth-
ods; and in particular the extra assumptions that have to be made regarding the relevance
of prior information. This implies that specific methodological guidelines are needed to
guide statisticians as to the necessary steps one should take and consider [100]. The CON-
SORT guidelines provide guidance on what and how aspects of trials should be reported
in a trial report [119, 120]. Some participants suggested they would be more likely to in-
clude external evidence in trials if they had methodological and reporting guidelines to
follow, or if funders asked for it. Many participants were also concerned as to whether
Bayesian methods would be accepted in practice by funders and decision makers, as well
as other colleagues and clinicians. We believe by creating guidelines, trialists and deci-
sion makers would feel more confident using informative priors, particularly in situations
where existing evidence could be advantageous over current practice.
Another major concern is that the infrastructure is not in place. Many trials units are not
integrated with a systematic review team. Second, there is not an easily accessible reposi-
tory of relevant data, ideally individual patient data. Although there have been many calls
in the UK for a platform of all individual trial data, it is probably still a while off [121]. As
such, we still need to first improve access to existing data so that it can be incorporated. A
possible solution to bridge this gap is for each trials unit to synthesise each of their own
trials to learn about adverse event rates and predict the probability of a patient with par-
ticular characteristics having an event. This could then be used to look at potential sample
size parameter assumptions and to predict adverse events. Furthermore, most trials from
the same trials unit have a greater chance of being more similar in terms of population and
setting. For example, a trials unit that specialises in cardiovascular trials is more likely to
run trials in similar populations.
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3.5 Conclusions and implications for remainder of thesis
The results of the qualitative study highlighted that trialists felt they could be making
more use of existing data to inform the design and analysis of a clinical trial in particular
scenarios. We found that trialists are using existing evidence in a lot of ways; ranging from
using it to justify that there is a gap in the evidence base (such as using a systematic review
to show there is an unanswered clinical question) or using it to inform parameters in the
sample size calculations (such as the expected control group event rate). However, trialists
rarely (never in our sample) explicitly combine this previous evidence statistically with
their actual trial through a Bayesian analysis. This was consistent with the results from our
INVEST survey. We found the main reasons a Bayesian analysis was not conducted could
be categorised into three main areas (i) personal feelings of a trialist (lack of confidence
in Bayesian methods and relevance of the data); (ii) perceived practical challenges of use
(hard to access data, anonymisation issues, Bayesian software) and (iii) concerns about
lack of acceptance in the field (negative perceptions of Bayesian methods).
We found trialists do not think about bias adjustment, partly because they were not aware
of meta-epidemiological methods. In Chapters 4 and 5, we extend current meta- epidemi-
ological methodology, looking specifically at how a trialist might use such evidence for
bias adjustment in their trial. Second, although trialists were unaware of explicitly incor-
porating information from an existing meta-analysis into sample size calculations, many
thought it was a good idea. In Chapter 6, a comparison of methods is undertaken to dis-
cuss the advantages and limitations of incorporating external evidence in such calcula-
tions in practice. We also found participants felt current methods for determining how
likely adverse events were a safety concern could be improved. In particular, participants
felt they could use existing data to inform adverse event rates when the event rate in the
control arm is not adequately powered. In Chapter 7, we develop methods which use a
synthesis of control data to inform the likely event rate in the control arm of a new study.
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In Chapters 5, 6, and 7, specific attention will be drawn to how existing data could be
pooled and summarised and used by a trialist in practice.
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4 A meta-epidemiological investigation of the impact of
blinding on estimated treatment effects in randomised
clinical trials: the MetaBLIND study
The MetaBLIND study was a collaboration with the following researchers: Helene Moust-
gaard (HM), Asbjørn Hróbjartsson (AH), Hayley Jones (HJ), Julian Higgins (JH) Jelena
Savović (JS), Jonathan Sterne (JS) and the wider MetaBLIND team Phillippe Ravaud (PR),
Isabelle Boutron (IB), Lars Jørgensen (LJ), David Laursen (DL), Mette Frahm Olsen (MFO)
and Asger Paludan-Müller (APM). My role has included management of the dataset, per-
forming all statistical analyses, including extending current methods and drafting some
of the written outputs.
4.1 Context and overview
We know RCTs offer one of the best sources of evidence to answer a specific research
question [2]. However, RCTs may still have their limitations, despite best efforts by the
trial team [21, 63] (see Section 1.2.2 for examples of the different types of biases). Trial
analyses can adjust for biases in an RCT context, in the same way this has been proposed
for the meta-analysis context [55]. Meta-epidemiological studies provide empirical evi-
dence for such adjustments. We can then use this information about such biases to adjust
the treatment effect estimate in a new study, allowing the analyst to assess the sensitiv-
ity of their findings. In an example where it was not possible to blind a particular party,
this would enable the trial team to answer, “what result would we have seen if we were
able to blind the study”. An opportunity arose for me to get involved in a major new
meta-epidemiological study, MetaBLIND. I, therefore, describe the study and some novel
methodological developments I made. This is the first of two chapters on using meta-
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epidemiological studies to adjust for bias in an RCT.
4.2 Introduction and aims
Meta-epidemiology is a recognised method to quantify the difference, on average, in treat-
ment effects between trials which differ by a characteristic or set of characteristics. The
first meta-epidemiological study [20] analysed a set of meta-analyses that included simi-
lar trials, to investigate the impact of several methodological factors that could potentially
bias estimated treatment effects. Schulz et al reported that concealment of allocation was
very important, with treatment effects exaggerated by 41% (95% CI 27% to 51%) on av-
erage among trials without relative to trials with adequate allocation concealment, whilst
double-blinding was less important, with treatment effects exaggerated by 17% (95% CI
4% to 29%) on average. Since that pivotal study a number of similar analyses have been
conducted, with inconsistent results [122, 123].
In 2012, a combined re-analysis of seven meta-epidemiological studies reported that, on
average, odds ratios were exaggerated by 13% (95% CI 4% to 21%) in trials without double-
blinding and this was greater in trials with subjectively measured outcomes, 22% (95% CI
8% to 35%) [64]. However, in both types of outcomes there was evidence of heterogene-
ity in the average bias across meta-analyses. A key limitation of these previous meta-
epidemiological studies arises from the ambiguity of “double blind”: it is unclear from
this term precisely which parties were blinded [79, 124]. Previous studies have relied pre-
dominantly on the labelling of trials as “double blind” in published trial reports and not
attempted to access information on actual trial conduct. Importantly, the comparison be-
tween “double-blind” trials and not “double-blind” trials has not enabled a separation
of the impact of lack of blinding of outcomes assessors and the impact of lack of blind-
ing of patients and/or healthcare providers. Previous studies have also not taken into
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account whether the outcomes were assessed and reported by patients or by other ob-
servers. Overall, these conceptual and methodological limitations may, at least partially,
explain the inconsistent results.
We therefore describe the first meta-epidemiological study aimed at disentangling the im-
pact of different types of blinding to enable the clear separation of the two main types of
blinding-related bias: ’performance bias’ and ’detection bias’ (described in Section 1.2.2).
We examine separately the impact of blinding participants, healthcare providers and out-
come assessors, and examine how this might vary by type of outcome. We analysed the
data using a hierarchical bias model proposed by Welton et al [55], which has been pre-
viously applied in meta-epidemiological research [64, 81] and is described in the next
section. Our study also introduces the following methodological novelties. Previous stud-
ies have modelled binary and continuous data separately. We therefore model continuous
and binary data simultaneously in a single model, assuming a mixture of normal and bi-
nomial likelihoods but modelling the underlying bias on the same scale. We also extend
this model to incorporate covariates, in particular, to explore the association between de-
gree of subjectivity of the outcome and the average magnitude of bias.
The five main analyses investigate:
 (Ia) the effect of blinding patients to the treatment they are receiving, in outcomes
which are assessed by the patient (patient reported outcomes) [performance bias and
detection bias];
 (Ib) the effect of blinding patients where the person assessing the outcome is blinded
to the treatment the patient has received [performance bias];
 (IIa) the effect of blinding those providing care or those making a decision on a
treatment for patient, in outcomes which are assessed by the same person (i.e. those
which gave them a particular treatment, defined as healthcare provider decision out-
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comes) [performance bias and detection bias];
 (IIb) the effect of blinding those providing care or those making a decision on a treat-
ment for patients, in outcomes where the person assessing the outcome is blinded to
the treatment the patient has received [performance bias];
 (III) the effect of blinding the outcome assessor, in outcomes which are subjectively
assessed (by the same person) [detection bias].
The chapter is structured as follows. Section 4.3 give the background to meta-epidemiology
and current methods. Section 4.4 details the methods applied to MetaBLIND including the
extension of current statistical methodology. The chapter concludes with a discussion of
the findings and the implications for using the results of meta-epidemiological studies to
adjust for biases in a new trial.
4.3 Background to meta-epidemiological methods
To assess the RoB of methodological components in a trial, such as allocation concealment
and blinding, it is common to use a RoB tool. This assessment is often conducted as part
of a systematic review and, when applicable, to quantitatively synthesise effect estimates
from studies, in a meta-analysis. The Cochrane Risk of Bias tool is one way of carrying
this out. The tool has individual methodological components set within several domains.
These domains include ’selection’, ’performance’, ’detection’, ’attrition’, ’reporting’ and
any other bias which is not covered in those domains. Example of how these biases can
occur in trials are given in 1.2.2. Each individual methodological component is classified
as being either at a ’high RoB’, ’low RoB’ or ’unclear RoB’.
Since 2012, the Cochrane RoB tool has included separate components for different types
of blinding: ’Double-blinding’ has been replaced with ’Blinding (participants and person-
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nel)’ and ’Blinding (outcome assessment)’. These now fall under the ’performance’ and
’detection’ bias domains. We therefore use this information to inform the assessment of
blinding status for each trial. A ’low RoB’ trial is defined as a trial with the methodolog-
ical component, i.e. with blinding of the outcome assessor. A ’high RoB’ trial is a trial
without the methodological component or one in which it is unclear.
There are different methods used in meta-epidemiology to estimate the average amount
of bias attributed to a specific methodological limitation. One of the first studies was by
Schulz et al [20] who wanted to see if methodological limitations were associated with
evidence of bias in estimating treatment effects. He used logistic regression to model the
association of treatment effects between studies at a high RoB and studies at a low RoB,
for a specific methodological flaw. Thus, assuming the underlying association was fixed
or constant across studies.
Sterne et al extended this method by allowing the average bias to vary across meta-analyses
in an intuitive two stage approach. In the first stage, the amount of bias attributed to a spe-
cific methodological limitation is estimated within each meta-analysis. This is quantified
using ratio of odds ratios (RORs), ROR = ORhigh-riskORlow-risk , based on comparing the summary odds
ratio from studies without the study characteristic of interest with the summary odds ratio
from studies with the characteristic. In the second stage, the amount of bias is averaged
across meta-analyses to get the average ROR. The between study variability in the average
bias is denoted by ϕ2.
Welton et al hypothesised that it is likely trials will have been influenced differently by the
effects of blinding or any flawed study characteristic [125]. Therefore, they developed a
model that allows the bias between trials and additionally the bias within meta-analyses
to vary and implemented this in a one stage Bayesian framework. We first outline this hier-
archical model, as described by Welton et al model. We build upon this model to combine
binary and continuous outcomes and stratify the average magnitude of bias and degree
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of subjectivity in observer reported outcomes.
4.3.1 Welton et al model
The Welton et al model allows for the treatment effect to vary across studies, the aver-
age amount of bias across meta-analyses to vary and additionally the study specific bias
across trials to vary in a one stage approach. It therefore assumes biases are broadly simi-
lar (exchangeability assumption) within a meta-analysis, and assumes the average bias is
broadly similar (exchangeability assumption) across meta-analyses.
The outcome ra,i,m for arm a of trial i in meta-analysis m is assumed to have a binomial
likelihood (for given denominator na,i,m):
ra,i,m ∼ binomial (pa,i,m, na,i,m) (4.1)
The probability of success, pa,i,m , is modelled by a logistic regression:
logit(pa,i,m) =
 µi,m control armµi,m + δi,m + βi,mCi,m treatment arm (4.2)
µi,m is the log-odds of success in the control arm. δi,m is the treatment effect, on the log
odds ratio scale, in each study. We assume each δi,m is normally distributed with mean









 1 if study i at a high or unclear RoB0 if study i not at RoB (4.4)
122
Ci,m indicates whether the methodological limitation is present, for example, if the out-
come assessor is blinded (Ci,m = 1, non-blinded; Ci,m = 0, blinded). βi,m is the bias in
treatment effect in study i of meta-analysis m. A hierarchical model is put on the study-














The ROR is given by exp(b0). κ
2 is the average increase in between-trial heterogeneity
among studies with, relative to those without, the characteristic. ϕ2 is the between meta-
analysis variability in mean bias, that is, the variation in average bias across meta-analyses.
We note that between study heterogeneity, τm, is estimated separately for each meta-
analysis, whereas κ is shared across all meta-analyses.
To study the impact of potential confounding factors, such as whether or not patients were
blinded, on the difference in intervention effects, we include binary covariates at the trial
level. Using the same notation, we add the term b1xi,m to equation (4.2):
logit(pa,i,m) =
 µi,m control armµi,m + δi,m + βi,mCi,m + b1xi,m treatment arm (4.7)
xi,m is the value of the covariate in the data for each trial within each mth meta-analysis
and b1 is the regression coefficient of the trial level covariate.
All of the models presented are implemented and carried out using WinBUGS version
1.4.3 (MRC Biostatistics Unit, Cambridge, UK [126]). For location parameters (overall
mean bias, baseline risk, treatment effects), Normal (0, 1000) priors were assumed. Vague
priors were assumed with a modified Inverse Gamma (0.001, 0.001) prior on all variance
components to allow increased weight on small values. This was chosen from the earlier
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BRANDO analysis by Savovic et al [127] who found this prior to perform the best (with
the lowest average mean squared error) having conducted a simulation study. It is well
known with this type of modelling that variance components can be sensitive to the prior
distributions [128].
Meta-analyses with only one high risk or only one low risk trial are prevented from con-
tributing to the estimation of κ. This is implemented using the ‘cut’ function in WinBUGS,
originally applied in the BRANDO analysis [64]. In situations where there is only one
high or low RoB trial, it is not possible to estimate κ. When there is only one high RoB
trial, it does not make sense to estimate the variability in bias between the high RoB trials.
When there is only one low RoB trial, it is not possible to estimate both between study
heterogeneity and κ. We apply this to all of the following models with a binary study
characteristic.
For meta-analyses with few studies, the between study heterogeneity, τm, can be impre-
cisely estimated. We therefore conducted sensitivity analyses with a hierarchical model
on this parameter for each of the five main analyses. We took the log of the between
study standard deviation from each meta-analysis, which we assumed was normally dis-
tributed, thereby allowing us to borrow strength from the meta-analyses which estimated
the between study heterogeneity more precisely. Although we may expect the estimates
for τm to change, we checked our parameters of interest (b0, κ, ϕ) did not change. For
all analyses, 2 parallel chains were run, with a burn-in of 250,000 iterations followed by
at least a further 1,000,000 iterations, with a thinning of 5. We assessed convergence by
checking the agreement of each of the chains in history plots and density plots. 95% CrIs
are provided with each parameter estimate.
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4.4 Methods
4.4.1 Screening and data extraction
1042 Cochrane reviews (all reviews published or updated between 01/02/2013 (Cochrane
Library Issue 2 2013) and 18/02/2014) were screened for informative meta-analyses. We
define a meta-analysis as ’informative’ if it includes at least one contrast of the type of
blinding status. For example, a meta-analysis containing at least one trial with blinded pa-
tients and one trial with non-blinded patients would be ’informative’ for patient blinding.
The meta-analysis had to be informative for at least one of the blinding contrasts (patient,
healthcare provider or outcome assessor blinding) to get through the screening stage.
Since a Cochrane review often contains multiple meta-analyses, the first meta-analysis
was checked for informativeness, based on the criteria above. If it was not informative,
the second meta-analysis (or analysis) in the review was checked and so on, until an infor-
mative meta-analysis was identified. Once an informative meta-analysis was identified,
subsequent meta-analyses were not checked. The Cochrane RoB tool was used initially as
an assessment of blinding status to check informativeness.
Outcome measures were classified as observer-reported, patient-reported (via interviewer
or directly reported), healthcare provider decision outcomes or as mixed (in cases where
the outcome was a mixture of more than one category, e.g. both patient and observer-
reported elements). The screening process identified 395 potentially informative meta-
analyses, of which 226 were potentially informative in relation to blinding of outcome
assessors and 169 in relation to blinding of patients or healthcare providers. For pragmatic
reasons, we continued with a random subsample of 120 of the 226 meta-analyses that
were potentially informative in relation to blinding of outcome assessors and all 169 meta-
analyses in relation to blinding of patients or healthcare providers, i.e. 289 meta-analyses
in total. Figure 4.1 shows the flow of data through the study, from contributing studies to
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final datasets.
Trial characteristics and blinding information were extracted manually from trial publica-
tions. Trial results were extracted automatically from the Cochrane Database of Systematic
Reviews via the Archie database interface: number of patients in intervention and control
groups, for binary outcomes the number of events, and for measurement scale outcomes
the means and standard deviations. Extraction of the name of the Cochrane review group,
and review authors’ RoB assessments for the domains “Allocation concealment” and “In-
complete outcome data” was automated. In cases where trial publications could not be
retrieved, they were requested from the review authors. If the blinding status of trial par-
ticipants was unclear and the trial was published after 1999, authors were contacted via
e-mail, asking for information on the blinding status of all groups within the trial.
4.4.2 Classifications
The blinding status of patients, healthcare providers and outcome assessors was assessed
using a modified algorithm derived from that of Akl et al [129]. “Blinded” is defined as be-
ing unaware of the intervention status of individual patients or the patient’s own blinding
throughout the trial (as opposed to, for example, being unaware of the hypothesis of the
trial). Healthcare providers were coded as “blind” if all staff involved in patient treatment
and care were described as blinded, and as “non-blind” if all or a subgroup were de-
scribed as non-blinded. Staff responsible for the determination of any healthcare provider
decision outcomes was thus also covered by the coding of blinding status of “healthcare
providers”. The assessment of blinding status was done by two observers independently
(APM, DL, LJ, MFO, HM or AH), and differences were resolved by discussion. The team
differentiated between what we took to be definitive information on blinding status (“def-
initely yes”/”definitely no”) based on explicit description or on contact with trial authors,
and assessments based on other information in publications (“probably yes”/”probably
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no”).
Classification of interventions as ‘experimental’ and ‘control’ was based on descriptions
in the trial publications, except when some treatment was clearly labelled as “placebo”,
“control”, “standard care” or “treatment as usual”. In any of the latter cases we followed
the labelling used by the review authors and classified these interventions as ‘controls’. To
ensure consistent comparisons of estimated bias across meta-analyses, we excluded meta-
analyses in which intervention classifications were unclear. We excluded meta-analyses in
which trials did not all have the same type of outcome (e.g. patient-reported), unless there
was an informative subset of trials with the same type of outcome. We also excluded tri-
als included in more than one meta-analysis with the same outcome, if the meta-analyses
were due to be included in the same meta-epidemiological analysis. Such trials were re-
moved at random until the trial only occurred within one meta-analysis. After removal
of individual trials, some meta-analyses were no longer informative. Meta-analyses were
classified according to whether the underlying hypothesis was of benefit (e.g. reduced
mortality or increased live birth rate in the experimental intervention group); or of harm
(when an intervention is assessed based on a hypothesis that some unwanted occurrence
will increase, or some wanted occurrence decrease in the intervention group, typically
“adverse events”).
Observer-reported outcomes were subdivided into “objective: all-cause mortality”, “ob-
jective: other than total mortality” (e.g. automatized non-repeatable laboratory tests), “sub-
jective: pure observation” (e.g. assessment of radiographs) and “subjective: interactive”
(e.g. assessment of clinical status). Subjective observer-reported outcomes were scored 1-3
according to degree of subjectivity (i.e. the extent to which determination of the outcome
depended upon the judgement of the observer, 1 meant low degree of subjectivity). For
example, the outcome FEV1 increase was assigned a score of 1 and improvement in de-
pression a score of 3. The scoring of subjectivity was done by two observers (HM and
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MFO) independently and masked to any results of trials or meta-analyses, with differ-
ences resolved by discussion. The classification of outcome type and experimental and
comparison interventions were conducted to facilitate comparisons with an earlier meta-
epidemiological study [10]. We further categorized experimental interventions as alterna-
tive/complementary or conventional medicine.
We excluded trials with binary outcomes in which no or all participants had the outcome
event and trials with continuous outcomes where the required information for calculating
the standardized mean difference (SMD) was missing.
4.4.3 Data analysis
Intervention effects of binary outcomes were modelled as log odds ratios (ORs) and coded
such that an OR<1 meant a beneficial intervention effect. For continuous outcomes the
SMD and corresponding standard error were used and coded such that SMD<0 meant a
beneficial intervention effect.
Bayesian hierarchical models for meta-epidemiological research developed by Welton et
al [55] were used to estimate the average amount of bias associated with lack of each
type of blinding, the average variability in this bias within a meta-analysis (quantified
by the standard deviation [SD] increase in between trial heterogeneity, κ), and variability
in average bias between meta-analyses (quantified by the SD of mean bias across meta-
analyses, ϕ) . This model is explicitly described in Section 4.3.1.
To maximize the number of studies included in the analysis, I extended the Welton model
to include both binary and continuous outcomes. As this is one of two methodological
novelties in this chapter, we explain the rationale of why this is potentially appropriate in
more detail in the following section.
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Figure 4.1: Study flow diagram.
 
*Meta-analyses contributing with trials whose outcome measures were categorized as “mixed” (i.e. not possible to classify 
as either patient-reported, healthcare provider decision or observer-reported since they contained elements from more 
than one of these types) not counted here. “Mixed” outcome trials did not contribute to the main analyses. 
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- 106 trials where either no or all participants experienced the outcome event (not 
possible to calculate OR) 
- 2 trials missing the required information to calculate the SMD 
- 1 trial removed since included with the same outcome in two meta-analyses due 
to be included in the same meta-epidemiological analysis. Removed at random 
from one of the meta-analyses 
Removed meta-analyses: 
- 28 meta-analyses (300 trials) in which it was not clear which intervention is 
experimental and which is control 
- 5 meta-analyses (57 trials) with inverse variance outcomes (not SMD) 
- 14 meta-analyses (83 trials) were lost as they were non-informative across the 
effect of blinding patients, care providers or the outcome assessor due to removal 
of individual trials 
 
 
All Cochrane reviews published or updated between 1 February 2013 and 18 February 2014 
1042 reviews 
Excluded reviews containing no potentially informative meta-analyses based on 
Risk of Bias scores: 
747 reviews 
Excluded meta-analyses based on random sampling due to excess of meta-
analyses with observer-reported outcomes: 
116 meta-analyses with observer-reported outcomes 
Potentially informative meta-analyses based on Risk of Bias scores 
395 meta-analyses (extracted from 295 reviews): 
226 meta-analyses with observer-reported outcomes 
169 meta-analyses with patient-reported or healthcaret provider decision outcomes 
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The MetaBLIND analysis dataset 
142 meta-analyses (1153 trials) 
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Transforming continuous outcomes to binary outcomes on the log odds ratio scale
Since meta-analyses on the SMD scale can be difficult to interpret, Anzures-Cabrera et al
provide an explanation of how it is possible to convert such continuous outcomes on the
SMD scale to binary outcomes on the log odds ratio scale using a multiplicative factor of
1.81 [130]. We first show how 1.81 is derived and second interpret the assumptions we
make in our meta-epidemiological study.
Suppose we have a continuous outcome with a true underlying mean and standard de-
viation for a single arm of a two arm study, that is, X1 ∼ N(µ1, ν21). As always, we have
the summary statistics of the sample mean and sample standard deviation. Now sup-
pose there exists an underlying (because we only have summary level data) cut point C
where the observations less than or equal to C determine the number of events in that




PC1 = P (X1 ≤ C) be the true probabilities of the events in arm or group 1. If µ1 increases,
then PC1 = P (X1 ≤ C) decreases. This dependency can be expressed as PC1 (µ1). We can
also take the logit of this, logit(PC1 (µ1)). Anzures-Cabrera et al looked at whether there
were instances when the relationship between µ1 and logit(PC1 (µ1)) was linear across val-















+ logit(PC1 (µ1)) (4.8)





= logit(PC1 (µ1))− logit(PC2 (µ2)) = log(OR)C (4.9)
Now suppose the continuous data (or again one arm of a study) have a logistic distri-


















which is a linear relationship between logit(PC1 (µ1)) and µ1 for a given C and ν. The fol-
lowing property of a logistic distribution can be derived for the difference between two















that holds for any cut point with K = − π√
3
. Thus,
log(OR)C = − π√
3
∗ SMD ≈ −1.81 ∗ SMD (4.13)
In our study, we therefore modelled continuous and binary data simultaneously in a single
model, assuming a mixture of normal and binomial likelihoods but modelling the under-
lying bias on the same scale. For the continuous outcomes, this required re-expressing the
SMDs as log odds ratios by multiplying the SMD and standard error by 1.81 [130, 131].
Although there is a minus sign in the derivation by Anzures-Cabrera et al, we multiply
the SMD by positive 1.81 as both types of outcome were already coded such that an OR<1
and SMD<0 meant a beneficial treatment effect. By transforming the SMD to the log odds
ratio scale, an underlying logistic distribution is assumed for continuous variables. We
assume approximate an normal distribution for the effect estimate and therefore assumed
normal likelihood for each trial i:
SMD ∗ 1.81 = lnor ∼ Normal
(




θi,m = δi,m + βi,m (4.15)
βi,m are assumed to have same model structure as above (equations (4.5) and (4.6)) so that
b0, κ and ϕ are informed by both types of data together. We assume a binomial likelihood
for the binary data with a logit link function (as described by equations (4.1) and (4.2)) and
a normal likelihood for the continuous data with an identity link function (as described
by equations (4.14) and (4.15)). To check the underlying assumption holds, we present the
RORs separated by outcome type.
For the primary analyses we categorised trials as a “high risk” of bias if the blinding
status of relevant parties were “definitely no” or “probably no” or in which it was unclear
and “low risk” of bias if the blinding status were “definitely yes” or “probably yes”. We
conducted univariable analyses for each type of contrast in blinding status (i.e. of patients,
healthcare providers and outcome assessors) using all informative meta-analyses for that
characteristic.
In assessing the effect of blinding outcome assessors, we also studied the impact of our
subjectivity scores on the difference in intervention effect. To do this, I extended the Wel-
ton et al model [55] to incorporate a three-level categorical covariate (low versus moder-
ate versus high) at the meta-analysis level in the second methodological novelty in this
chapter. The reference group was chosen to be the low level of subjectivity and indicator
variables for high and moderate were added. Thus, allowing a different average amount
of bias for each meta-analysis, to be estimated, by the level of subjectivity [55, 132]. Using
the same notation as previously, we add the terms b1x1m + b2x2m to equation (4.5):
βi,m ∼ N
(




b1 is the regression coefficient of moderate subjectivity compared to low subjectivity. Sim-
ilarly, b2 is the regression coefficient of high subjectivity compared to low subjectivity. x1m
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is the indicator variable for moderate subjectivity in the mth meta-analysis. Similarly, x2m
is the value of the indicator variable for high subjectivity in the mth meta-analysis. As
described previously, equation (4.6) remains the same and vague prior distributions are
assumed for b1 and b2. The association between degree of subjectivity of the outcome and
the average magnitude of bias is interpreted for each level of bias in comparison to the ref-
erence group. We denote exp(b0) as the magnitude of bias for outcomes with a low degree
subjectivity score. exp(b1) is the magnitude of bias for outcomes with a moderate degree
compared to a low degree subjectivity score. Similarly, exp(b2) is the magnitude of bias for
outcomes with a high degree compared to a low degree subjectivity score. The code for
both models can be found in Appendix B.
The risk of confounding by other limitations in trial design was assessed in multivariable
analyses by re-running the main analyses with adjustment in the model for: concealment
of the allocation sequence, RoB due to incomplete outcome data (attrition bias) , trial size
and blinding status of patients (the latter only in the analysis of outcome assessor blinding
[III]). The model is described in equation (4.7). We adjusted for each of these characteristics
in turn in separate analyses: we did not adjust for combinations of the covariates. The
multivariable model allows the covariate (potentially confounding variable) to act on the
mean bias but not to explain additional variability in bias; the models therefore included
the same variance components as the main univariable analyses. In sensitivity analyses
we excluded trials in which it was unclear whether the relevant parties had been blinded:
(i) excluding only those with a classification of “unclear”, (ii) excluding trials with an
“unclear”, “probably yes” or “probably no” classification, such that only “definitely yes”
and “definitely no” remained.
In order to facilitate comparison of our study with previous meta-epidemiological stud-
ies we also compared trials described as “double blind” or “triple blind” having both
patients, care providers and outcome assessors described explicitly as blind in the publi-
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cation with those trials for which neither was the case. Secondary analyses were stratified
by outcome type (for example, objective outcomes (and subtypes), outcomes classified as
mixed).
4.5 Results
Table 4.1 shows characteristics of the 142 meta-analyses and 1,153 trials included in the
analysis dataset. The median year of publication of the included trials was 2003, and the
median sample size was 768 patients for meta-analyses and 106 for trials. Twenty-two
meta-analyses (16%) assessed outcomes related to adverse effects of the treatment , fol-
lowed by resource use (19 meta-analyses [13%]) and clinician assessed outcomes (12 meta-
analyses [9%]). There were 68 meta-analyses with observer-reported outcomes, of which
subjectively assessed outcomes were reported most often, in 53 meta-analyses (78%), fol-
lowed by all-cause mortality (11 meta-analyses [16%]). Of 1153 trials included in the anal-
ysis dataset 1112 trials (96%) had a parallel trial design and 753 (65%) were drug trials.
Trial authors were contacted in 5% of trials (54/1153). The authors response rate was
52% (28/54). This reduced the fraction of trials with “unclear” blinding status from 8%
(95/1153) to 6% (67/1153). Full details can be found in Appendix A, Table A.4 .
Various methodological characteristics were highly correlated with each other across tri-
als. There were very high correlations amongst types of blinding whilst there were lower
correlations between blinding and other (non-blinding) RoB judgements. For example, tri-
als with blinded patients were more likely to have blinded outcome assessors (OR, 75.0
[95% CI, 38.6 to 145.8]), compared to trials with unblinded patients. Trials with blinded
outcome assessors were more likely to have adequate allocation concealment (OR, 3.0
[95% CI, 2.2 to 4.0]) and complete outcome data (OR, 2.0 [95% CI, 1.5 to 2.8]). Compared
to trials with unblinded patients, trials with blinded patients were more likely to have
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blinded outcome assessors (OR, 75.0 [95% CI, 38.6 to 145.8]). Full details on these aspects
can be found in Appendix A, Table A.5. Figure 4.2 summarises results for each of the five
main analyses (Ia, Ib, IIa, IIb, III). For illustration, forest plots of results from individual
meta-analyses are presented for each of the main analyses in Appendix A, Figure A.5.
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Table 4.1: Characteristics of included Meta-analyses and Trials. Overall dataset and main analyses (Ia, Ib, IIa, IIb, III).
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Table 4.1 – continued from previous page
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Table 4.1 – continued from previous page
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Table 4.1 – continued from previous page
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Table 4.1 – continued from previous page
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Table 4.1 – continued from previous page
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Table 4.1 – continued from previous page


























































































































(Ia) The effect of blinding patients in trials with patient-reported outcomes
Information was available on 18 informative meta-analyses with a hypothesis of benefit,
containing 132 trials. Patient blinding was assessed as “probably yes” or “definitely yes”
in 33 of these trials (25%) and “probably no”, “definitely no” or “unclear” in 99 (75%).
The overall ROR was 0.91 (95% CrI, 0.61 to 1.34) comparing trials with lack of or unclear
blinding of patients with those with blinded patients. The average increase in between-
trial heterogeneity among the trials with non-blind patients was estimated to be an SD of
0.22 (95% CrI, 0.02 to 0.60) and the between–meta-analysis variation in average bias was
estimated to be SD, 0.20 (95% CrI, 0.01 to 0.74).
(Ib) The effect of blinding patients in trials with blinded observer-reported outcomes
Information was available on 14 informative meta-analyses with a hypothesis of benefit,
containing 95 trials. Patient blinding was assessed as “probably yes” or “definitely yes”
in 57 (60%) of these and “probably no”, “definitely no” or “unclear” in 38 (40%). The ROR
was 0.98 (95% CrI, 0.69 to 1.39) when comparing effect estimates from trials with lack of
or unclear blinding of patients with effect estimates from trials with blinded patients. The
increase in between-trial heterogeneity among the trials with non-blinded patients was
SD = 0.10 (95% CrI, 0.01 to 0.60).
(IIa) The effect of blinding healthcare providers in trials with healthcare provider de-
cision outcomes
Information was available on 29 informative meta-analyses with a hypothesis of bene-
fit, containing 173 trials. Healthcare provider blinding was assessed as “probably yes”
or “definitely yes” in 93 of these trials (54%) and “probably no”, “definitely no” or “un-
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Figure 4.2: Estimated RORs and effects on heterogeneity associated with blinding status
of patients, healthcare providers and outcome assessors.
 
Trial group (Contributing meta-
analyses, contributing trials) 
(Ia) Patients – patient-reported 
outcomes (18, 132) 
(Ib) Patients – blinded observer 
reported outcomes (14, 95) 
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clear” in 80 (46%). The overall ROR was 1.01 (95% CrI, 0.84 to 1.19) when comparing
effect estimates from trials with lack of or unclear blinding of healthcare providers with
effect estimates from trials with blinded healthcare providers. The estimated increase in
between-trial heterogeneity among the trials with non-blinded healthcare providers was
SD = 0.06 (95% CrI, 0.01 to 0.30).
(IIb) The effect of blinding healthcare providers in trials with blinded observers/patients
assessing the outcome
Information was available on 13 informative meta-analyses with a hypothesis of benefit,
containing 91 trials. Healthcare provider blinding was assessed as “probably yes” or “def-
initely yes” in 61 trials (67%) and “probably no”, “definitely no” or “unclear” in 30 (33%)
of these trials. The overall ROR was 0.97 (95% CrI, 0.64 to 1.45) when comparing effect
estimates from trials with lack of or unclear blinding of healthcare providers with effect
estimates from trials with blinded healthcare providers. The increase in between-trial het-
erogeneity among the trials with non-blinded healthcare providers was SD = 0.10 (95%
CrI, 0.01 to 0.59).
(III) The effect of blinding outcome assessors (i.e. observers) in trials with subjective
outcomes
Information was available on 46 informative meta-analyses with a hypothesis of benefit
containing 397 trials. Outcome assessor blinding was assessed as “probably yes” or “def-
initely yes” in 199 of these trials (50%) and “probably no”, “definitely no” or “unclear”
in 198 (50%). The overall ROR was 1.01 (95% CrI, 0.86 to 1.18) when comparing effect
estimates from trials with lack of or unclear blinding of outcome assessors with effect
estimates from trials with blinded outcome assessors, in meta-analyses with subjectively
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assessed outcomes. The increase in between-trial heterogeneity among the trials with non-
blinded outcome assessors was SD = 0.05 (95% CrI, 0.01 to 0.22). Investigating the impact
of the degree of subjectivity, using our extension to the Welton model, described in Section
5.4.3, equation (1.10), gave RORs of 0.94 (95% CrI, 0.71 to 1.21), 1.05 (95% CrI, 0.83 to 1.38)
and 1.10 (95% CrI, 0.75 to 1.63) for the meta-analyses with the lowest, middle and highest
score for subjectivity, respectively.
For each of the main analyses, excluding (Ia), there appeared to be only limited between–meta
analysis heterogeneity in mean bias, ϕ , although the 95% CrIs were wide (between meta-
analyses SD (Ia) 0.20 (0.01, 0.74), (Ib) 0.11 (0.01, 0.55), (IIa) 0.06 (0.01, 0.26), (IIb) 0.13 (0.01,
0.82) and (III) 0.09 (0.01, 0.31) for the five main analyses).
For each of the five main analyses, separate adjustment for concealment of the allocation
sequence, attrition and trial size did not change the result (Table 4.2). Estimated increases
in between trial heterogeneity and estimates of between–meta-analysis variability in aver-
age bias were also little changed, compared with the unadjusted main analyses. Excluding
trials with “unclear” blinding status of the relevant group from the unadjusted main anal-
yses did not change the results substantially.
Secondary analyses
Secondary analyses looking separately at the effect of blinding patients, healthcare providers
or outcome assessors across different types of outcomes can be found in the Table 4.3.
For example, an analysis based on observer-reported outcomes classified as objective also
showed no effect of outcome assessor blinding status (ROR 0.94 [95% CrI 0.61 to 1.26])
(meta-analyses with a hypothesis of benefit only). Analyses comparing trials described as
“double blind” (or “triple blind”) with those not so described or “unclear” did not show
any effect when meta-analyses with any type of outcome were included (ROR 0.99 [95%
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(Ia) ROR 0.91 (0.61, 1.35) 0.91 (0.63, 1.31) 0.89 (0.59, 1.29) 2 1.10 (0.72, 1.69)
ϕ 0.20 (0.02, 0.74) 0.17 (0.01, 0.70) 0.18 (0.02, 0.74) 0.19 (0.02, 0.76)
κ 0.21 (0.01, 0.61) 0.18 (0.01, 0.60) 0.18 (0.01, 0.60) 0.23 (0.02, 0.61)
(Ib) ROR 1.07 (0.74, 1.56) 1.08 (0.63, 1.31) 0.99 (0.69, 1.39) 1.00 (0.70, 1.44)
ϕ 0.11 (0.01, 0.57) 0.10 (0.01, 0.52) 0.10 (0.01, 0.54) 0.11 (0.01, 0.58)
κ 0.10 (0.01, 0.57) 0.13 (0.01, 0.72) 0.10 (0.01, 0.57) 0.10 (0.01, 0.60)
(IIa) ROR 1.03 (0.84, 1.23) 0.98 (0.72, 1.58) 1.00 (0.83, 1.19) 0.97 (0.77, 1.18)
ϕ 0.07 (0.01, 0.29) 0.06 (0.01, 0.28) 0.06 (0.01, 0.27) 0.08 (0.01, 0.36)
κ 0.06 (0.01, 0.28) 0.07 (0.01, 0.30) 0.06 (0.01, 0.29) 0.07 (0.01, 0.39)
(IIb) ROR 1.03 (0.67, 1.54) 1.07 (0.80, 1.17) 0.98 (0.63, 1.44) 0.96 (0.64, 1.45)
ϕ 0.13 (0.01, 0.80) 0.12 (0.01, 0.77) 0.13 (0.01, 0.82) 0.14 (0.01, 0.82)
κ 0.10 (0.01, 0.60) 0.09 (0.01, 0.60) 0.09 (0.01, 0.58) 0.10 (0.01, 0.68)
(III)3 ROR 1.04 (0.89, 1.23) 1.02 (0.87, 1.19) 1.03 (0.88, 1.21) 1.01 (0.85, 1.20)
ϕ 0.10 (0.01, 0.36) 0.08 (0.01, 0.33) 0.10 (0.01, 0.34) 0.11 (0.01, 0.35)
κ 0.05 (0.01, 0.21) 0.05 (0.01, 0.19) 0.06 (0.01, 0.25) 0.06 (0.01, 0.25)
1 Number of meta-analyses, trials: (Ia)=(16, 116); (Ib)=(14, 94); (IIa)=(28, 160); (IIb)=(13, 90); (III)=(43,
365).
2 One meta-analysis (3 trials) were removed which did not specify the size of the trial due to the for-
mat given in the review.
3 Adjusted for patient blinding ROR=1.03 (95% CrI: 0.87 to 1.23), ϕ=0.10 (95% CrI: 0.01 to 0.32),
κ=0.06 (95% CrI: 0.01 to 0.22).
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CrI, 0.86 to 1.09]), nor when only meta-analyses with subjective observer-reported out-
comes and a hypothesis of benefit were included (ROR 1.11 [95% CrI, 0.86 to 1.44]) (Table
4.3).









Lack of double blinding or unclear double blinding (vs double blind):
All outcomes (94, 722) 0.99 0.07 0.06
(0.86, 1.09) (0.01, 0.29) (0.01, 0.18)
All outcomes – benefit (74, 583) 1,02 0.06 0.07
(0.90, 1.13) (0.01, 0.27) (0.01, 0.19)
All outcomes – harms (20, 139) 0.64 0.15 0.13
(0.38, 1.04) (0.01, 0.89) (0.01, 1.23)
Observer-reported outcomes (36, 37) 1.04 0.14 0.08
(0.84, 1.25) (0.01, 0.57) (0.01, 0.23)
Subjectively assessed
observer-reported outcomes


















outcomes as analysis (Ia)
(13, 53) 0.89 0.15 0.12
(0.57, 1.40) (0.01, 0.83) (0.01, 0.88)
Healthcare provider outcomes
Same outcomes as analysis (IIa)
(24, 147) 0.98 0.07 0.07
(0.79, 1.19) (0.01, 0.31) (0.01, 0.36)
The effect of blinding patients in trials with the following outcomes:
Private patient-reported outcomes
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The effect of blinding healthcare providers in trials with the following outcomes:
Observer-reported outcomes















The effect of blinding outcome assessors in trials with the following outcomes:
Any objective outcomes (15, 207) 0.94 0.23 0.13
(0.61, 1.26) (0.02, 0.82) (0.02, 0.39)
All-cause mortality (11, 168) 0.91 0.29 0.1
(0.51, 1.31) (0.02, 1.15) (0.02, 0.32)
Subjective interactive outcomes









Subjective pure observation outcomes
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4.5.1 Comparison between binary and continuous outcomes
Figure 4.3 shows each of the five main analyses split by binary and continuous outcomes.
We see that for all but analysis (Ia) the results from binary and continuous outcomes are
comparable so there is no particular reason to doubt the assumptions made. In analysis
(Ia) the meta-analysis with Cochrane number CD005056 appears to be an outlier. Having
looked at the original data from this Cochrane study it is correct with only two studies,
each showing the opposite effect, making the difference in the treatment effects extreme.
As this pattern was not seen in the other four analyses, we do not see this as evidence
against the model assumptions. As our models are based on the Bayesian hierarchical
model conducted in WinBUGS, the studies with only one low RoB study would be given
relatively little weight, driven by its prior distribution.
150
Figure 4.3: RORs from individual meta-analyses and from analyses combined across all
meta-analyses. Results for individual meta-analyses are frequentist estimates with confi-
dence intervals, based on comparing the summary odds ratio from studies with the study
characteristic of interest with the summary odds ratio from studies without the character-
istic. The overall estimates of RORs are results based on the Bayesian hierarchical model
described in the main text. CD numbers are identifiers of individual Cochrane reviews,
from the Cochrane Database of Systematic Reviews.
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D+L Subtotal  (I-squared = 0.0%, p = 0.944)
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D+L Overall  (I-squared = 35.5%, p = 0.010)

















































































































































































































































































































(e) (III) The effect of blinding outcome assessors (i.e. observers) in trials with subjective outcomes
4.6 Discussion
4.6.1 Overview of key findings
In this chapter, the first meta-epidemiological study was conducted to look separately at
the effect of blinding patients, those providing care or deciding on other aspects of a pa-
tient’s care and outcome assessors. We estimated the influence of study design characteris-
tics on average intervention effect estimates and on heterogeneity within a meta-analysis.
To our surprise, we found no evidence for bias, on average, resulting from a lack of blind-
ing of patients, those providing care or those or deciding on other aspects of a patient’s
care or outcome assessors in randomised clinical trials. This was the case even among
trials with the most subjectively measured outcomes. For all the results, CrIs were wide
showing considerable uncertainty in our estimates which encompassed both considerable
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difference and no difference. Our main findings were unaffected by adjustment for pos-
sible confounders and in sensitivity analyses. Estimates of the difference in between-trial
heterogeneity associated with lack of blinding provided only weak evidence of an in-
crease, except in the analysis concerning patient blinding and patient-reported outcomes.
The same pattern was found when comparing “double-blind” with not “double blind”
trials.
Often, meta-epidemiological studies are published with either all binary outcomes or all
continuous outcomes. However, since some meta-epidemiological studies can be small,
due to the pooling of data being labour intensive, we combined binary and continuous
outcomes in a single model. We have shown it can be helpful to combine meta-analyses
with binary and meta-analyses with continuous outcomes, by re-expressing standardised
mean differences from continuous outcomes, as log odds ratios. One advantage of this is
it allows the underlying bias to be modelled on the same scale, whilst still using a bino-
mial likelihood for the binary outcomes. The incorporation of more studies can improve
precision of the estimate in some settings. We also extended the Welton et al model to in-
clude meta-analysis level covariates rather than conducting separate analyses. This can
be advantageous when the separate analyses have small sample sizes and therefore lower
power. This can also benefit the analyst by producing stratified analyses to enable the av-
erage bias to be compared across levels of subjectivity or any other relevant categories,
whilst making use of all the trials in the dataset.
This result is based on a sample of meta-analyses from Cochrane reviews with no restric-
tion on topic, and thus comprising a broad sample of clinical areas, interventions and
outcomes. We based our classification of trials as blinded or non-blinded on information
on actual trial conduct, rather than relying on the ambiguous label of “double blind”. This
was achieved by studying explicit descriptions in the trial publications and, if necessary,
contacting trial authors. To our knowledge, contact to trial authors or information on trial
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conduct has been attempted in no other meta-epidemiological study. Accessing informa-
tion on actual trial conduct allows classification of the blinding status of each group of
participants in a trial separately: patients, healthcare providers and outcome assessors.
This in turn enables disentangling of the effects of blinding outcomes assessors and pa-
tients. Individual trial outcomes were carefully classified, based on information in trial
publications, according to who was involved in their determination, so as to separately
look at patient reported outcomes, healthcare provider and observer reported outcomes.
4.6.2 Limitations
This study attempts to measure the effect of blinding of patients, those providing care
or deciding upon the treatment and of the process of outcome assessment through an
observational design: trials with inadequate blinding are compared with trials in which
blinding was adequate, within meta-analyses. As with any observation design, there will
be a higher risk of confounding. We have compared trials within meta-analyses, which
should reduce some confounding since these sets of trials should be comparable regarding
interventions, patient populations etc. However, trials within a meta-analysis may still
differ in a variety of other ways, including other methodological aspects and therefore
residual confounding is possible. The optimal design for a study attempting to measure
precisely the impact of lack of blinding of outcome assessors would be experimental, as
opposed to our observational design. The study would be randomised in design (half the
patients randomised to be blinded, half not blinded).
Figure 4.3(a) shows the effect of bias from the continuous and binary data are in oppo-
site directions. Although this is surprising, the remaining four analyses do not show this,
suggesting that we do not see this as evidence against the model assumptions. However,
further work could look at this in more detail through a simulation study. A simulation
study would determine at which point the model assumptions break down and provide
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guidelines on when it may be appropriate/not appropriate to pool binary and continuous
outcomes in a meta-epidemiological model.
Our study had potentially lower power than we anticipated, as we had to disregard lots
of meta-analyses which were non-informative.
When trial publications explicitly and clearly described blinding status, we did not con-
tact the authors for further information. Further, only about half of the trial authors that
were contacted by the team (HM) answered and the remaining unclear RoB trials could
therefore lead to some misclassification of blinding status. However, our main result per-
sisted after exclusion of all trials where blinding status was not based on direct explicit
description or information gained through contact with authors.
4.6.3 Comparison to recent meta-epidemiological studies
The absence of an apparent effect of lack of blinding in our study contrasts the effects of
lack of double blinding detected in earlier meta-epidemiological studies. As is common
in epidemiology, more recent studies have generally estimated less of an effect than early
studies. Earlier meta-epidemiological studies on blinding have had somewhat conflicting
results but have generally found evidence of some effect of lack of blinding [20, 122, 123].
The 2012 combined re-analysis of seven earlier studies found an average of 13% exagger-
ation of intervention effects (odds ratios) and 22% in subjective outcomes with lack of or
unclear double blinding compared to double blinding [64]. When our data were analysed
based on the labelling as “double blind” vs. non-“double blind” (or unclear) for com-
parison with previous studies we did not find evidence of overestimation. Either for all
outcomes combined (ROR 0.99 [95% CrI, 0.86 to 1.09]), or for subjective observer-reported
outcomes specifically (ROR 1.11 [95% CrI, 0.86 to 1.44]. However, the CrIs were wide and
overlap with the confidence intervals from the previous studies comparing “double blind”
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and non-“double blind” trials.
A 2012 systematic review included all randomised clinical trials, in any clinical area, di-
rectly comparing blinded and non-blinded assessment of the same outcome within the
same trial within the same patients [133]. This does sidestep a lot of the important issues
of confounding involved in the (indirect) meta-epidemiological approach, which we have
taken. This is, however, still observational, as it does not include randomising groups to
blinded and non-blinded assessments. The systematic review found evidence of substan-
tial bias, concluding that non-blinded outcome assessors of subjective binary outcomes
exaggerated odds ratios by 36% on average, in stark contrast to our results [133]. This
discrepancy could be due to confounding in meta-epidemiology (as this is based on com-
paring trials within meta-analyses rather than within-trial comparisons). Alternatively, it
is possible we included less subjective outcome types, or a set of studies that are differ-
ent in some other way. However, it may be also be that the cohort of trials studied by
Hróbjartsson et al was not representative of medical trials in general. This is because, the
particular trial design using both blinded and non-blinded outcome assessment may have
been chosen by the trialists, precisely due to suspicions of a particular susceptibility of the
outcome measures to observer bias. Further studies measuring these effects, for trials with
different types of outcome measures, would be warranted and could serve to qualify in
important ways the assessment of RoB in randomised clinical trials. Such studies would
require careful consideration of the outcome types involved, by whom they were assessed,
and the specific groups blinded.
The contrast with other results of existing studies is less clear when comparing with stud-
ies that have estimated separately the effect of blinding of patients, healthcare providers
and outcome assessors. A 2016 systematic review of meta-epidemiological studies found
a limited number of smaller studies making such separate comparisons [65]. To explore
this further, in our MetaBLIND study, we calculated the predicted mean bias expected in
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a new meta-analysis without the study characteristic to see if the average bias effect from
previous studies lies within this interval. This predictive interval takes into account the
between meta-analysis variability. This is shown in Table 4.4. We found all previous stud-
ies were consistent with our study except the 2012 Hróbjartsson et al study (as described
earlier), which compared the blinded and non-blinded assessments within the same trial.
This is shown in Table 4.5 and Figure 4.4. Four studies estimated the effect of blinding
patients: Balk 2002 (ROR 0.95 [95% CI, 0.70 to1,13]) [134], Bialy 2014 (ROR 0.96 [95% CI,
0.78 to 1.19]) [135], Chaimani 2013 (ROR 0.85 [95% CI, 0.31 to 2.13]) [136] and Nuesch
2009 (difference in standardized mean difference -0.15 [95% CI, -0.39 to0.09]) [137]. Two
studies estimated the effect of blinding personnel: Balk 2002 (ROR 0.98 [0.75, 1.20]) and
Bialy 2014 (ROR 1.01 [0.82, 1.23]). Four studies estimated the effect of blinding outcome
assessors: Balk 2002 (ROR 1.02 [0.82, 1.22]), Bialy 2014 (ROR 1.08 [0.85, 1.33]), Chaimani
2013 (ROR 0.87 [0.63, 1.20]) and Hartling 2014 (ROR 1.00 [0.82, 1.22]) [138]. A 2017 meta-
epidemiological study looking at physiotherapy trials and analysing separately the effect
of blinding patients and outcome assessors found estimates of the difference in standard-
ized mean difference (dSMD) indicating underestimation of treatment effect associated
with lack of blinding, but with wide confidence intervals: lack of blinding of patients
dSMD 0.12 (-0.06, 0.30) and lack of blinding of outcome assessors dSMD 0.07 (-0.08, 0.22)
[139].
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bias in a new
meta-analysis
Predicted bias
in a new Trial
Lack of/unclear blinding of participants (versus blinding)
Patient reported outcomes (Ia) 0.91 (0.61, 1.34) 0.22 (0.02, 0.60) 0.20 (0.01, 0.74) 0.91 (0.41, 1.95) 0.91 (0.32, 2.62)
Patient reported outcomes where the
outcome assessor is blinded (Ib)
0.98 (0.69, 1.39) 0.10 (0.01, 0.60) 0.11 (0.01, 0.55) 0.98 (0.56, 1.73) 0.98 (0.46, 2.05)
Lack of/unclear blinding of outcome assessor (versus blinding)
Observer reported outcomes 1.01 (0.89, 1.14) 0.09 (0.01, 0.30) 0.08 (0.01, 1.21) 1.01 (0.73, 1.36) 1.01 (0.69, 1.45)
Subjective observer reported outcomes (III) 1.01 (0.86, 1.18) 0.05 (0.01, 0.22) 0.09 (0.01, 0.31) 1.01 (0.73, 1.41) 1.01 (0.68, 1.43)
Lack of/unclear double blinding (versus double blinding)
Outcomes (excluding a harms hypothesis) 1.02 (0.90, 1.13) 0.07 (0.01, 0.19) 0.06 (0.01, 0.27) 1.02 (0.77, 1.28) 1.02 (0.73, 1.36)
Observer outcomes (excluding a harms
hypothesis)
1.04 (0.84, 1.25) 0.08 (0.01, 0.23) 0.14 (0.01, 0.57) 1.04 (0.58, 1.81) 1.04 (0.56, 1.87)
Subjective observer outcomes 1.11 (0.86, 1.44) 0.09 (0.01, 0.42) 0.13 (0.01, 0.61) 1.11 (0.62, 2.03) 1.11 (0.56, 2.23)
Lack of blinding personnel (versus blinding personnel)
Healthcare provider outcomes (IIa) 1.01 (0.84, 1.19) 0.06 (0.01, 0.30) 0.06 (0.01, 0.26) 1.01 (0.75, 1.30) 1.01 (0.68, 1.43)
Healthcare provider outcomes when the
outcome assessor is blinded (IIb)
0.97 (0.64, 1.45) 0.10 (0.01, 0.59) 0.13 (0.01, 0.82) 0.97 (0.46, 2.08) 0.97 (0.39, 2.34)
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Figure 4.4: Plot of the predictive distributions of the effect of bias from MetaBLIND with















Lack of/unclear blinding of participants (versus blinding)
Balk 2002: All ROR 0.95 (0.70, 1.13)
Bialy 2014: All ROR 0.96 (0.78, 1.19)
Chairmani 2013: All ROR 0.86 (0.70, 1.05)
Chairmani 2013: Mortality ROR 0.85 (0.31, 2.13)
Hróbjartsson 2014b: Other objective dSMD -0.02 (-0.22, 0.18)
Hróbjartsson 2014b: Subjective dSMD -0.56 (-0.71, -0.41) NA I2=60%
Nuesch 2009a: Subjective dSMD -0.15 (-0.39, 0.09) NA 0.26
Lack of/unclear blinding of outcome assessor (versus blinding)
Balk 2002 ROR 1.02 (0.82, 1.22)
Bialy 2014 ROR 1.08 (0.85, 1.33)
Chairmani 2013 ROR 0.87 (0.63, 1.20)
Hartling 2014 ROR 1.00 (0.82, 1.22)
Hróbjartsson 2012: Subjective ROR 0.64 (0.43, 0.96) NA I2=45%
Hróbjartsson 2013: Subjective dSMD -0.23 (-0.40, -0.06) NA I2=46%
Lack of/unclear double blinding (versus double blinding)
BRANDO (Savović 2012): All outcomes (95% CrI) ROR 0.87 (0.79, 0.96) 0.20 (0.02, 0.39) 0.17 (0.03, 0.32)
Moher 1998 ROR 1.11 (0.76, 1.83)
BRANDO (Savović 2012): Mortality (95% CrI) ROR 0.92 (0.80, 1.04)]. 0.09 (0.01, 0.44) 0.08 (0.01, 0.42)
Unverzagt 2013 ROR 0.84 (0.69, 1.02)
BRANDO (Savović 2012): Other objective (95% CrI) ROR 0.93 (0.74, 1.18)]. 0.10 (0.01, 0.50) 0.20 (0.02, 0.85)
BRANDO (Savović 2012): Subjective (95% CrI) ROR 0.78 (0.65, 0.92)]. 0.24 (0.02, 0.45) 0.20 (0.04, 0.39)
Lack of blinding personnel (versus blinding personnel)
Balk 2002 ROR 0.98 (0.75, 1.20)
Bialy 2014 ROR 1.01 (0.82, 1.23)
Lack of blinding patients/personnel (versus blinding patients/personnel)
Hartling 2014 dSMD 0.00 (-0.09, 0.09)
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4.6.4 Conclusions and rationale for remainder of thesis
We found no evidence of a difference, on average, in estimated treatment effect between
randomised clinical trials with blinded and non-blinded patients, between trials with
blinded and non-blinded healthcare providers, and between trials with blinded and non-
blinded outcome assessors. Lack of blinding of patients in trials with patient-reported
outcomes was associated with some increase in between-trial heterogeneity. The apparent
lack of a major average impact of blinding on estimated treatment effects is surprising and
at odds with methodological standard practises and some empirical studies, but not with
several more recent meta-epidemiological studies. It is therefore unclear to what extent
our results reflect that blinding is less important than previously believed, or reflect limi-
tations in the meta-epidemiological approach, for example residual confounding by other
trial characteristics.
We have extended current statistical methodology in meta-epidemiology to (i) combine
binary and continuous outcomes and (ii) use meta-analysis covariates in order to pro-
duce stratified analyses by particular groups. It is then possible for a trialist to use these
outputs to conduct bias adjustment of their own trial; considering whether it should be
based on the most relevant other trials/meta-analyses (similar interventions, outcomes
etc). Thereby allowing the trialist to correct and down weight the results of their trial at a
high RoB. However, we have treated ‘high RoB’ trials as ‘high or unclear RoB’ trials. There-
fore, if a trialist wanted to use the results from these models to adjust the treatment effect
in their trial, the effect of an unclear RoB trial on treatment effects is likely not applicable.
A trialist, working on their own trial, will likely know which methodological components
are at a high or low RoB. Further work should therefore explore how these models can
account for unclear RoB trials. These findings are also consistent with the results from our
qualitative work in Chapter 3 which suggested current meta-epidemiological methods
needed extending for trialists to use them in practice.
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We therefore extend current methodology of meta-epidemiology studies to categorical
and numerical study characteristics in Chapter 5. We address the role of unclear RoB tri-
als which have so far been treated as ‘high risk’. We explore how this can be modelled
categorically so that a trialist can adjust their high RoB trial. Second, we extend these
models to look at the association of continuous study characteristics on estimated treat-
ment effects, which has so far not been considered.
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5 Statistical considerations in meta-epidemiological evidence
of non-dichotomous study characteristics
5.1 Context and overview
Current methodology for modelling meta-epidemiological evidence has looked at binary
and dichotomous study characteristics; specifically, comparing high RoB trials to low RoB
trials. However, most RoB assessments from individual trials are classified as high, low or
unclear, and there is still no consensus on how unclear RoB trials should be classified in
meta-epidemiological analyses [21].
Researchers conducting meta-epidemiological studies often group unclear RoB trials with
high RoB trials [55, 64, 81]. However, the assumption that all unclear RoB trials are all at
a high RoB could be too strong, as there could be other reasons why a RoB assessment is
unclear, such as a trial being poorly reported [21]. Moreover, if a trialist wanted to use the
results from such a model to adjust the treatment effect in their trial, the effect of an un-
clear RoB trial on treatment effects, is likely not applicable. Trialists working on their own
trial will likely know if it is either at a high or low RoB, whether that be overall, or for spe-
cific methodological components, i.e. there is no ‘unclear’ category. For example, a trialist
will know if their trial was unblind but not necessarily whether people sought additional
healthcare. We would also expect estimated associations to be diluted by assuming all
unclear RoB trials are high RoB trials, when in fact some of them will be low RoB trials.
Another possible approach by those conducting meta-epidemiological research is to con-
duct two separate analyses: high vs low and unclear vs low RoB trials [64]. However, this
often results in a loss of information and the inclusion of much fewer studies.
It can be hypothesised that smaller studies are at a higher RoB than larger studies because
smaller studies could be conducted less rigorously [21]. Previous meta-epidemiological
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studies have explored this by dichotomising the continuous variable (study size) to define
a binary characteristic [140]. Methods, such as the Welton et al model described in the
previous chapter (Section 4.3.1) can then be applied [140]. However, dichotomisation can
result in a loss of information. We may therefore prefer to model the study characteristic
of interest, sample size, continuously, to make use of all available information. From an
appraisal perspective, it provides an empirical association to allow a trialist to see whether
smaller trials are associated with more extreme treatment effects.
In this chapter we develop and describe approaches to model the association between
treatment effect estimates and (i) categorical study characteristics and (ii) continuous study-
level characteristics. We use high vs unclear vs low RoB trials and sample size as examples.
We make use of the database from the ROBES meta-epidemiological study [81]. We use the
ROBES database, rather than the MetaBLIND database, to provide an exemplar of these
methods using a more typical meta-epidemiological result. This database consists of 228
meta-analyses and 2443 trials each with a completed RoB table, extracted from the April
2011 issue of the Cochrane Database of Systematic Reviews.
The remainder of the chapter is structured as follows. Section 5.2 describes the meta-
epidemiological models for categorical study characteristics, with an application to the
role of unclear RoB trials. Section 5.3 similarly details the rationale and application of
using a continuous study characteristic, with an application to the association between
sample size and estimated treatment effects. This chapter concludes with discussion of
the findings and highlights the potential advantages these models can have to inform bias
adjustment for a new trial.
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5.2 Meta-epidemiological considerations for categorical study charac-
teristics with an application to the role of unclear risk of bias trials
5.2.1 Description of models
In this section a description of each of the models briefly introduced above are given.
A bivariate meta-epidemiological model
As described in the earlier section, an individual trial in a meta-analysis can be classi-
fied as either high, low or unclear RoB for a particular methodological characteristic. An
analyst may want to model a study characteristic with three categories. One way to do
this is to compare between two categories and have a common reference group. There-
fore, correlation between the high vs low and unclear vs low bias estimates may arise
from the common reference group of low RoB trials. We first describe the bivariate meta-
epidemiological model, which is an extension of the Welton et al model described in Chap-
ter 4.
We assume each study i, in meta-analysis m which has the baseline value of the categor-
ical variable (i.e. in this case has been assessed as low RoB), provides an estimate of the
underlying treatment effect δi,m. As in the Welton et al model, we assume a normal ran-
dom effects distribution for δi,m with mean dm and variance τ 2m specific to meta-analysis
m, given by equation (4.3). τ 2m represents the between study variability between the low
RoB trials or those who have the baseline level of the variable. Since we have a three-level
categorical variable, two indicator variables are created for the unclear RoB trials, denoted
IU i,m and high RoB trials, denoted IH i,m. When IU i,m = 1 and IH i,m = 0 this indicates
the unclear RoB trials. When IU i,m = 0 and IH i,m = 1 this indicates the high RoB trials.
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The outcome ra,i,m for arm a of trial i in meta-analysis m is assumed to have a binomial
likelihood (for given denominator na,i,m), given by equation (4.1), in Section 4.3.1. The
probability of success, pa,i,m, is modelled by a logistic regression, with reference to the
regression equation (4.2) where the binary study characteristic has been replaced by two
indicator variables:
logit(pa,i,m) =
 µi,m control armµi,m + δi,m + β1i,mIU i,m + β2i,mIH i,m treatment arm (5.1)
To account for the correlation between the unclear vs low, β1i,m, and high vs low, β2i,m,
RoB trials, we assume a bivariate normal distribution for these parameters.














As in the Welton et al model, b1m is the difference in treatment effects between the unclear
and low RoB trials in the mth meta-analysis. Similarly, b2m is the difference in treatment
effects between the high and low RoB trials in the mth meta-analysis.
The average SD increase in between-trial heterogeneity among the unclear RoB trials and
the high RoB trials is κ1 and κ2, respectively. In contrast to the Welton et al model, κ1 and
κ2 are estimated in the within meta-analysis variance-covariance matrix, to account for the
correlation between β1i,m and β2i,m. The within meta-analysis variance-covariance matrix
is given by Ω where κ21 = var(β1i,m) and κ22 = var(β2i,m) and cov (β1i,m, β2i,m) = ρwκ1κ2.
ρw indicates whether β1i,m and β2i,m are correlated and is estimated from meta-analyses
which include high, unclear and low RoB trials.
In the second part of the model, we use these ROR bias estimates per meta-analysis of, b1m
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Here, b01 is the average ROR of the unclear vs low RoB trials and b02 is the average ROR
of the high vs low RoB trials (on the log scale). The between meta-analysis variance co-
variance matrix is given by Σ and contains the between meta-analysis variances of the
high vs low and unclear vs low RoB effect estimates (in the diagonal ϕ21, ϕ22). The between
meta-analysis covariance for the high vs low and unclear vs low cov (b1m, b2m) = ρBϕ1ϕ2.
ρw is interpreted as the correlation in the estimated study-specific biases in the unclear vs
low RoB trials and high vs low RoB trials, within meta-analyses. ρB is interpreted as the
correlation in the estimated meta-analysis specific biases in the unclear vs low RoB trials
and high vs low RoB trials, between meta-analyses. Therefore, in the context of meta-
epidemiological models, the index of w and B refer to the correlation in biases within
meta-analyses and between meta-analyses.
Specification of a prior distribution for variance-covariance matrices (Ω and Σ) can be
problematic [142, 143, 144, 145, 146]. The two most common ways to do this is to ei-
ther use a conjugate prior on the variance-covariance matrix, given as a 2-dimensional
Wishart prior [142, 146] or re-parametrise using a series of univariate distributions, where
the mean of one of the distributions is conditional on the other, known as the product nor-
mal formulation [143, 144, 145]. To compare our results to the standard model, we use the
product normal formulation model to allow the separation of the variance-covariance ma-
trices and use the same prior distributions for a true comparison. It has also been shown
that the inverse-Wishart prior is particularly sensitive its scale [128]. In either case, the
prior distributions chosen must ensure the variance covariance matrix is positive semi-
definite [144, 145]. We ensure the variance covariance matrix is positive semi-definite by
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using the same prior for the variances as in the standard Welton et al models, and by choos-
ing a uniform prior distribution for the correlation which restricts it to values between −1
and +1. In a sensitivity analysis the correlation was restricted to values between 0 and +1.
Product normal formulation
The product normal is a re-parameterisation of the bivariate model. This is convenient for
estimation purposes, as it allows priors to be placed on the SDs and correlations directly.
It is therefore the same model, just written differently. We assume the estimated bias in
the unclear RoB trials, β1i,m, are normally distributed with a meta-analysis specific bias
b1m and between study variability κ21 which is estimated as fixed across all unclear RoB
trials.
β1i,m ∼ N(b1m, κ21) (5.4)
We re-parametrise the bias parameters for the high RoB trials, β2i,m so that their distribu-
tions are conditional on the bias in the unclear RoB trials β1i,m:
β2i,m|β1i,m ∼ N(η2i,m, κ.re22) (5.5)








We similarly re-parametrise the mean bias parameters for the high RoB trials, b2m so that
their distributions are conditional on the mean bias in the unclear RoB trials b1m:
b1m ∼ N(b01, ϕ21) (5.9)
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b2m|b1m ∼ N(µ02,m, ϕ.re22) (5.10)








Any given meta-analysis within a meta-epidemiological study might include:
 (i) A combination of low, unclear and high RoB trials
 (ii) A combination of low and unclear RoB trials only
 (iii) A combination of low and high RoB trials only
In a Bayesian hierarchical modelling framework, the contrast (ROR) between high ver-
sus low RoB trials and between unclear versus low RoB trials can be estimated in each
meta-analysis, regardless of which of these three groups the meta-analysis belongs to.
By allowing for correlation between these contrasts within meta-analyses, we can ‘borrow
strength’ across categories as well as across meta-analyses. As described in Chapter 4, Sec-
tion 4.3.1, meta-analyses with only one high risk or only one low risk trial are prevented
from contributing to the estimation of κ.
Probability model estimating the proportion of unclear RoB trials which are high risk
We previously developed a bivariate model which makes use of all available data in the
meta-epidemiological study, whilst simultaneously estimating a high vs low average RoB
estimate and an unclear vs low average RoB estimate. However, we can also model the
unclear RoB trials in a different way and quantify how likely they are truly high RoB trials
using a probability model [82].
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In the context of a NMA, Dias et al hypothesised that some trials may be of a poor method-
ological quality and overestimating the true effect of some interventions [82]. However, a
lot of the trials were assessed as an ’unclear RoB’. Therefore, Dias et al developed a model
whereby any study with an unclear RoB classification has a probability p of being at RoB.
This model provides a bias-adjusted analysis and can identify specific trials (with an ’un-
clear RoB’) as having a high probability of bias.
We extend the probability of bias model applied to a NMA by Dias et al [82], for use in
the context of meta-epidemiological data. Rather than categorising trials in the standard
Welton et al model as high or unclear vs low RoB (equation (4.4)), we can extend this
classification to include a probability coefficient for the unclear risk of trials, Bi,m as in the
Dias et al model, which is drawn from a Bernoulli distribution:
Ci,m =

1 if study i at RoB
Bi,m if RoB of study i is unclear
0 if study i not at RoB
(5.14)
where
Bi,m ∼ Bernoulli(p) (5.15)
Bi,m is interpreted as the posterior probability that an unclear RoB study i in meta-analysis
m is at RoB. Therefore, the overall probability that a study with unclear RoB is actually at
risk is denoted by the posterior mean of p. Since this is a quantity that is estimated in the
model, p has the following prior distribution:
p ∼ uniform(0, 1) (5.16)




 µi,m control armµi,m + δi,m + βi,m(Bi,mIU i,m + IH i,m) treatment arm (5.17)
Since IU i,m and IH i,m are dummy variables, we link this to Ci,m in equation (5.14). When
study i is at RoB, then IH i,m = 1 and IU i,m = 0, the terms inside the brackets of equation
(5.17) reduce to 1, that is, Ci,m = 1. When study i is at an unclear RoB, then IH i,m = 0
and IU i,m = 1, the terms inside the brackets of equation (5.17) reduce to Bi,m, that is,
Ci,m = Bi,m. When study i is not at RoB, then IH i,m = 0 and IU i,m = 0, the terms inside
the brackets of equation (5.17) reduce to 0, that is, Ci,m = 0.
We expect that for unclear RoB trials that have a treatment effect closer to the average
treatment effect of the high RoB trials to have a higher probability of being truly high risk.
Additionally, by allowing Bi,m to be estimated from the unobserved data, we do not have
to assume the proportion of unclear RoB trials is constant.
Probability model - extended to use sample size as a predictor of how likely an unclear
trial is high risk
Rather than basing the probability that an unclear RoB trial is actually high risk on its
treatment effect alone, we extend the model to predict the probability of whether a trial is
high risk using its sample size. We hypothesise that smaller trials are more likely to have
study limitations, such as inadequate blinding and could therefore be used as a predictor
of whether an unclear RoB trial is actually at a high RoB. This may mean smaller trials
will have more extreme or exaggerated treatment effects than larger trials.
Rather thanBi,m being drawn from a Bernoulli distribution with mean p, we modify equa-
tion (5.15) to estimate a trial specific pi,m, which is predicted by some transformation of
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sample size, denoted by xi,m:
Bi,m ∼ Bernoulli(pi,m) (5.18)
logit(pi,m) = mxi,m + c (5.19)
This transformation could be log(ni,m) or 1ni,m and is discussed in more detail in Section
5.3). The coefficient of xi,m is m which can be interpreted as the log odds ratio of being
high risk compared to low risk for each unit increase in xi,m. c is the intercept and the log
odds of being high risk when xi,m = 0.
In practice, xi,m will be centred for model efficiency and improved interpretation. The
intercept c will then be interpreted as the log odds of being high risk for an average sized
trial. The estimated βi,m is the bias effect for a high vs low RoB in study i in meta-analysis
m.
However, it is not possible to estimate m based on the unobserved data in equation (5.18).
We therefore borrow the ‘slope’ (m) from the observed high vs low RoB trials. Using the
observed data, of the high and low risk of trials where highj is an indicator variable for
j trials which are either high or low RoB. highj is therefore Bernoulli distributed with
the probability that a trial is at a high RoB, denoted by, probhighj , when xj is used as a
predictor.
highj ∼ Bernoulli(probhighj) (5.20)
xj is a function of sample size.
logit(probhighj) = mxj + α (5.21)
This allows the intercept, α, to be different to c (exchangeable) but the slope, m, (impact of
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trial size) is shared.
The WinBUGS code for all the models described can be found in Appendix B.
5.2.2 Case study application
We analysed data from 1678 trials included in 144 binary outcome meta-analyses that
were informative to detect differences in intervention effects between either high vs low
and/or unclear vs low RoB trials i.e. all meta-analyses in ROBES that were informative.
This dataset was derived by creating two separate datasets and then combining these. We
created a dataset containing informative meta-analyses to detect differences in interven-
tion effects between either high vs low RoB trials i.e., meta-analyses that included at least
one high risk and at least one low risk trial. There were 917 trials included in 97 meta-
analyses. We similarly derived a dataset which included only meta-analyses which were
informative to detect differences in intervention effects between either unclear vs low risk
trials. This dataset consisted of 1029 trials included in 98 meta-analyses. When these two
datasets were combined there were 51 meta-analyses consisting of 268 trials which were
in both. Therefore 35% (51/144) of the meta-analyses in our analysis dataset include high
and unclear (and low) risk trials, while 32% (46/144) contain only high and low and 33%
(47/144) contain only unclear and low.
The same priors as in the univariate (Welton et al) model are used with the addition of a
uniform prior (-1,1) for the correlations of ρw and ρB. Sensitivity analyses were conducted




Results for each of the models described above are given in Table 5.1.
We found as in the original Welton model, when we code the dichotomous variable as
high or unclear versus low RoB, that treatment effects were exaggerated by 14% (ROR of
0.86, 95% CrI, 0.80 to 0.93). The estimated increase in between trial heterogeneity amongst
high or unclear vs low RoB trials was SD=0.11 (95% CrI, 0.02 to 0.25) and the between
meta-analysis variation in average bias was estimated to be SD=0.09 (95% CrI, 0.01 to
0.20).
When we model only the high vs low risk trials and the unclear vs low risk trials, i.e.
stratified analyses, we see that the average bias is slightly bigger in high vs low risk trials
compared to the unclear vs low RoB estimates. In the high vs low RoB analysis, treatment
effects were exaggerated by 18% on average (ROR of 0.82, 95% CrI, 0.74 to 0.92) whilst the
average bias in the unclear vs low RoB trials was estimated closer towards the null (ROR
of 0.89, 95% CrI, 0.74 to 0.92). However, in both cases the CrIs are wider, highlighting more
uncertainty, as there are less trials and meta-analyses included. The estimated increase in
between trial heterogeneity amongst the unclear RoB trials is lower SD=0.06 (95% CrI, 0.01
to 0.20), in contrast to, the between trial heterogeneity which is higher amongst the high
risk trials SD=0.17 (95% CrI, 0.02 to 0.36). However, the CrIs do overlap.
Bivariate normal model
The bivariate normal model estimates the ROR as almost identical as the separate models
when only the unclear RoB trials are included and when only the high RoB trials are
included. However, there was no gain in precision in the average biases when modelled
simultaneously. When a uniform (-1,1) was used, ρw was estimated to be -0.04 (95% CrI, -
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0.94 to 0.97) and ρB was estimated as -0.08 (95% CrI -0.94, 0.91). Similarly, when a uniform
(0,1) was used, this gave ρw an estimate of 0.51 (95% CrI 0.03, 0.98) and ρB an estimate
of 0.45 (95% CrI 0.02, 0.95). However, the results from each of our parameters of interest
remained the same.
The estimated between-study heterogeneity, κ, of the high vs low RoB trials remained the
same in the bivariate normal model as it did when they were estimated univariately. This
estimated increase in between trial heterogeneity was 0.18 (95% CrI (0.02, 0.35)). However,
the estimated between-study heterogeneity of the unclear vs low RoB trials increased from
0.06 (0.01, 0.20) when modelled univariately to 0.14 (0.01, 0.29) in the bivariate normal
model. The between meta-analysis variation in average bias,ϕ, of the unclear vs low RoB
trials increased from 0.08 (0.01, 0.20) in the univariate model to 0.14 (0.02, 0.29) in the
bivariate model. Similarly, the between meta-analysis variation in average bias, ϕ, of the
high vs low RoB trials increased from 0.06 (0.01, 0.21) in the univariate model to 0.10 (0.01,
0.32) in the bivariate model. It is likely these differences can be attributed to the variance
components being estimated poorly in meta-epidemiological models due to their wide
CrIs.
Probability models
The probability model estimated the average bias for high vs low RoB trials as ROR=0.81
(95% CrI, 0.74 to 0.90). This gives a similar ROR and narrower CrI, in contrast to when the
high vs low RoB trials are estimated univariately, ROR of 0.82 (95% CrI, 0.74 to 0.92). This
may because the probability model includes all 1678 trials (144 meta-analyses) whilst the
high vs low RoB univariate analysis includes 97 meta-analyses (917 trials).
The estimated overall probability is given by 0.44 (95% CrI, 0.13 to 0.88). This probability
varied by trial, such that the more extreme unclear RoB trials with treatment effect esti-
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mate further from the null and closer to that of high risk trials had a higher probability.
Figure 5.1 shows the distribution of individual probabilities from each of the unclear RoB
trials, i.e. the probability an unclear RoB trial is high risk. Towards the right-hand side
of Figure 5.1, we can see the more extreme unclear RoB trials, with individual treatment
effects which are further from the null, have a higher probability of being at a higher RoB.
Figure 5.2 shows the distribution of study sizes from each of the RoB categories; high-
lighting that unclear RoB trials do have study sizes which are more similar to the high
RoB trials and smaller than the low RoB trials.
When we use sample size as a predictor of whether an unclear RoB trial is actually high
risk, we see the ROR is the same as in the probability model, given by ROR= 0.81 (95%
CrI, 0.73 to 0.90). Figure 5.3 shows the distribution of the mean posterior distribution of
B, when being predicted by sample size, however we see a slightly different pattern to
Figure 5.1. To see this more clearly, we plot the individual probabilities of an unclear RoB
trial being high risk from both the probability model (green) and the probability model
(black) when predicted by sample size in Figure 5.4. We broadly see that as the individual
study size of a trial increases, the probability that a trial is high risk decreases. We can also
see the probabilities are higher for smaller sample sizes and lower for bigger sample size
in the probability model predicted by sample size rather than the probability model.
We can also plot the slope of the sample size regression from Table 5.2. Figure 5.5 shows
that as sample size increases the predicted treatment effect decreases.
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ROR 0.86 0.89 0.82 0.89 0.83 0.81 0.81
(95% CrI) (0.80, 0.93) (0.80, 0.97) (0.74, 0.92) (0.81, 0.98) (0.75, 0.92) (0.74, 0.90) (0.73, 0.90)
κ 0.11 0.06 0.17 0.14 0.18 0.18 0.18
(95% CrI) (0.02, 0.25) (0.01, 0.20) (0.02, 0.36) (0.01, 0.29) (0.02, 0.35) (0.03, 0.35) (0.03, 0.35)
ϕ 0.09 0.08 0.06 0.14 0.10 0.14 0.13
(95% CrI) (0.01, 0.20) (0.01, 0.20) (0.01, 0.21) (0.02, 0.29) (0.01, 0.32) (0.02, 0.30) (0.02, 0.29)
All priors on the variance components κ, ϕ and τ were the modified Inverse Gamma (0.001, 0.001) distribution, as described in Sec-
tion 4.3.1.
178
Figure 5.1: Plot of the individual probabilities of unclear RoB trials being high risk trials
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Unclear RoB trials: median sample size is 113, IQR: 60 to 241, 95% percentile: 26-793.
High RoB trials: median sample size is 100, IQR: 50 to 206, 95% percentile: 22-935.
Low RoB trials: median sample size is 136, IQR: 61 to 324, 95% percentile: 28-2282.














from m(xi,m) + c, where xi,m is centred, m is the
slope (shared between the observed and unob-
served); c is the intercept of the unobserved sam-
ple size regression and α is the intercept in the ob-
served sample size regression. Reported on the log
scale.
180
Figure 5.3: Plot of the individual probabilities of unclear RoB trials being high risk trials,
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Figure 5.4: Plot of the mean posterior distribution of B against study size, for all unclear
RoB trials, for both the probability model and the probability model when using sample
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Figure 5.5: Plot of the individual probabilities of unclear RoB trials being high risk trials,
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5.2.4 Using the outputs of meta-epidemiological models to inform a new trial
The models developed in the first part of this chapter can be used to formulate a prior
distribution for the likely amount of bias in a trial when analysed in a Bayesian frame-
work. External information from these meta-epidemiological studies can be used to form
the prior distribution, related to the bias characteristic and type of outcome. This adds un-
certainty around the treatment effect to appropriately down-weight them. The estimated
(posterior) intervention effect in a new study will change in light of which prior distribu-
tion is formulated and the assumptions made in each.
Bias adjustment in this way has not (to our knowledge) been used in an individual trial
context and rarely used within a meta-analysis context [80, 140]. We assume that the high
vs low bias estimate and its associated κ and ϕ are used from either the bivariate model
or probability model to form a prior distribution on the amount of bias suspected to ad-
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just the treatment effect in a new trial. There are several possible ways of forming the
prior based on these outputs. We briefly describe possible prior distributions that could
be considered. These include:
 the predictive distribution for bias in a new trial; a predictive distribution is drawn
from the ROR distribution but additionally reflects the uncertainty as to where a ran-
domly selected study setting might lie in this distribution, as well as the uncertainty
in κ and ϕ [147]. This assumes that the target setting for the decision is “similar”
to those in the studies included in the meta-epidemiological study. This is a prior
based on the mean and all variation. Trialists may be happier to use this in practice
as it includes all the uncertainty in the bias estimate, however, it will then also lead
to imprecise estimates.
 Shrunken meta-analysis specific estimate; we can use the shrunken estimate drawn
from the ROR (depending on the relative size of the study and the degree of hetero-
geneity) of a specific meta-analysis [147]. This meta-analysis could be chosen based
on how closely related it is to a trial, for example based on the outcome measured or
inclusion/exclusion criteria. The meta-analysis specific ROR will be more precisely
estimated than the study estimates alone because it is “borrowing strength” from
the other study estimates.
 a prior based only on the mean ROR; a prior based only on the mean will adjust the
biased study and add only uncertainty from the ROR CrI. This may not be as extreme
as some of the other options for bias adjustment and would allow the analyst to
assess the sensitivity of their findings.
 a prior based on bias in an extreme meta-analysis (with large bias) and within-meta-
analysis variation. This prior is likely to be used when a trialist has a very strong
suspicion that their trial result is at a very high RoB. To obtain an extreme meta-
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analysis we take the 95% upper range of the between-meta-analysis variation. The
variance is obtained by adding the variance (uncertainty) of the mean bias to the
within-meta-analysis variance in bias. This prior should make a marked adjustment
to the study and add considerable uncertainty.
5.2.5 Summary
In current meta-epidemiological methodology, a binary variable is modelled, usually ‘un-
clear’ is grouped with ‘high’ RoB. Therefore, the difference investigated is between a high
or unclear RoB trial characteristic compared to the study without the characteristic. What
may be more relevant to trialists working on individual trials is the difference between
a high vs low RoB trial. Rather than excluding the unclear of bias trials, we developed
a bivariate model which includes all the data and allows for high vs low estimates and
an unclear vs low estimate. The key thing here is that it not only makes maximal use of
the data but also in principle allows us to borrow strength between the high and unclear
RoB estimates, which may be expected to be correlated. The bivariate (conditional product
normal) model does have an extra computational complexity compared to the standard
Welton et al model which took several more days for convergence to be achieved. This
may be a significiant draw back to this model.
In the probability model, we estimated how likely a trial classified as unclear is in fact a
high RoB trial. In our dataset, we found that the probability model gave an average ROR
estimate which was consistent with the ROR from the high vs low RoB model but slightly
more precisely estimated. The model estimates the probability that blinding was not ad-
equate in each trial where reporting of blinding was unclear. In cases where the unclear
RoB trials actually had the methodological characteristic, this will cause the average bias
to be underestimated in the standard Welton model (i.e. when the unclear RoB trials are
grouped as high RoB). Therefore, when there are many unclear RoB trials, the standard
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Welton et al model could be either over estimating or underestimating the true amount of
bias between high/unclear and low RoB trials.
5.3 Meta-epidemiological considerations for continuous study charac-
teristics: examining the association of sample size on estimated treat-
ment effects
5.3.1 Introduction and aims
Not all study characteristics of interest are binary or categorical, some are continuous.
For example, more recent trials may be at less RoB than older ones due to improve-
ments in trial conduct and methodology. We could therefore look at the impact ‘years’
has on estimated treatment effects. It can also be hypothesised that smaller studies are at
a higher RoB than the larger studies. However, current meta-epidemiological models of-
ten dichotomise continuous study characteristics, using an arbitrary cut-off to characterise
trials into ’high RoB’ and ’low RoB’ groups [148, 149, 140].
Therefore, our aim, in this section, is to develop meta-epidemiological models with a con-
tinuous study characteristic. A description of the models are given in Section 5.3.2. Section
5.3.3 is a case study using sample size, in which model fit and interpretation are discussed
in relation to the Welton et al model with a binary study characteristic. The results and key
findings are given in Sections 5.3.4 and 5.3.5.
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5.3.2 Description of the models
Continuous study characteristic
We first introduce the model(s), describing analogous models to the Welton et al model
with a binary covariate, and denoting the continuous covariate as xi,m. The Welton et al
model with a binary covariate is described explicitly in Chapter 4, where the average bias
between the high and low RoB trials and the variability in the average bias is estimated
(ϕ2) and additionally the variability in the high RoB trials (τ 2 + κ2). For brevity, we first
simplify this model by not estimating the variability in bias, i.e. not estimating κ2.
We modify the Welton et al model, such that βi,mCi,m, in the regression equation (4.2)
is replaced by bmxi,m. This fits a regression line with slope, bm, for each meta-analysis,
estimating the effect of xi,m on the estimated treatment effects:
logit(pa,i,m) =
 µi,m control armµi,m + δi,m treatment arm (5.22)
where
δi, m ∼ N(dm+bmxi,m, τ 2m) (5.23)
In contrast to the Welton et al model with a binary study characteristic, dm is the inter-
vention effect when xi,m = 0 for meta-analysis m. In practice, xi,m is likely to be centred.
bm is the effect of xi,m in meta-analysis m, given by equation (4.6). τ 2m is the heterogene-
ity in meta-analysis m. b0 is the average association between xi,m and effect size across
meta-analyses and ϕ2 is the variation in association of xi,m across meta-analyses.
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Continuous study characteristic and between trial heterogeneity
Comparing the model described above with the structure of the Welton et al model for bi-
nary characteristics, there is a difference, which is allowing for the extra variability within
the high RoB trials. This is fixed between meta-analyses, denoted by κ and explicitly de-
scribed in Section 4.3.1. We therefore extend the model with the continuous covariate
(5.22) to allow for a potential association of the continuous variable with heterogeneity,
as well as with the average effect size. To account for the variability of the covariate, xi,m
on the treatment effect, we multiply xi,m by κ2:
δi, m ∼ N(dm+bmxi,m, τ 2m + κ2xi,m) (5.24)
This allows the heterogeneity to also depend on sample size. We therefore provide the
analogous model with a continuous study characteristic to the Welton et al model with a
binary study characteristic when the bias in the high risk trials is allowed to vary.
The WinBUGS code for all the models described can be found in Appendix B.
5.3.3 Case study application: sample size
It can be hypothesised that smaller studies are at a higher RoB than the larger studies.
Here, the Welton et al meta-epidemiological model of a binary covariate (high vs low
RoB) is extended to look at the association of a continuous covariate, sample size, on the
treatment effect. To do this, we want a coefficient from each meta-analysis on how the
treatment effect (log OR) is associated with sample size, if there is a relationship at all.
In deciding which function of sample size, n, to use as the covariate in our analyses, we
draw on relevant literature [87, 150, 151, 152, 153]. Smaller studies could be done less rig-
orously and/or be at risk of publication bias, that is, they are only published if they find
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a significant treatment effect. Suppose in a (single) meta-analysis, study i contributes a
treatment effect βi such as a log of the OR, and an associated SE, se (βi) [151]. To look for
an association between study size and treatment effect estimate in an individual meta-




. To examine if such studies were at risk of po-
tential publication bias, Egger et al explored whether there was funnel plot asymmetry by












The underlying hypothesis was, the smaller the trial, the less precise it will be. In this
regression, a is the intercept and if it is not equal to 0, this would indicate funnel plot





when β̂i is on the log odds ratio scale.
In an attempt to correct this, Harbord et al used the variance rather than the standard
error for when the log odds ratio is the outcome; but did still not advocate its use [87].
Peters et al then suggested using 1
n
to see how sample size is associated with treatment
effect estimates [154]. Moreno et al [152] compared each of these methods and found 1
n
to
be more useful than Eggers test. This motivates the use of 1
n
and subsequent use of 1√
n
[153]. This also has the nice property that when you extrapolate to an infinite sample size,
the amount of bias tends to 0. We additionally use log(n) and n as a comparison. To aid
comparisons across models, we dichotomise sample size using a cut-off value previously
used when the study characteristic was treated as binary [140].
Rhodes et al have previously used the ROBES database to look at the differences in inter-
vention effect between trials with sample size less than 100 participants and those with
larger sample sizes [140]. We therefore dichotomise the sample size of trials as less than
100 and greater than or equal to 100 in order to compare our results when we treat sam-
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ple size as continuous. We analysed data from 2058 trials included in 180 binary outcome
meta-analyses.
A uniform prior over the interval (0,5) was assumed for κ.
Model fit
The deviance information criterion (DIC) [155] was used to compare each of the models to
help assess model fit by (i) comparing which study characteristic fits the dataset best and
(ii) whether the extra extension to include the between-study variability (i.e. the inclusion
of κ2) is needed. The deviance is defined as – 2 * log(likelihood). The posterior mean of the
residual deviance can be used to assess model fit, which is expected to be roughly equal
to the number of unconstrained data points for non-hierarchical models, if the model fits
well. The posterior mean of the total residual deviance is usually denoted by D̄ and the
point estimate of the deviance obtained by substituting in the posterior means is denoted
by D̂. PD is the posterior mean of the deviance minus the deviance of the posterior means
and defined as ‘the effective number of parameters’ [155], and is given by:
PD = D̄ − D̂ (5.26)
PD should be approximately equal to the true number of parameters for more simple,
non-hierarchical models with uninformative priors. The DIC is defined as
DIC = D̄ + PD = D̂ + 2PD (5.27)
DIC is a generalisation of Akaike’s Information Criterion, more commonly known as AIC.
The model with the smallest DIC is said to be the model that would be the closest to
predict a dataset with the same structure as the one observed [156]. It has been reported
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that models with differences of more than 10 may be viewed as significant whilst any
models with differences smaller than 5 could mean there is little to choose from and focus
should be more on inferences of the research question. Since D̄ incorporates a degree of
penalty for complexity it is viewed as a measure of model ‘adequacy’ rather than model
fit [157].
Interpretation of continuous study characteristics analogous to binary study character-
istics
Fitting a model with a continuous study characteristic means it can be difficult to compare
our results to the standard Welton et al model which has a binary study characteristic. In
order to get something comparable, the median sample size of the dichotomised larger vs
smaller sample size was compared in order to get the ROR. The median sample size of the
smaller trials (those with sample sizes less than 100) was 56 and the median sample size
of the larger trials (those with sample sizes greater than 100) was 207.
We use the average estimated bias, ROR (b0), from each of the models described to predict
the estimated treatment effect, on the log odds ratio scale, for a trial with a study size of
56 and 207, respectively.
lnORn=207 = b0xn=207 (5.28)
lnORn=56 = b0xn=56 (5.29)
We then calculate the ROR, that is the predicted odds ratio for study of size 207 divided





Extrapolation to a new study
190
We can use the model to see what size a study would need to be, under the assumption
that the larger studies become less biased, for the estimated treatment effect to have no
association with its sample size. We therefore want to know what size a study will need
to be for the amount of bias to be negligible. For an arbitrary effect size, δ (on the log odds
ratio scale), we wish to see what size xn will need to be for the average bias, b0, to tend to
zero in our regression:
Predicted treatment effect = δ + b0xn (5.31)
We approximate the value of xn that will give us a ’predicted treatment effect’≈ δ. For the
functions of sample size of xn = 1n and xn =
1√
n
, as xn → ∞, b0 → 0. We plot this for
a range of sample size values to graphically show the impact which sample size has on
the estimated treatment effect. We choose an arbitrary effect size of δ = 0, i.e. an OR=1.
We could have chosen any effect size and the same relationship would be shown because
we are interested in the relationship between b0 and xn when the ’predicted treatment
effect’≈ δ.
5.3.4 Results
The results from each of the models, with and without κ, and comparing to the binary
model when sample size is dichotomised, are given in Table 5.3. The model with the low-
est DIC was when sample size was modelled as a function of 1
n
with DIC=21785. This
model included κ2 which is the increase in heterogeneity for each unit increase in 1
n
. How-





significantly smaller DIC to the original binary model. The model with sample size as a
function of n had the worst model fit with DIC=21826.
Figure 5.6 suggest there is no association between sample size and treatment effect for
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sample sizes greater than approximately 10,000 participants when 1
n
is used. However,




When comparing to the results of the median sample size in each of the dichotomised
groups, we found that when taking the median sample size in each group it was also
consistent. For example, when the function 1
n
was used, the ROR=1.21 (95% CrI 1.13 to
1.30), whilst in the standard Welton et al model, the ROR=1.19 (95% CrI 1.09 to 1.30).
192













































































































D̄ is the posterior mean of the total residual deviance, PD is the effective number of parameters, DIC is the deviance information criterion
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Figure 5.6: Plot of the association between sample size and the predicted treatment effect
when 1
n























































Figure 5.7: Plot of the association between sample size and the predicted treatment effect
when 1√
n
























































Previous meta-epidemiological studies have so far only looked at the association between
sample size and estimated treatment effects using either quartiles [149] or a dichotomised
study characteristic [140]. We have provided the analogous model with a continuous
study characteristic to the Welton et al binary study characteristic model which allows for
the treatment effect to depend on sample size. It can also be used to predict what value a
new study needs to have of this variable to provide an unbiased estimate of the treatment
effect.
In each of the models we assume linearity between the outcome and covariate which
means for each increase in the covariate we therefore expect the outcome to increase by
the same amount. It may therefore be expected that the model which included the total
sample size n as a covariate fit the data poorly.
To look at the association between treatment effect and sample size, and treating sam-
ple size as continuous, we found the best fitting model (in this case study) modelled the
intervention effect as a linear function of 1
n
as the study characteristic.
5.3.6 Comparison to other studies
In the Rhodes et al paper, the authors looked at the association of sample size on treatment
effect, dichotomising sample size as a binary study characteristic, greater than or equal to
100 vs less than 100 and found a ROR=1.17 (95% CrI, 1.08 to 1.25) [140]. Using almost
the same dataset, this is consistent with our final model result treating sample size as
continuous.
Dechartres et al looked at the influence of trial size on estimated treatment effects in a
meta-epidemiology study consisting of 735 trials from 93 meta-analyses across various
196
medical conditions [158]. To do this, trials were split by quartiles and in a separate anal-
ysis split according to the number of patients in a trial, within each meta-analysis. In the
analysis using quartiles: quarter 4 (containing 25% of the largest trials) was compared
to quarter 1 (containing 25% of the smallest trials) using multilevel logistic regression.
In quarter 4 vs quarter 1 they found a ROR=0.68 (95% CI, 0.57 to 0.82). In the analysis
split using the size of the trial: trials of 1000 patients or more (large trials) were used as
a reference group – to compare with trials of less than 50 patients (small size trials) and
secondly trials of size 500-999 patients (moderate sized trials) . In secondary analyses they
also compared trials <100 vs ≥ 100 and found a ROR=0.74 (95% CI, 0.65 to 0.85) which
shows slightly more of an association than we found and is estimated less precisely. This
is consistent to our study when we compared trials >100 vs trials ≥ 100 giving a ROR of
1.19 (95% CI, 1.09 to 1.30), as the analogous to this is <100 vs ≥ 100 giving a ROR of 0.84
(95% CI, 0.77 to 0.92).
5.4 Conclusions
In this chapter, extensions of the standard meta-epidemiology model have been described
which can account for common scenarios of categorical and continuous study character-
istics to allow for greater flexibility and understanding of meta-epidemiological data.
We have discussed the possible model implications for how to treat unclear RoB trials in
meta-epidemiological studies so that trialists can estimate the average bias in high vs low
RoB trials which can then be used for bias adjustment. We have shown that estimating
the average bias attributed to high vs low and unclear vs low RoB trials in the bivariate
model gives the same results as modelling the contrasts separately, in this case study data
set. Therefore, in this dataset, there does not seem to be an advantage to using a bivariate
model compared to modelling high vs low RoB trials separately.
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We also modelled the probability that an unclear RoB trial is truly high risk which pro-
vides an estimate for the average effect of high risk trials. In this dataset we found the
probability model estimates the average bias in high risk trials more precisely. More case
studies are therefore needed using these models (bivariate and probability), given the ex-
tra computational time over the standard models.
To our knowledge, this is the first meta-epidemiological study to use a continuous study
characteristic. Using a continuous study characteristic, rather than dichotomising at an
arbitrary value, can make more use of the data. This would allow the analyst to look at
the association between a continuous study characteristic and the estimated treatment
effect. For example, whether there was an association between the percentage of missing
data and the estimated treatment effect.
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6 Comparing methods for incorporating external evidence
on the effect size in sample size calculations
This chapter was a collaboration with Professor Nicky Welton and Dr Marta Soares. All
work in this chapter is my own except the actual running of the EVSI analyses (in Section
6.4.3) which were run by Marta Soares.
6.1 Introduction and aims
The results of the INVEST survey in Chapter 2 highlighted that trialists were not using
evidence synthesis methods to inform sample size calculations as much as they would
like. Yet, funders often highlight the importance of considering existing evidence during
the design of a RCT [3]. The justification of a sample size for a new trial is usually given in
a grant application, a study protocol and/or in the statistical methods when the results of
a trial are published; and these are almost always based on ‘traditional’ power calculations
[159, 160]. Ultimately, what is often of interest is what size a new trial needs to be in order
to update the existing evidence base and impact on policy and/or clinical practice. It may
therefore be beneficial to conduct a meta-analysis of existing evidence and work out what
size a new trial would need to be to demonstrate an intervention is effective, based on
the totality of evidence. Several methods have been suggested for explicitly incorporating
information from an existing meta-analysis into power or sample size calculations [6, 13,
73, 74], but it is unclear which of these (if any) to use in practice.
Notably, no one has compared all of these approaches in a single case study before. There-
fore, the aim of this chapter is to describe and compare the following methods: (1) ‘tra-
ditional’ power calculations; (2) calculations based on the power of a Bayesian analysis
of the new trial with an informative prior distribution based on a meta-analysis using: (i)
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expected and (ii) conditional power; (3) calculations based on the power of an updated
meta-analysis using: (i) expected and (ii) conditional power; (4) EVSI calculations (first
described in Section 1.3.3), a type of VoI calculation based on the ability of the new trial to
change the decision based on a cost-effectiveness model [161]. All of the approaches are
used to determine optimal sample size, but EVSI is not based on ’power’. EVSI is used to
determine the optimal sample size, through means other than power and is therefore not
directly comparable to the other methods. Advantages and limitations of each method,
and additionally their differing assumptions and interpretations, will be discussed.
These methods are illustrated using one case study meta-analysis: an existing meta-analysis
looking at the effectiveness of steroids for traumatic brain injury. The information avail-
able in 2002 showed inconclusive results. Based on this, the international, multi-centre
trial of steroids for traumatic brain injury, CRASH [83, 162], was funded. We take a retro-
spective look and compare how information from the available meta-analysis could have
informed the sample size calculation for the CRASH trial.
The remainder of the chapter is structured as follows. Section 6.2 gives some background
to the role of previous evidence in power or sample size calculations, Section 6.3 sum-
marises the case study for CRASH and Section 6.4 introduces each of the methods to be
compared. These methods are contrasted in Section 6.5 and the advantages and limita-
tions are discussed in Section 6.6, along with recommendations for use in practice and
further research.
6.2 Background
In this section we first describe the power of a trial and the current role that existing
evidence has in such a calculation. We then explicitly describe the null and alternative
hypothesis, which is shared across approaches (1) to (3). Classical power is then described.
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Finally, the concepts of conditional and expected power are introduced.
We focus on calculating sample size/power for a standard parallel clinical trial in which
we sample from two groups of patients, say the experimental and control arm, assuming
an equal number of patients in each. A power calculation calculates the probability of
rejecting the null hypothesis for a specific sample size. Therefore, power depends crucially
on sample size and we can set the same sample size, such that the power is 80%, for
example. There are various possible extensions for different trial designs, for example, in
cluster RCTs sample size also depends on the ICC [163, 164]. However, in this chapter we
focus on a standard two arm trial.
The ‘traditional’ use of existing evidence in sample size calculations is to inform param-
eters about which we need to make assumptions, for example the likely size of the event
rate in the control group or the typical standard deviation [160]. More specifically, the
event rate hypothesised in the control group is likely to come from previous literature,
whilst the clinician provides the minimal clinically important difference (MCID), which
determines the event rate or risk in the treatment group [165]. The SD in patient outcomes,
is the variability within individuals in which a value also needs to be assumed. A standard
sample size calculation requires assumed values of these parameters. A meta-analysis of
results of a set of similar, existing trials could provide information on these parameters.
Reviews of trials funded by the NIHR HTA programme found that although 94% (32/34)
of the trials examined used a referenced systematic review to justify the treatment com-
parison in the new trial, only 9% used it to inform the standard deviation (3/34) and none
to estimate the control group event rate [57]. Jones et al found that 16.2% (6/37) of appli-
cations used a systematic review to inform the likely effect size [11]. Our INVEST survey
found that 57% (59/103) of trialists surveyed use information from a meta-analysis to in-
form a sample size calculation. However, we did not collect precisely which parameters
were informed by the meta-analysis.
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We will use normal approximations throughout this chapter, to facilitate close form for-
mulae and comparisons across approaches. The formulae we describe are based on using
a normal likelihood to model the distribution of the data rather than a binomial likelihood
for binary outcomes. Although this will often require some approximation it allows us to
produce closed form formulae to calculate the required sample size or power methods.
These methods can be extended to model exact count data using a binomial likelihood.
Suppose data will be collected for a new trial to estimate the intervention effect, say Yn,
where Yn is, for example, a log odds ratio, based on a hypothetical sample size of n pa-
tients. We assume that Yn will be normally distributed with mean equal to the true treat-
ment effect δ and variance, σ
2
n








As in any standard sample size or power calculation, we re-express the hypothesised vari-
ance in the new trial as σ
2
n
, where n is the total number of patients in the new trial. σ2 in
this equation is defined as the variability in outcomes between two randomly selected pa-
tients, it is not the between patient variability in outcomes. Our notation here is based on
Spiegelhalter et al [13].
The null and alternative hypotheses
For a given outcome, we express the null hypothesis to be no effect (δ = 0) and the two-
sided alternative hypothesis [166]. We therefore define the two-sided null hypothesis H0 :
δ = 0 vs. the alternative hypothesis H1 : δ 6= 0. When we test this hypothesis, we can make
one of two decisions; either we reject the null hypothesis, or we do not reject it. However,
as this is a sample from the population that we are trying to make inferences from, there
is a possibility that we make the wrong decision. We can quantify the level of error we
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are willing to accept. We do this by setting the significance level to an arbitrary level of
α = p (reject H0|H0 true) (usually (α = 0.05), that is, there a maximum probability of 5%
that we reject the null hypothesis is true, when in fact there is no difference).
Alternative hypotheses might be tested, however, in order to compare all approaches, we
assume throughout the chapter that this is the hypothesis of interest. This hypothesis is
shared across approaches (1) to (3). In this next section, we derive the ’classical’ power
calculation and introduce the test statistic needed to determine whether to reject the null
hypothesis (or not). The test statistic compares our future data Yn with what is expected
under the null hypothesis. We then introduce the concept of ’conditional’ and ’expected’
power frameworks.
6.2.1 Classical power - (1)
Rejecting of the null based on the CI or (equivalently) Z statistic
In a traditional analysis, the result will be declared statistically significant (H0 rejected) if
a (1−α)% confidence interval (CI) around the estimate Yn lies wholly above 0 or below 0,






∼ N [0, 1] under H0 : δ = 0 (6.2)
Since the Z statistic has a standard normal distribution, we can visualise this under the
null hypothesis in Figure 6.1. Since the alternative hypothesis is two-sided we divide α
evenly between the tails of the distribution, given by α
2
. If the null hypothesis is true,
there will be only a 100×α% chance that the Z values are in the tails of the distribution.
Values far out in the tail areas therefore give strong evidence against the null hypothesis.











Figure 6.1: The standard normal distribution
area under the curve to the right of zα
2
is equal to α
2
) is defined as the critical value at the
upper boundary or right tail. It is defined as the critical value because it separates where
we reject/do not reject the null hypothesis. Similarly, for the lower boundary or left tail.
From equation (6.2) we can define these as boundaries ± zα
2
, such that we reject the null
hypothesis if Z > zα
2
or Z < −zα
2
.
We also make use of some useful properties of the standard normal distribution function.














where Φ is used to denote the cumu-
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The probability of rejecting the null, given a hypothetical effect size
In traditional power calculations, a true value of the intervention effect, δ = δ∗ is assumed.
We will refer to this as ’conditional’ power, since the calculated power is conditional on






where δ = δ∗, the
event at the upper boundary (equation (6.3)), will occur with probability:

















































Therefore, the probability of rejecting the null hypothesis, given a hypothetical true effect





















The total sample size can also be adjusted for expected dropout, n*=n/percentage ex-
pected to complete the trial [167], but we will not explore this further in this chapter.
Consideration of external evidence in sample size calculations
As described above, the ’classical’ power approach is within the ’conditional’ power frame-
work as we use a pre-specified effect size. A ’conditional’ power calculation calculates the
probability of rejecting the null hypothesis, given a hypothetical effect size for a specific
sample size. Sample size calculations for new trials are only informally guided by previ-
ous evidence in the classical power approach. However, more recently proposed methods
explicitly incorporate external information from an existing meta-analysis with the as-
sumption it will be used in the analysis stage of the trial [6, 13, 73, 74]. This previous
evidence, based on a meta-analysis, can be incorporated by the use of a prior distribu-
tion in a Bayesian framework [13]. However, meta-analyses are rarely used in this way in
practice [78]. In this chapter, we focus on the use of external evidence synthesis (through
a meta-analysis) on the intervention effect rather than the SD or control group event rate.
As described in Section 1.3.2, meta-analyses use either a fixed effect or a random effects
statistical model which are based on different assumptions. When there is substantial het-
erogeneity, a random effects meta-analysis should be used, however, this can have impli-
cations for the appropriate use of a meta-analysis to inform sample size calculations. We
focus on the case of an inverse-variance weighted meta-analysis (Section 1.3.2) throughout
this chapter.
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We also introduce the concept of "expected power". This is an inherently Bayesian ap-
proach, as it involves averaging across a prior distribution. We distinguish between the
situation when the target of inference is the new trial and when the target of inference is
an updated meta-analysis in both the ’expected’ and ’conditional’ frameworks.
6.3 Case study: The CRASH trial
The CRASH trial was funded in 2002, to look at the effect of cortisterioids vs placebo after
traumatic brain injury, following almost 25 years of inconclusive evidence and the most
recent study showing a potentially beneficial effect of steroids in acute spinal cord injury
[83]. We take a retrospective look at the evidence available before the CRASH trial was
conducted to compare the required sample sizes according to each of the methods we de-
scribe in Section 6.4. Figure 6.2 shows the results from a random effects meta-analysis syn-
thesising results from trials which were available before the CRASH trial was designed.
The ‘pooled’ estimate of the OR is 0.92 (95% CI 0.73 to 1.17) indicating an 8% reduction
in the odds of death but with a wide, inconclusive, CI. However, there is evidence that
the true intervention effect varies across studies, as shown by the between-study standard
deviation τ̂ estimate of 0.19. The 95% prediction interval has a much wider range of in-
tervention effects from 0.57 to 1.51 reflecting uncertainty as to where in the distribution of
study effects a new study population might lie [42]. Since both of these intervals overlap
an OR of 1, we cannot rule out the possibility that steroids may be harmful.
The original CRASH sample size calculation
“If the real mortality difference is 15% vs 13% then there is about a 65% chance that a
trial involving 10,000 patients will achieve 2P<0.01, and a 95% chance that a trial in-
volving 20,000 patients will do so [CRASH trial protocol [ISRCTN74459797]].”[168]
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Figure 6.2: Results from a random effects meta-analysis looking at the effect of cortisteri-
oids versus placebo after traumatic brain injury. The black diamonds represent the odds
ratios of the individual studies, and the horizontal lines their 95% confidence intervals.
The grey squares represent the weight which each study contributes to the overall pooled
result. The results of the 16 trials have been pooled in an inverse-variance (I-V) weighted
random effects meta-analysis to give an overall weighted average of the treatment effect.
NOTE: Weights are from random effects analysis
.       (0.57, 1.51)with estimated predictive interval
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N.B ’P’ is α in our notation. Replicating the initial sample size calculation for CRASH
which assumed that steroids would reduce the mortality difference from 15% to 13%, at a
power of 95% and an α of 0.01, the trialists aimed to include 21,442 patients. This power
calculation is based on binary outcomes but all of the approaches in this chapter are based
on normal approximations. The trialists calculated the classical power using the following
equation (6.11), which is based on the same principles as (6.10) but uses binary outcomes
directly.
The following equation is therefore equivalent to (6.10).



















To compare the methods published [13, 73, 74], we present formulae based on the total
sample size of a trial needed in order to detect a hypothetical treatment effect. In contrast
to presenting the control group event rate and then the hypothesised event rate in the
treatment group to detect the MCID, as is typically done in traditional sample size calcu-
lations, we present the hypothesised treatment effect between the two groups. Here, we
present the odds ratio but the difference in means or risk ratio could also be presented.
We replicate the initial CRASH sample size calculation by using odds ratios and normal
approximations to facilitate a comparison across methods. We convert the event rates in













We then need to hypothesise some uncertainty in this hypothetical treatment effect via
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its variance (σ2) in equation (6.1). A value for σ2 needs to be assumed. We assume the
median value of sei
√
ni across i previous trials [169]. To do this, we use the trials which
were available before CRASH and are part of the meta-analysis. Using this, we obtain
an estimate σ̂ = 4.52. Using equation (6.10) as above and assuming p-value of 0.05(α),
(which is more typical than 0.01 used in the original sample size calculation), we find that
a sample size of 6000 is required to have an 80% chance of detecting an effect, the true
effect is an OR of 0.85.
6.4 A comparison of methods for power calculations
In this section, a brief description of each of methods (2) - (4) is outlined.
Inference is based on the new clinical trial
We have already described the first approach when inference is based on the new clini-
cal trial in Section 6.2.1, that is, classical power. The traditional approach to sample size
calculations, as shown in (1) (Equation 6.10) only informally uses previous evidence [165]
to provide information on the size of the effect that the trial is powered to detect and/or
the typical standard deviation. It is also assumed that the results from the new trial will be
analysed in isolation, using a hypothesis test. Therefore, the test statistic in classical power,
given by equation (6.3) at the upper boundary, does not include any prior information.
In the next section, we introduce two ways, through the expected and conditional frame-
works, in which prior information can be incorporated into a sample size calculation when
inference is based on the new clinical trial. We also highlight the differences in the test
statistic compared to the classical power derivation (method (1)).
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6.4.1 Bayesian analysis of the new trial with an informative prior distribution - (2)
Lau et al first suggested expressing the results of a meta-analysis in the form of a prior
distribution to inform a power calculation [6]. They argue that since a meta-analysis al-
lows you to see if an intervention effect exists, it is possible to allow this evidence (via
the prior) to be incorporated in some way when determining the sample size of a new
trial. The main idea is to reduce research waste and use the results from a meta-analysis
to formulate a sensible distribution of likely treatment effects in terms of a prior distri-
bution [170], which adequately reflects the evidence base and its relationship to the new
trial. There are several possible options for this prior distribution, for example it might
be based on the predictive distribution or the shrinkage estimate from the meta-analysis
for the most relevant previous trial [169]. Jones et al [169] suggest the predictive distribu-
tion is most generally applicable if you have no information about the potential causes of
heterogeneity.
Following a fully Bayesian approach, inference will be based on the prior information
from the meta-analysis and the estimate of the treatment effect of the new study. Thus,
the prior will contribute to whether the null hypothesis is rejected or not. We use prior in-
formation for the overall treatment effect δ, based on an existing meta-analysis (assuming
one does exist):
δ ∼ N (δ0, V (δ0)) (6.13)
Where δ0 is the mean and V (δ0) is the variance of the prior distribution for δ. V (δ0) can
also be re-parameterised such that V (δ0) = σ
2
n0
for some n0 in which n0 is the ‘effective
sample size’ [13]. Here, δ0 and V (δ0) can take on any value, based on some output from
the meta-analysis. Following a fully Bayesian approach, inference will be based on the
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The posterior mean is a weighted average of the prior estimate (δ0) and trial estimate (Yn).
We define δ̂1 =
Ynn+µ0n0
n+n0





We may then wish to calculate the probability of obtaining a ‘significant’ posterior result
when testing the same null and alternative hypothesis as before. We will reject H0 if the
(1−α)% posterior CrI does not cross 0, i.e. upper bound of interval < 0 or lower bound of
interval > 0 [13]. That is, a two-sided test at some pre-specified α rejects the null hypothesis
H0 : δ = 0 if Pr(δ > 0|Yn) < α2 or Pr(δ < 0|Yn) <
α
2
. To get a significant result at the upper




V (δ̂1) > 0 (6.15)






n+ n0 − δ̂0n0
n
(6.16)
Note that equation (6.16) reduces to equation (6.3) in Section 6.2.1 where there is no exist-
ing evidence, i.e. δ̂0 = 0 and n0 = 0.














We now describe the probability of rejecting the null hypothesis (i.e. probability of equa-
tions (6.16) or (6.18)) in the case of (i) expected power (first described by Spiegelhalter
[13]) and (ii) conditional power (methodological novelty in this context).
2(i) Expected power
Spiegelhalter et al suggest averaging across the prior distribution to calculate the uncon-
ditional probability of a significant result, known as the ‘expected power’ [13], rather than
setting a value for the alternative hypothesis. When inference is based on the new trial,
the predictive distribution is chosen as the prior distribution to summarise the existing
meta-analysis, as by definition it is the predicted intervention effect in a new study. The
predictive distribution of Yn is used to average over the prior and evaluate the chance of













Recall at the upper boundary, given by equation number (6.16), under the predictive dis-












Averaging over the predictive distribution, given by equation (6.19):










































































The formula described above is derived in the same way as that in Jones et al [169] but
based on a two-sided instead of one-sided hypothesis test and based on a different null
(resulting in precise formula being slightly different). O’Hagan et al have suggested a sim-
ilar approach of averaging across a prior for sample size calculations but not using the
prior in analysis [171].
2(ii) Conditional power
Rather than averaging across values of the prior distribution, we might base inference
on the posterior distribution (6.14) but still calculate ’power’ conditional on some pre-
specified effect size, δ = δ∗, more similar to a classical power calculation (Section 6.2.1).
This allows us to answer the question, given the data so far, quantified by the prior distri-
bution (predictive distribution/random effects mean distribution), what is the chance of
getting a ‘significant’ result, if the true effect is at least as big as the MCID?
Although conditional power has not to our knowledge been derived within the context of
using the results of an existing meta-analysis to predict whether the new trial will result
in a posterior probability for the null hypothesis being rejected, it has been widely used in
the context of interim analyses [13]. In an interim analysis trialists are looking at, given the
accumulation of evidence in the trial so far (essentially the prior), what is the conditional
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probability that the future data collected in the trial will result in the posterior including
the MCID and the null hypothesis being rejected?






, the event at the upper boundary,





































































Therefore, the two-sided conditional power of the new trial to detect the hypothetical






























When there is no prior information, i.e. when δ̂0 = 0 and n0 = 0, equation (6.29) is the
traditional sample size calculation or classical power, given in equation (6.10).
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Inference is based on the updated random effects mean
6.4.2 Updated meta-analysis - (3)
So far in this chapter we have assumed that the focus of inference is on the intervention
effect in the new trial. Now suppose we are interested in whether a new trial can impact
an existing meta-analysis. Inference will therefore be based on the updated meta-analysis
including the new trial data, the focus of which is usually the updated random effects
mean [73, 74]. This assumes that the intervention effect of the new trial will be drawn
from the random effects distribution.
Suppose that the current estimate of the random effects mean, µ, (based on existing data

























Then, if we assume that the true treatment effect in the new trial will be drawn from the
random effects distribution, then the predictive distribution of Yn, given µ and a fixed










Inference will be based on the updated meta-analysis, that is, the updated random effects




YnV (µ̂0) + µ̂0Vp (Yn)
V (µ̂0) + Vp (Yn)
,
V (µ̂0)Vp (Yn)
V (µ̂0) + Vp (Yn)
)
(6.34)
Where Vp (Yn) = σ
2
n
+ τ 2 and written within a Bayesian framework. We denote µ̂1 =
YnV (µ̂0)+µ̂0Vp(Yn)
V (µ̂0)+Vp(Yn)





We may then wish to calculate the probability of obtaining a classically ‘significant’ result
when testing the two-sided null hypothesis H0 : µ = 0 vs. the alternative hypothesis
H1 : µ 6= 0 for some α = Pr (reject H0|H0). This is equivalent to the (1− α)% CrI for µ not
crossing 0, i.e. upper bound of interval < 0 or lower bound of interval > 0. That is, a two-
sided test at some pre-specified α rejects the null hypothesisH0 : µ = 0 if Pr(µ > 0|Yn) < α2







V (µ̂1) > 0 (6.35)
Substituting µ̂1 and V (µ̂1) and re-arranging for Yn we have:


















V (µ̂1) < 0 (6.37)















Two methods in each of the ‘expected’ [74] and ‘conditional’ [73] power frameworks have
been proposed to calculate the power of the new trial to impact upon the meta-analysis
mean.
3(i) Expected power
The expected power approach was first described by Sutton et al [74] and calculates the un-
conditional probability of a significant result of the updated random effects meta-analysis
mean with the new trial. Sutton et al [74] used a binomial likelihood rather than a nor-
mal approximation. This requires a simulations-based approach but it is more exact and
should perform better for small counts (in particular, can handle counts of 0). Their ap-
proach also accounts for the full uncertainty in the between-study standard deviation τ .
The authors assumed the control group event rate in a future study is equal to the (un-
weighted) average of those in the existing trials of the meta-analysis. A new study is sim-
ulated from the predictive distribution (6.32). The simulated study is then included in the
meta-analysis and a rule used to establish whether the meta-analysis is conclusive, where
‘conclusive’ is defined as statistical significance. This is done N times. The expected or av-
erage power is estimated by calculating what proportion of the N simulations are deemed
to give conclusive results. Jones et al [169] present a normal approximation version to pro-
duce a closed form solution, which is equivalent to the following derivation.
To make predictions concerning future values of Yn (and therefore predict the uncon-
ditional chance of a ‘significant result’, in a meta-analysis), considering the uncertainty
about its mean µ, we can average over the prior µ ∼ N (µ0, V (µ0)) so that the predictive
distribution of Yn is given by:
Yn ∼ N (µ̂0, V (µ̂0) + Vp (Yn)) (6.39)
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Then under this distribution, equation (6.39), the probability of rejecting the null hypoth-
esis at the upper boundary, given by equation (6.36) is:
EPREMA = P
(
































































Therefore, the (two-sided) expected power of the new trial to impact the updated meta-































When τ = 0 equation (6.44) refers to the expected power of an updated fixed effect meta-
analysis.
The formula given in the Jones et al paper again refers to testing the one-sided null hy-
pothesis H0 : µ > θ vs. the alternative hypothesis H1 : µ < θ for some α = p (reject H0|H0)
but is otherwise equivalent to 6.42.
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3(ii) Conditional power
Similar to method 2(ii), Roloff et al [73] suggest rather than averaging across values of
a prior distribution, the hypothetical effect size can be set, say µ = µ∗, to calculate the




























































































Therefore, the (two-sided) conditional power of the updated meta-analysis (with the new











































When τ = 0 equation (6.49) refers to the conditional power of an updated fixed effect
meta-analysis, having observed the fixed effect meta-analysis result.
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Although inference is made on the updated meta-analysis result, Roloff et al do not strictly
perform this within a Bayesian framework [73]. In contrast, Roloff et al has used informa-
tion size or precision based on variance of the log odds ratio using assumptions for the
event rate in the control group based on previous studies, rather than our normal approx-
imation where we make an assumption regarding σ2.
Assumption of heterogeneity parameter for methods (3(i) and 3(ii))
The authors [73, 74] additionally give a formula for calculating power given multiple ad-
ditional studies and they note that this will increase power to impact on the random effects
mean (rather than one large study) when existing between study heterogeneity is moder-
ate to high. When this is the case, heterogeneity can be partitioned into the between study
heterogeneity from the existing studies and the new estimate of the between study het-
erogeneity from the new study/studies. The extent of future heterogeneity (τ 2new) needs to
be specified. Two possibilities suggested are (i) to assume τ 2new is it’s the same as in exist-
ing studies, which is the approach we have used above or (ii) τ 2new could be larger than
existing studies if different subgroups of patients are studied.
Inference is based on the updated cost effectiveness model
6.4.3 Updated cost-effectiveness analysis, EVSI - (4)
Decisions on which treatments to recommend in clinical guidelines and guidance consider
both costs and benefits of interventions, usually based on a cost-effectiveness model [52].
We may be uncertain as to which is the most cost-effective intervention and a new RCT
will increase our certainty as to which is the best intervention. EVSI measures the benefit
we gain from being able to reduce the uncertainty in a decision by adding to the evidence
base through running a new RCT of a given sample size. The EVSI can be compared with
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the cost of running an RCT with such a sample size to find whether such a study would
be an efficient use of research resources, and also to identify the optimal sample size. To
calculate the sample size based on the results of an updated cost effectiveness analysis
(assuming a decision model is already in place):
1. A prior distribution is specified for the treatment effect (6.13). Prior information for
the treatment effect can be given by the predictive distribution of the random effects
meta-analysis (although any prior can be used, predictive may be more applicable),
assuming a fixed value of the between-study variance, τ 2, given by equation (6.13).
2. A hypothetical sample size is given to a new study (size n) which will provide new
data, D. Following a fully Bayesian approach, inference will be based on the poste-
rior distribution of δ, given the new trial data, Yn, instead of the data alone, given by
equation (6.14).
3. We then use this posterior distribution to update the cost-effectiveness model.
4. If the optimal decision changes, there is a gain in net benefit (NB), which is the dif-
ference in incremental benefit and cost from using the new optimal treatment. If the
optimal decision is unchanged there is no gain in NB.
5. This is done multiple times over future possible datasets D to calculate the aver-
age gain and obtain the EVSI, defined as the expected NB from a particular study
design minus the expected NB of current information. This requires posterior updat-
ing within simulation over new data. It is only possible to get a closed form formula
for EVSI for very simple situations because it depends on the NB function. We then
find the expected NB averaging over the posterior distribution of all the parame-
ters conditional on new data. If the NB is linear in all parameters, then we can use
conjugacy arguments to find approximate normal posteriors and plug their expec-
tations into the formula [52]. However, the function is often non linear and depends
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on products of parameters that are correlated. In this case it is not possible to plug
in the means.
6. This process (steps 2-5) is repeated for multiple hypothesised sample sizes.
7. Then for each sample size the difference between the EVSI and the costs of sampling
(i.e. monetary values) for specific designs gives the expected net benefit of sampling
(ENBS), allowing the optimal sample size to be calculated [52]. Therefore, when the
benefits of collecting more information are bigger than the costs of doing so, ENBS
will be positive.
8. The optimal sample size design can then be determined from the ENBS which mea-
sures the difference between the cost and benefit of designs with different sample
sizes [172]. The benefits are always in terms of the NB function, however that is de-
fined. In health economics net benefit is usually defined in terms of monetary units,
and health benefits are converted to monetary units via quality adjusted life years
(QALYs) for a given willingness to pay per QALY.
Again, for this case study analysis Marta Soares provided the EVSI results but not the
ENBS results. This would have to be contrasted with the cost of sampling to determine
the optimal sample size. However, EVSI can still show where further gains are minimal.
Table 6.1 summarises each of the methods described.
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Table 6.1: Summary of the closed form equations for methods (1) – (3). Method (4) does not give a closed form solution
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For each of the methods in Table 6.1, we give the results of the two-sided hypothesis test
in Section 6.4 including the ability for a new trial to update a fixed and random effects
meta-analysis.
We set the two-sided alternative hypothesis that there is a non-zero effect and the MCID
to be OR=0.85 (i.e. δ∗ or µ∗ = log(0.85)) as in the original CRASH sample size calculation
and use a significance level of α = 0.05, that is, we calculate the power of the new trial to
detect a 15% reduction in odds of death in the treatment group compared to the control
group. When applying the methods to CRASH we need to choose our prior distribution.
We choose the predictive distribution from the meta-analysis as the prior throughout. We
therefore take µ̂0 = ln(0.92) = −0.0833, and assuming σ = 4.52 and τ = 0.19 this gives
n0 = 331. Figure 6.3 displays the relationship between the new sample size, n, and the
power for each of the four methods. Figure 6.4 displays the relationship between the new
sample size, n and the EVSI.
Random effects meta-analysis
Figure 6.3 shows that the traditional power calculation (1) suggested 6000 patients were
required for a power of 80%.
6.5.1 Bayesian analysis of the new trial with an informative prior distribution - (2)
For the same sample size, the ‘expected power’ of a Bayesian analysis (2(i)) with an infor-
mative prior based on the predictive distribution of the existing meta-analysis was 74%.
However, the expected power of a Bayesian analysis (method 2(i)) is greater than the clas-
sical power (1) of smaller sample sizes. For example, for a total sample size of 1500 patients
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the traditional power calculation gives only 29% compared to an ‘expected’ power of 50%.
Assuming a true effect of δ = δ∗ = log(0.85), the conditional power of a Bayesian anal-
ysis of the new trial incorporating the prior (2(ii)), is visibly lower for a sample size of
1000 patients than the traditional power calculation (1). This seems slightly unintuitive as
we are incorporating prior information equivalent to data on an additional 331 patients.
However, note that the effect we wish to detect of (OR=)0.85 is more extreme than the
prior mean (OR=0.92 (95% CI, 0.57 to 1.51)). As the sample size increases, the data from
the future trial dominates the posterior and any influence of the prior becomes negligible.
6.5.2 Updated meta-analysis - (3)
The expected power (3(i)) and the conditional power of the random-effects meta-analysis
to detect an effect at least as big as (OR=) 0.85 having observed a difference of OR = 0.92
[0.57; 1.51] (3(ii)) is <10% across all possible sample sizes.
6.5.3 Updated cost-effectiveness analysis, EVSI - (4)
In contrast, the EVSI (4) calculation in Figure 6.4 shows that, to reduce the uncertainty in
the decision model, regarding whether or not cortisterioids should be used in practice, a 2-
arm randomised trial with approximately 2000 patients would provide a net health gain of
almost 15000 QALYs. We see that there is only minimal gains in QALYs for a sample size
greater than 2000 patients (and costs would increase). The uncertainty in the treatment
effect as seen in the wide prediction interval (Figure 6.2) may be driving the impact on
the decision model as EVSI measures the value of collecting evidence from a given study
design to reduce decision uncertainty [162].
226
Figure 6.3: Power curves for the two-sided test H0 : δ = 0 vs. the alternative hypothesis
H1 : δ 6= 0. Methods 2(i)) and 3(i) require a prior (to average across) and uses the predictive
distribution. Method 3(ii) doesn’t require a prior and instead updates the meta-analysis.
Method 2(ii) uses the predictive distribution as a prior. We assume α = 0.05 and a ‘typical’
standard deviation σ of 4.52 (estimated as the median across studies). Additionally, for
methods (1), (2(ii)) and (3(ii)) a hypothetical effect is set to detect an OR=0.85.
227
Figure 6.4: EVSI values according to total sample size of a new trial informing probability
of the event and treatment effect in both groups (in terms of quality adjusted life years
(QALYs) , ENBS is not worked out here and is therefore not given in terms of cost
Fixed effect meta-analysis
We now choose to investigate the ability a new trial has to impact a fixed effect meta-
analysis result, i.e. when equations 3(i) and 3(ii) have τ = 0. When τ = 0 , methods 3(i)
and 3(ii) reduce to 2(i) and 2(ii) respectively. The fixed effect meta-analysis distribution
now becomes the prior distribution: OR=0.93 (95% CI, 0.76 to 1.14). We therefore take
µ̂0 = ln(0.93) = −0.0833, and assuming σ = 4.52 (as earlier) and τ = 0. This gives n0 =
1446.
As in the random effects case, we find that the conditional power of the Bayesian anal-
ysis (incorporating prior information equivalent to data on 1446 patients) is less than the
classical power (ignoring the previous data) across all sample sizes. Again, this is because
the prior mean is much closer to the null than the effect we are trying to detect. In con-
trast, to the random effects case, power for methods 3(i) and 3(ii) is higher (i.e. with no
heterogeneity).
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Figure 6.5: Power curves for the two-sided test H0 : δ = 0 vs. the alternative hypothesis
H1 : δ 6= 0. Methods 2(i)) and 3(i) require a prior (to average across) and uses the predic-
tive distribution. Method 3(ii) doesn’t require a prior and instead updates the fixed effect
meta-analysis. Method 2(ii) uses the predictive distribution as a prior. We assume α = 0.05
and a ‘typical’ standard deviation σ of 4.52 (estimated as the median across studies). Ad-
ditionally, for methods (1), 2(ii) and 3(ii) a hypothetical effect is set to detect an OR=0.85.
When τ = 0 , methods 3(i) and 3(ii) reduce to 2(i) and 2(ii) respectively and therefore
curves 3(i)= 2(i) and similarly 3(ii)=2(ii).
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6.6 Discussion
In this chapter, we have compared methods for using external evidence on the effect size
in sample size calculations, using an application to a real case study of CRASH [83]. A
meta-analysis of results from existing RCTs can help determine whether there is a need
for a new RCT and inform the sample size calculations. Although many studies have
identified funders require a systematic review and/or meta-analysis [3], little analytical
attention has been paid to how this previous evidence should be used to inform sample
size calculations. We have addressed this issue by comparing recently proposed methods
that use information from an existing meta-analysis in order to show what size a new trial
would need to be, to show the intervention is effective, depending on whether the target
of inference is the new trial or the updated meta-analysis mean. This is in contrast to tra-
ditional sample size calculations, where previous evidence is used to make assumptions
about key parameters, but under the assumption that the trial will be analysed in isolation
(not in combination with previous evidence). The key findings are displayed in Figure 6.6
and discussed in more detail below.
6.6.1 Overview of key findings
We found that in the case study of steroids for traumatic brain injury, a standard sam-
ple size calculation suggested approximately 6000 patients were required to detect a 15%
reduction in odds of mortality for a power of 80%.
The predictive estimate from the existing meta-analysis is 0.92 (95% predictive interval,
0.57 to 1.51) indicating an 8% reduction in the odds of death in a new population. Since
we are trying to detect a 15% reduction in the odds of death (OR=0.85) this will have
some effect on the sample size needed. For this example, we found the classical power is
greater than the power of a Bayesian analysis of the new trial incorporating the prior. This
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is likely to be because the prior mean is closer to the null, than the effect we are trying
to detect, so that the prior pulls the posterior distribution closer to the null. For the same
sample size, the ‘expected power’ of a Bayesian analysis with informative prior based on
the predictive distribution from the meta-analysis was only 74%.
The power of an updated meta-analysis was <10% across all sample sizes: a new trial
had practically no ability to impact upon the estimated mean in a random-effects meta-
analysis, due to high levels of heterogeneity. This was the same in both the ‘expected’
and ‘conditional’ power frameworks, although they cannot be strictly compared as ex-
pected power is estimating the average power by averaging over the predictive distribu-
tion whilst conditional power conditions on a hypothetical effect size to detect. This has
been noted previously [38, 74, 73]: that if there is high heterogeneity in a meta-analysis,
no new trial is likely to change the random effects mean. In contrast, the EVSI calculations
suggested that the required sample size was lower.
We have seen that each of these approaches can lead to very different conclusions for tri-
alists. Trials are conducted for a variety of reasons: such as (i) to obtain licensing for a
drug; (ii) to identify doses/settings/different populations where the treatment is effec-
tive; (iii) to get the treatment adopted by NICE or similar organisations; (iv) to confirm
the results of previous/smaller trials [173]. When deciding whether to run a new trial,
and the appropriate trial design, it is important to consider how the results of that trial
will be used. In order for the results to change clinical practice, there needs to be a change
in clinical guidelines and policy, and these need to be adopted by clinical practitioners.
This can occur through 3 main routes. First, clinicians could be convinced by a journal
article publishing the trial results. Second, the trial could have influence as a contribut-
ing study in a meta-analysis. Third, the influence could be through the trial’s contribution
to a cost-effectiveness analysis model. Meta-analyses are carried out in the development
of all clinical guidelines developed by NICE in the UK, and similar organisations world-
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wide [174]. Cost-effectiveness models typically use the results of a meta-analysis to inform
the effectiveness parameter, but also combine this information with other information on
longer-term outcomes, costs, utilities for various outcomes (including adverse events),
and natural history parameters describing disease progression. Cost-effectiveness models
are used to inform reimbursement decisions by NICE in the UK, and similar organisations
worldwide.
Figure 6.6: Key findings from a case study analysis
 The traditional power calculation (method (1)) suggested 6000 patients were re-
quired for a power of 80%.
 Sample size calculations based on the conditional power of a Bayesian analysis of
the new trial, using an informative prior (method (2(ii)) gave lower power than
method (1). This is likely due to the prior mean in this case study being closer to
the null than the effect size we were trying to detect.
 A new trial had practically no ability to impact upon the estimated mean in a
random-effects meta-analysis. This was likely due to high levels of heterogeneity
in the meta-analysis.
 In contrast, the EVSI calculations, which are measured in QALYs and not power,
suggested that the required sample size was lower.
 As the different approaches lead to very different conclusions, it is important for
a trialist to decide their perspective: whether the target of inference is the (i) trial
(ii) meta-analysis or (iii) cost-effectiveness analysis.
6.6.2 Are these methods implementable in routine trial design?
Methods (2) to (4) all require a systematic review and meta-analysis as an input for form-
ing a prior distribution. However, funders often require a systematic review or meta-
analysis to have been done to justify the need for the trial [9]. In these situations, it could be
viewed as not much extra effort to formulate a prior distribution and, as part of a sensitiv-
ity analysis, to see the impact prior evidence can have compared with a traditional power
calculation. Expected power estimates the average power whereas the conditional power
framework conditions on the hypothetical effect to detect. Therefore, expected power av-
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erages over all possible values of the prior distribution rather than detecting a MCID. In
an interim analysis trialists are looking at whether given the accumulation of evidence in
the trial so far, how likely future data collected will result in finding the MCID (and the
null hypothesis being rejected). Although conditional power isn’t routinely used in the
context of using information from an existing meta-analysis, it can be seen as a natural ex-
tension of interim analyses [13] with design considerations the same as when conducting
a conventional power calculation and may be more applicable than the expected power
approach. The conditional power approach has also been extended to a NMA setting [175].
We think this could have particular application for trials which are expected to have a
small number of events, i.e. for rare event data. If there has been a meta-analysis look-
ing at the comparison of interest it may be intuitive to incorporate this information in a
Bayesian analysis of a new trial, when the target of inference is the new trial, rather than
the updated meta-analysis. Whether there is a gain in power or reduction in sample size
will be determined by the relationship between the MCID and prior information from the
meta-analysis.
6.6.3 Towards recommendations
If the plan is for the results of the trial to be placed in the context of existing evidence at
the end of the trial, then it seems sensible to conduct the meta-analysis in the planning
of the trial and include it in the power calculation. Caution should however be exercised
here as the appropriate use of these methods is heavily dependent on the purpose of
the trial. For example, different stakeholders will always use results differently and the
new trial will need to be powered according to how the results will be used. From the
perspective of a trialist there is often no consideration of the meta-analysis at design stage
of component studies, even though the updated meta-analysis may be more influential
than any of the studies in isolation, in order to change policy and practice [176]. This
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was also consistent with the findings in our qualitative study: trialists recognised it was
often the body of evidence that changes practice but did not think about whether their
trial results would end up in a future meta-analysis. It is therefore possible that from
an individual trial perspective that meta-analyses are considered by-product of research.
However, it may be more coherent from a trialists perspective to design a trial based on
results of the updated meta-analysis [5, 74].
Currently, all these methods are rarely used in practice [10, 11]. A possible recommenda-
tion is to make conditional or expected power calculations a standard output of Cochrane
reviews, NIHR HTA monographs and/or in grant applications to HTA. This would allow
trialists to assess the impact a new trial would have on the existing meta-analysis. Sim-
ilarly, VoI analyses could be a required output from NIHR HTA monographs that have
cost-effectiveness models, which are becoming more increasingly included. NICE tech-
nology assessments also often perform VoI analyses and make recommendations for pri-
orities for further research, but this doesn’t link directly to what is prioritised by funding
bodies such as the NIHR HTA.
6.6.4 Areas for further research and consideration
Methodology for EVSI is relatively new and still developing. Throughout applying these
methods, we have focussed on random effects rather than a fixed effect meta-analysis be-
ing used. One of the main reasons for this, is that a fixed effect meta-analysis makes a
rather strong assumption, that are trials are estimating the same single treatment effect.
However, random effects models have their own interpretability issues; one of the ma-
jor challenges is how to interpret and incorporate heterogeneity between existing studies.
Assumptions of exchangeability between previous studies and new study need consider-
ation. Additionally, under the power of updated meta-analyses methods, conclusions can
be that lots of small studies are needed instead of one large “definitive” study in order
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to change statistical significance [38, 74, 73]. This can again be unintuitive and an area for
further research.
Ultimately, a trialist is likely to only focus on the trial in front of them and not think in
the wider context of how the results will be used in a meta-analysis or cost-effectiveness
analysis. In some situations, a trialist may conduct such an analysis which concludes that
their study is not worth doing. As such, educating trialists and panel members on these
methods might be useful so that a priority is put forward to do these analyses as part of
a feasibility phase; enabling efforts to be focussed on more impactful research. The main
area for future work is on training with a focus on trialists performing different sample
size calculations as part of a sensitivity analysis and to assess how the incorporation of
previous evidence could impact upon the required sample size.
Multi-arm multi-stage (MAMS) trials allow several new interventions to be tested against
a single control within one trial and at predefined stages, each new intervention is anal-
ysed, much like an interim analysis, and dropped if the intervention does not show enough
of an effect. New interventions can also be added in order to answer research questions
more quickly and efficiently. Adaptive trial designs such as MAMS are being increasingly
used with results from earlier phases in the trial to determine the design in later phases,
including early-stopping decisions. As such this is a natural place for evidence synthesis
to be used and a potential area for future research [177].
We have focussed on sample size determination, but other design features which address
a much wider range of design questions can be considered using the EVSI approach, such
as which patient subgroups to include, which interventions to include (and how many
treatment arms), and which outcomes to measure [178]. The other methods only focus on
uncertainty in effectiveness, which won’t necessarily translate into decision uncertainty
(for example, there may be high degree of uncertainty between two interventions, but
neither likely to be cost-effective. Or it may be very clear which intervention is most ef-
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fective, but on a surrogate outcome, so that a trial is warranted to establish longer-term
effects) [53]. However, EVSI requires a cost-effectiveness model to be developed, which
takes time and resources to build [94], and computations can be intensive and require
specialist expertise.
RCTs require equipoise from both the clinician recruiting and the patient being randomised.
However, if there is an existing body of evidence on the comparative effectiveness and/or
cost-effectiveness of the interventions being trialled, then this may raise ethical questions
for the randomisation to that trial [177]. As is briefly mentioned in Section 3.4.5, it is usu-
ally the case that there is some evidence available, and that neither the clinician or patient
is in 50:50 ambivalence between two treatments. However, there may be a lot of uncer-
tainty around this preference, and a meta-analysis and/or VOI analysis can quantify this
uncertainty, and therefore has an important role to play in the interpretation of equipoise.
This is an area for further consideration and development.
6.6.5 Conclusions
It seems logical to use previous evidence in the form of a prior distribution explicitly in
sample size calculations rather than analysing a trial in isolation. We have shown there
are several methods to do this, however the choice of method should depend on the pri-
mary purpose of the trial. When designing and powering a trial, consideration should be
given to how the study results may be used and interpreted: (i) in isolation, (ii) in terms
of its impact upon an updated meta-analysis, or (iii) in terms of its impact upon a cost
effectiveness analysis.
In order to increase the use of previous evidence in sample size calculations, we recom-
mend funding bodies advise trialists to report how the results of their trial will be in-
terpreted (in relation to scenarios (i), (ii) and/or (iii)) during a feasibility stage. This will
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require increased collaborations between funders, trialists and the NICE technology as-
sessments. As these methods are still relatively new, assumptions of such statistical mod-
els should be transparent and further training undertaken. In addition, the input to these
analyses require at the very least a systematic review and detailed guidelines for a frame-
work on how existing evidence should be used in sample size calculations is encouraged
to streamline its use in practice.
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7 Using external evidence on adverse outcomes with an ap-
plication in first in human studies
The work presented in this chapter was performed in collaboration with Laurence Colin,
Baldur Magnusson, Yue Li and Asher Schachter at Novartis AG, Switzerland.
7.1 Context and overview
In a standard two arm RCT, the control arm acts as a comparator to the experimental arm.
The control arm can be the intervention which is already current practice, or it can be a
placebo. In Chapter 3 we saw that an area where trialists thought they could potentially
benefit from the incorporation of external evidence synthesis was when trials were not
adequately powered to compare adverse events between the two groups. In these situa-
tions, current practice relies heavily on the clinician or chief investigator working on the
trial to decide whether the observed adverse event rate in the experimental arm is inline
with what would be expected or if it is a potential cause for concern, resulting from the
intervention.
In this chapter, we take a case study of using external evidence on particular outcomes in
"first in human" “(FIH)” studies [179]. These trials have very small sample sizes and are
therefore unlikely to be powered to detect adverse events. In FIH studies, an extremely
small placebo arm (e.g. 2 patients) acts as the comparator. We use a synthesis of placebo
data from a set of previous FIH studies to inform the expected adverse event rate in a new
or current FIH study. As this project was a collaboration with Novartis, the placebo data
synthesised were from Novartis sponsored healthy volunteer studies.
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7.2 Introduction and aims
FIH studies offer the first opportunity to test a new treatment in healthy human volunteers
(or patients in an oncology setting), bridging the gap between animal and human stud-
ies. They are part of the exploratory phase of drug development to investigate safety and
tolerability. The primary objective is to identify a suitable dose or dose range. Once a safe
dose is found, efficacy is assessed in phase I and/or II studies. They are usually placebo
controlled with subjects randomised to either the active drug or a placebo [180]. Typically,
a FIH study is split into groups of subjects each assigned to particular doses. Within each
group, known as cohorts, there are usually 8 subjects of which 6 will be given the active
drug and 2 a placebo. Due to the typically small sample sizes of cohorts, safety signals are
often difficult to interpret, particularly in the absence of a robust placebo group. There-
fore, when analysing a FIH study, those working on such studies often need to decide if
an adverse, or safety event on a new drug is likely due to the drug or if the event is likely
to occur by chance. It is difficult to judge whether certain adverse events or abnormal lab-
oratory values are occurring because they are caused by the new drug or simply because
these events do occur on placebo frequently in the general population [181].
A report published in 2014 revealed that about half of all FDA rejections and delayed ap-
provals in recent years were due, at least in part, to safety deficiencies [182], with cardio-
vascular and hepatic issues being the most common concerns. One of the most common
reasons a drug does not make it to the next phase, phase I of drug development, is if it is
thought to be too toxic and likely to cause drug induced liver injury (DILI). Biomarkers,
such as alanine aminotransferase (ALT), measured from a blood test, are used as a poten-
tial indication of DILI if they are outside the normal range. Kobayashi et al found elevated
ALT levels in volunteers after administration of placebo in a phase I study in 1993. This
suggested there is some background event rate to be monitored on healthy volunteers tak-
ing placebo. However, elevations in biomarkers can be caused by many other things such
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as concomitant medications, whether a subject is ill (short term such as a cold or longer
term) or patient demographics. Clinicians working on FIH studies often need to decide if
adverse events on a new drug are likely due to the drug or occurring by chance. They do
not want to withdraw the drug if it is indeed safe but on the other hand do not want to
ignore a potential safety concern such as DILI.
Quantitative tools that identify and characterise safety issues earlier in the life cycle of
investigational compounds would have a large impact on the efficiency of drug develop-
ment, since the costliest phases of drug development are phase II and phase III [183]. Yet,
early phase studies often lack quantitative evaluations of safety data. Previous attempts at
quantifying the background rate of liver enzyme elevations in placebo-treated healthy in-
dividuals [85, 184] were limited by small datasets and did not consider the demographic
and background characteristics of the healthy volunteers in their estimation of the inci-
dence rates. For most other safety events, no reference rates are available at all.
We first model the synthesised data to estimate the incidence of safety events account-
ing for potential study differences and subject characteristics. This chapter then explores
how teams working on such trials can use existing data of placebo incidence rates to in-
form the analysis of a new FIH study. It is therefore important to know the expected in-
cidence of safety signals, such as elevated biomarker levels in these populations, and in
particular, how this incidence varies in certain populations with different demographics.
Subsequently, how the results from the model are used to predict the probability of a
given subject experiencing a safety event above the upper limit of the normal range are
discussed.
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7.3 Summary of the available empirical data
All clinical studies included in this chapter were sponsored by Novartis and reviewed by
an institutional review board (IRB). We retrospectively reviewed all studies in the Novartis
database that involved healthy volunteers and were completed before 2016. Of those, we
excluded 67 studies that did not involve placebo and 44 studies that used a cross-over
design. There were 11 studies for which the laboratory and vital sign data were not readily
available. All the placebo data from the remaining 77 studies were pooled. Among these
77 studies, 10 were conducted in Japanese subjects and 1 in Chinese subjects. The number
of placebo subjects per study varied between 3 and 57, with a mean of 16.03 per study. The
number of post-baseline observations per study varied between 1 and 18, with a mean of
5.65.
Data on the following routinely measured safety parameters, was collected:
 Liver safety: ALT, aspartate aminotransferase (AST), bilirubin
 Cardiovascular safety: the Fridericia-corrected QT interval (QTcF), standing systolic
blood pressure (SBP), heart rate (HR)
 Renal safety: serum creatinine
 Pancreatic safety: lipase, amylase
While normal laboratory ranges are known for all of the parameters listed above, inci-
dences of randomly occurring values outside of the normal ranges for healthy subjects
receiving placebo in the setting of a clinical study are not known. The pooled database in-
cludes 1234 subjects with available measurements in at least one of the safety parameters
above.






 Baseline measurements of the above safety parameters
The demographic characteristics of the population are presented in Table 7.1. The median
age of subjects was 32 years (IQR 18-43) and 82.4% (1017/1234) were male. Age had a
slight bimodal distribution which may be explained by the inclusion of 5 studies which
had a specific inclusion criterion of >60 years. These studies were excluded as part of
a sensitivity analysis to check if any conclusions changed. The mean height and weight
were 174cm (SD=9.2) and 77.1kg (SD=12.5) respectively.
We present the raw incidences of various safety events in the pooled database and explain
how these can be used to give a preliminary assessment of whether signals observed dur-
ing the use of an investigational drug are in line with the expected incidence on placebo.
The raw incidence of various safety signals in our pooled database of healthy volunteers
receiving placebo are shown in Table 7.2, by target organ. This information can be used to
judge how frequently random safety findings occur in a healthy population. For example,
we see that increases in HR by more than 20 beats per minute from baseline occur in about
14% of healthy subjects receiving placebo. Now suppose we observe heart rate increases
of this magnitude in 2 subjects (out of a cohort of 6 subjects) receiving the active drug.
However, this would not necessarily be a concern, since it is not unlikely to happen in the
same population receiving placebo: the probability of observing at least 2 subjects with an
event in a cohort of 6, if the event truly occurs with a 14% probability, is 20.3% (from the
binomial distribution, see Table 7.3).
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Table 7.1: Demographics of the placebo database.
N=1234 subjects n %
Sex: Male (n, %) 1017 82.4
Ethnicity (n, %):
White 662 53.6
Hispanic or Latino 259 21
Asian 141 11.4







Age (years) (Median, Q1-Q3)1 32 25 - 43
Height (cm) (Median, Q1-Q3), N=12122 175 168.2 - 181.0
Weight at baseline (kg) (Median, Q1-Q3)3 77.1 68.0 - 85.8
1 Q1 = first quartile (25th percentile), Q3 = third quartile (75th
percentile). Age ranged from a minimum of 18 to a maximum
of 78 years.
2 Height ranged from a minimum of 143.8 to a maximum of
199.0 cm.
3 Weight ranged from a minimum of 47.7 to a maximum of
116.1 kg.
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Table 7.2: Raw incidence (unadjusted for study effect) of safety signals in pooled database
of placebo-treated healthy volunteers.




ALT > ULN 77/1234 6.24
ALT > 2 x ULN 10/1234 0.81
ALT > 3 x ULN 4/1234 0.32
Bilirubin > ULN 92/1180 7.80
Bilirubin > 2 x ULN 36/1180 3.05
Bilirubin > 3 x ULN 30/1180 2.54
ALT or AST > 3 x ULN; & Bilirubin > ULN 0/1234 0
Cardiovascular system2:
QTcF change > 60 ms & QTcF < 500 ms 7/1028 0.68
QTcF change > 60 ms & QTcF ≥ 500 ms 0/1028 0
HR increase > 20 bpm 165/1165 14.16
Standing SBP increase > 20 mmHg 64/790 8.10
Kidney3:
Serum creatinine increase > 50% 0/1234 0
Pancreas:
Lipase > 1.5 x ULN 34/1125 3.02
Lipase > 3 x ULN 7/1125 0.62
Amylase > 2 x ULN 4/1195 0.33
ALT=alanine aminotransferase; AST=aspartate aminotransferase; QTcF=Fridericia-
corrected QT interval; HR= heart rate; standing SBP= standing systolic blood pres-
sure (SBP) which is when blood pressure is taken when the subject is standing
up. Units: ULN=upper limit of normal; ms=milliseconds; bpm=beats per minute;
mmHg= millimetre of mercury.
1 (number of subjects with at least one event /total number of subjects) in pooled
early safety studies.
2 Baseline QTcF ranged from 347 to 481 ms, with a mean of 398.0 (SD=12.5). Baseline
HR ranged from 37 to 125 bpm, with a mean of 62.3 (SD=10.7). Standing SBP ranged
from 86 to 168 mmHg, with a mean of 119.5 (SD=11.9).
3 Baseline serum creatinine ranged from 35 to 168 umol/L, with a mean of 81.2
(SD=14.4). The ULN varied across studies with a median of 112 umol/L (IQR 106 to
115).
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In our second example, suppose we observe 2 events, of an ALT elevation above 1 times
the upper limit of normal, out of 6 subjects (Table 7.3). From Table 7.2, we know elevations
of ALT above 1 times the upper limit of normal only occur in 6.2% of healthy subjects
receiving placebo. We can use this information to try and make some inferences about
how likely 2 events in our hypothetical study would have occurred by chance. We assume
the probability that each person has an event is 6.2%, based on the population average.
Therefore, the probability of observing 2 or more events out of 6 subjects by chance under
placebo is 4.9%. As this is quite low, a clinician may attribute the cause of the event to the
drug.
Table 7.3: Hypothetical situations in FIH studies and the corresponding probability of
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Whilst these raw incidence rates are helpful in providing a quick assessment of the likeli-
hood for a safety signal to be caused by the active compound under investigation, more
accurate answers can be given with a model adjusting for differences between study and
individual subject characteristics. We use the liver enzyme ALT units per litre (U/L) as
an example. We explore this lab maker only for the remainder of the chapter. This is a lab
marker in the blood and is essentially a measure of how toxic a person’s liver is. If it is
elevated outside the normal range, it is defined as an adverse safety event.
245
7.4 Methods
We have seen the raw incidences of various safety events; however, a model that adjusts
for potential study differences and subject characteristics provides a more relevant assess-
ment. We aimed to estimate, through a random effects regression model, how control arm
ALT varies according to a number of demographic and baseline variables, including ALT
at baseline.
7.4.1 Outcome
For each subject within a study, ALT was recorded at baseline and each time point for the
duration of the study. Since each laboratory for a study (a study may have several lab-
oratories) has different upper limits of normal due to the assays used, normalized data
("ALT/ULN") is used to allow for a standardized comparison across all studies. The stan-
dard approach to do this is to convert U/L to multiples of the ULN by dividing the ALT
value by the ULN. For example, if the ULN was 45 U/L, then an ALT value of 12 U/L is
converted to 12/45=0.27 ULN. ALT/ULN then becomes the response variable.
Baseline ALT varied from 4 U/L to 123 U/L. The median was 21 U/L (IQR 16-28). Simi-
larly, the upper limit of normal varied. 77/1234 (6.2%) of subjects had at least one event
of ALT>ULN. 67/1234 subjects had at least one event between 1 and 2 x ULN, 6/1234
had at least one event between 2 and 3 x ULN, 4/1234 had at least one event greater than
3 x ULN. As this is a safety event, our interest is in the maximum ALT value (for each
person). 47% of studies had at least one patient with an event. By-study event rates are
usually below 0.2, on rare occasion exceed 0.3, as shown in Figure 7.1.
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Figure 7.1: Event rate by study.
Preliminary explorations
In the clinical trials community, clinicians are interested in whether ALT is greater than
the upper limit of normal and therefore the binary outcome of an event. The most efficient
way of modelling normalised ALT (not discarding information) is as a continuous vari-
able. We can then calculate the probability that a subject has at least one ALT > ULN or 2
x ULN, which should be (if the model fits the observed data) approximately 6.2% and 1%
respectively.
Our first approach was to model ALT/ULN as a continuous variable. Here we modelled
the maximum ALT/ULN value for each person. We took the log of this value to make the
outcome more normally distributed. Figure 7.2 shows the distribution of the maximum
log(ALT/ULN) value of each subject. We fit a linear mixed model allowing for the clus-
tering of subjects within each study (subjects i and study j). We therefore fit the following
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random intercept model, with a random effect on study:
(log(ALT/ULN)ij|xij, uj) = α + β1xij + uj + εij (7.1)
where εij ∼ Normal(0, σe2), and uj ∼ Normal(0, τ 2). Here, xij is the baseline value of ALT
for subject i in study j which is normalised (in units of ULN) and log transformed. How-
ever, when calculating the probability that a subject had at least one ALT > ULN the model
predicted only 3%, compared with the observed value of 6.2%, i.e. the model did not fit
the data well (Figure 7.3). We could not find a distribution that described the continuous
data adequately (especially the tails, which are crucial for this exercise), providing unbi-
ased predictions of the number of ALT > ULN events. In addition, the generalised mixed
model type of approach tries to model the means, but our research question is about esti-
mating the tails precisely which is difficult to do.
We therefore chose to dichotomise ALT, directly modelling the probability of an event
defined as the maximum ALT>ULN or normalised ALT > 1. A random effects logistic re-
gression model was fit with a random effect for study to allow for clustering of individuals
by study, similar to equation (7.1) above.
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7.4.2 Description of the model
We fitted a multilevel logistic regression model in a Bayesian framework using non-informative
priors as follows [185]. For subject i in study j we define the event yij = 1 if the subject
had at least one ALT measurement exceeding the ULN during the study.
yij =

1, if ALT> ULN
0, otherwise
(7.2)
The probability of this event was modelled as Bernoulli [pij] with:
logit(pij) = αj +Xijβ (7.3)
where αj represents the study-specific intercept used to account for between-trial vari-
ation, Xij is a vector of covariates specific to subject i (including the number of post-
baseline samples for subject i), and β is a vector of covariate parameters. The model was
fit in a Bayesian framework using the following weakly informative priors: αj = α + uj ,
uj ∼ Normal(0, τ 2) with α ∼ Cauchy(0, 10), τ ∼ Exponential(1) and β ∼ Cauchy(0, 2.5).
A Cauchy(0, 2.5) prior assigns roughly 0.7 prior probability that the logit-coefficient is be-
tween -5 and 5. The prior for the between-study standard deviation assigns a prior prob-
ability of 0.95 that τ < 3. Although only weakly informative priors are used, a Bayesian
paradigm allows for full parameter uncertainty in comparison to the frequentist approach
[13]. Since a logistic regression model is fit, model coefficient estimates are reported as the
odds ratios based on posterior medians rather than means, as they are likely to be skewed.
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7.4.3 Model covariates
Baseline ALT was taken post-randomization and prior to the placebo being given. His-
tograms of continuous covariates were produced to check for normality and potential
outliers. Log transformation was applied to baseline ALT and age. Baseline ALT was cal-
culated in the unit of ULN and then log transformed to obtain an approximately normally
distributed variable. Age was also log transformed for the same reason. Log transforma-
tion was initially attempted for the number of samples; however, this did not improve
model fit and therefore the original scale was used to aid interpretation. Weight was ap-
proximately normally distributed and therefore no transformation was considered neces-
sary. All variables were standardized to a scale with mean of 0 and standard deviation
of 1. The standardization was done via the typical approach, i.e. subtracting the mean of
the variable from each of the individual (subject) values and dividing by the overall stan-
dard deviation. This means that each coefficient is unit less and therefore has a similar
magnitude and better statistical properties [186].
7.4.4 Model selection and fit
The baseline covariates described in Table 7.1 were first included in random effects logistic
regression models in univariable analyses, to identify any variables which were individu-
ally predictive of an elevated ALT event. Model fitting was done using Stan [187] via the
R library (version 3.4.1) RStanArm (version 2.15.3) [188].
All of the baseline covariates were evaluated for inclusion in the final multivariable model,
using a forward selection approach that calculates the difference in deviance for nested
models [189]. Deviance was calculated using the leave-one-out (LOO) method which is
a measure of how much the posterior distribution would change if a single observation
were omitted [186]. The model with the smallest expected log point wise predictive den-
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sity was selected [186]. Model fit was checked by comparing posterior predictive distri-
butions to observed values. To check adequacy of model fit, we simulated observations
from the posterior predictive distribution, the distribution of the outcome implied by the
model after using the observed data to update our beliefs about the unknown parameters
[13]. These are simulated datasets based on the same observations of our covariates that
were used to estimate the model parameters and denoted by yrep [186]. If the model fits the
data well, then we would expect the simulated datasets from the model to be very similar
to the observed y. The LOO method can also be seen as a check of potential influential
observations or outliers which highlights any observations which are not predicted well
by the model based on the other data points.
7.4.5 Predicting from the model
The aim is to provide a tool for clinicians who want to interpret emerging results in an
ongoing FIH study. To do this, the final model is used to calculate conditional predictions
of an elevated ALT>ULN for each of the active-treated subjects using their specific covari-
ate values. If covariates are not available, the population average of 0.062 is used (from
Table 7.2). From this model, we can derive the subject-specific probability of experiencing
an event, conditionally on this subject’s covariates. For subject i in our dataset, we would
condition on the study-level effect αj , while for a new subject this probability would be
obtained by integrating over the study effect distribution [190, 191]:




1 + eα+ uj+xijβ
f (α, β, τ, uj) d(α, β, τ, uj) (7.4)
We substituted the subject’s covariate values into the posterior draws of the linear pre-
dictor using the inverse logit function and conditioned on the study they belong to. This
gives a matrix of size [N posterior draws] x [N subjects]. We therefore integrate with re-
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spect to the joint posterior of all the parameters. For a new subject, who does not belong
to an existing study, we additionally integrate over the distribution of study effects. This
is equivalent to deriving a marginal (population average) probability of a subject experi-
encing an event by averaging over the distribution of covariates. These probabilities were
calculated in R version 3.4.1 using the functions posterior_predict and posterior_linpred,
part of the R library RStanArm.
Due to the non-linearity of the model, the conditional probability of a subject with mean
covariate values is not expected to match the population mean marginal probability [185].
In other words, taking the mean before or after the logit transformation will not yield
the same results, as is always the case for generalized linear models with a non-linear
link function. In this setting, because we are mostly interested in predictions for specific
subjects in a new study (for whom we know the baseline covariates), the conditional prob-
ability is of most interest.
For a subject receiving the active drug in a new study, we produced the predicted prob-
ability of this subject experiencing an ALT > ULN event had he/she received placebo
instead of active drug, based on the model described above. We will call this prediction
the probability of a ‘virtual placebo twin’ to experience the event. Whether or not the vir-
tual placebo twin is also likely to have experienced an event will determine whether the
investigational drug is likely to have caused the event or not.
Finally, we combine the individual subjects’ probabilities to estimate the probability that
at least one subject experiences one event in a cohort of size n. This can be done by using
conditional probabilities (a different one for each subject) if subject-specific covariates are





Results from univariable analyses are shown in Table 7.4.
Table 7.4: Results of univariable analyses for each variable fit in a random effects logistic
regression model with a random effect on study. Results are reported as odds ratios and






variance elpd_loo p_loo looic
Baseline ALT/ULN
(log transformed) 4.65 (3.38, 6.69) 1.14 -215.4 28.4 430.9
Number of
post-baseline
samples taken 1.68 (1.26, 1.87) 1.19 -264.6 31.1 529.1
Age in years
(log transformed) 0.96 (0.74, 1.24) 1.17 -270.8 31.7 541.6
Height in cm 0.81 (0.68, 1.14) 1.13 -270 31 540
Weight in kg 1.14 (0.88, 1.49) 1.19 -270.2 32.1 540.4
Sex (male) 1.78 (0.89, 4.14) 1.2 -269.3 32.5 538.6
elpd_loo=the expected log predictive density; p_loo=the is the posterior mean
of the deviance minus the deviance of the posterior means and defined as is
‘the effective number of parameters looic=the leave one out information crite-
rion which is used to help compare models; the model with the smallest looic
is estimated to be the model that would best predict a replicate dataset which
has the same structure as that currently observed.
Following the model selection procedure described earlier, the LOO method (Table 7.5)
indicated that the best fitting model (i.e. that with the lowest leave-one-out information
criteria (LOOIC)) included baseline ALT, age, weight, and number of samples in the study
as fixed effects, and study as random effect (Table 7.6).
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Table 7.5: LOO deviance table when deciding on the final model.
Model elpd_loo p_loo looic
Null model -269.4 30.6 538.9
Null model + log(baseline/uln) -215.4 28.4 430.9
Null model + log(baseline/uln)
+samples -211.8 30.9 423.6
Null model + log(baseline/uln)
+samples + log(age) -210.9 31.8 421.8
Null model + log(baseline/uln)
+ samples + sex -212.3 32.3 424.6
Null model + log(baseline/uln)
+ samples + weight -211.6 32.2 423.1
Null model + log(baseline/uln)
+ samples + height -212.5 32.1 424.9
Null model + log(baseline/uln)
+ samples + log(age) + weight -210.4 32.8 420.4
Null model + log(baseline/uln)
+ samples + log(age) + height -210.5 32 421
Null model + log(baseline/uln)
+ samples + log(age) + sex -212.4 33.5 424.8
Null model + log(baseline/uln)
+ samples + log(age) + weight + sex -211.3 34.6 422.5
Null model + log(baseline/uln)
+ samples + log(age) + weight + height -211.7 33.7 423.4
Null model + log(baseline/uln)
+ samples + log(age) + weight + height + sex -211.3 35 422.6
Null model + log(baseline/uln)
+ samples + age + weight -209.9 33 420.4
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7.5.2 Model diagnostics
Figure 7.4 shows the mean of each of the simulated datasets (light blue) are very similar
to the mean observed proportion of events 77/1234=0.062 (dark blue).
Figure 7.4: Simulated mean proportion of events from the posterior predictive distribution
(light blue) and the observed proportion of events (dark blue).
Conclusions from the model remained unchanged when the following sensitivity analy-
ses were carried out: (i) removing studies with inclusion criteria of age greater than 60, (ii)
height added back into the final model. The final model was also replicated in WinBUGS,
with Normal (0, 1000) priors for all location paramters (regression coefficients) and a Uni-
form (0,5) for the between study SD, and each of the coefficients estimated were within
0.001 of each other.
7.5.3 Model estimates and interpretation
The final covariates and model coefficients are shown in Table 7.6.
The global/population mean and standard deviation for each of the predictors of the final
model are given in Table 7.7.
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Table 7.6: Final model coefficient estimates for the logistic model of the probability of a
subject experiencing an event of ALT > ULN.
Model coefficients1 Posterior median 95% credible
(Odds ratio) interval
Fixed effect coefficients:
Intercept 0.016 (0.0076, 0.028)
Baseline ALT/ULN (log transformed) 5.21 (3.67, 7.77)
Number of postbaseline samples taken 1.7 (1.25, 2.36)
Age in years (log transformed) 0.72 (0.53, 0.97)
Weight in kg 0.73 (0.52, 1.00)
Random effects coefficient:
Between-study variability τ̂ 2 1.20 (0.39, 2.84)
1 All variables are standardised to a scale with a mean of 0 and a standard de-
viation of 1.
Table 7.7: Mean and standard deviations of the variables used in the model
Mean SD
Log(baseline/uln) -0.93 0.43




Figure 7.5 shows the individual probabilities of ALT>ULN for all 1234 subjects in dataset
conditional on their covariates and the study they are in. It also illustrates that some sub-
jects have a high risk of ALT>ULN: those with baseline close to ULN, in studies with more
than 8 samples taken. For a typical subject with average covariate values (baseline ALT
value of 21.5 U/L, ULN of 55 U/L, aged 32.8 years with a weight of 77.1 kg, and 5.65
post-baseline observations over the study), the probability of developing an ALT > ULN
is 2.4%. This is substantially lower than the population mean of 6.2%, because the distri-
bution of probabilities is skewed to the right, and higher risk subjects drive the average
up.
Figure 7.5: Model-based predicted probabilities of a subject experiencing an event of ALT
> ULN
The most influential covariate is a subject’s baseline ALT value and how close it is to the
ULN. Figure 7.6a shows that the predicted probability of an ALT > ULN event varies
from 2% for a baseline of 20 U/L to 19% for a baseline of 40 U/L, controlling for all other
covariates.
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(a) Baseline ALT (U/L) (b) Number of samples
(c) Weight (kg) (d) Age (years)
Figure 7.6: Predicted probability of an ALT>ULN for a subject, assuming other covariates
are fixed at the mean population values. 25% and 75% quartiles are also displayed. The
median probability is assumed.
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The second most predictive covariate is the number of samples: subjects in studies with a
higher than average number of samples taken have a higher probability of an ALT>ULN.
The probability of an elevated ALT>ULN gradually decreases as weight and age increase.
The between-study variance is 1.20 (on the log odds scale), which represents 27% of the
residual variance. The estimated impact of age and weight on the probability of a subject
developing an ALT elevation above ULN during a study is small in magnitude, and per-
haps counter intuitively, is negative: increasing age and weight is associated with reduced
risk of a random ALT elevation under placebo. Of note, including sex did not improve the
model significantly; however, this could be due in part to the fact that 82% of the subjects
in our pooled database were male.
Table 7.8 compares the characteristics of subjects who had an elevated ALT>ULN (N=77)
compared to those who did not (N=1157). The distributions of age (Median=33, IQR: 26-
39 vs Median=32, IQR: 25-43) and weight (Median=78.4, IQR: 69-86 vs Median=77, IQR:
68-85) are similar in subjects who experience an event of ALT>ULN and those who did
not.
Table 7.8: Characteristics of subjects who had an elevated ALT>ULN (N=77) compared to







Characteristics Median IQR Median IQR
Age (years) 33 26-39 32 25-43
Weight (kg) 78.4 69-86 77 68-85
Baseline (U/L) 34 27-46 20 15.5-27
Number of samples 6 4-8 5 3-7
Upper limit of normal (U/L) 50 45-60 55 45-60
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7.5.4 Using the pooled placebo data to inform a new trial
Using the event ALT > ULN as an example, the raw incidence of elevations in healthy
volunteers taking placebo is 6.2%, as shown in Table 7.2. However, this prediction varies
substantially across individuals. We therefore use model based predictions which adjust
for potential study differences and subject characteristics rather than the population aver-
age.
When subject characteristics are available
To illustrate how these findings can be applied in practice in the setting of a dose escalation
study of a new investigational drug, consider a hypothetical cohort of 6 active-treated
subjects. We create a hypothetical data set in which some subject’s have high ALT values at
baseline, to illustrate the substantial impact of this variable. Other baseline characteristics
were selected at random within the interquartile range. Applying the model described
above generates the probability that each subject’s placebo twin would have had an event
(i.e. the probability that this subject would have developed an event had he/she been
receiving placebo), as shown in the last column of Table 7.9.
Table 7.9: Hypothetical cohort of active-treated subjects and individual model-based pre-















1 25 55 6 22 75 0.045 (0.0036, 0.31)
2 29 55 6 28 72 0.066 (0.057, 0.40)
3 33 55 6 47 70 0.067 ((0.057, 0.41)
4 42 55 6 25 80 0.22 (0.023, 0.73)
5 45 55 6 52 76 0.16 (0.015, 0.66)
6 49 55 6 32 74 0.32 (0.038, 0.82)
The probabilities are based on median values.
The probability of one or more of the subjects (with the same characteristics as those re-
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ceiving the active intervention) experiencing an elevated ALT > ULN event in the ’hypo-
thetical’ placebo group is 0.63 (63%).
Pr(at least one event) = 1 – P(zero event) = 1 – (0.955 * 0.934 * 0.933 * 0.78 * 0.84 * 0.68) =
0.63.
Therefore, if one or two such events were observed in the cohort receiving the compound
under investigation, the clinical team is likely to attribute this to chance. Figure 7.7 illus-
trates the probability of observing at least 1, 2, 3, 4, 5, or 6 placebo twins with an event
in this cohort. However, if the event occurred in subject number 1 or 2 then we may be
concerned. Furthermore, if a subject’s model based prediction was low but did have the
event, this may also raise safety concerns to the clinical team.
Figure 7.7: Probability of observing a given number of subjects with an event (ALT > ULN)
by chance in the hypothetical cohort described by Table 7.9.
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When subject characteristics are unavailable
When subject specific data is unavailable a clinician would use the population average of
6.2%. That is, on average, we expect a healthy volunteer to have a 6.2% chance of an ALT
> ULN at any time during the study. In a cohort of 6 subjects, this translates into a 32%
chance of observing at least one ALT>ULN in at least one of the six subjects.
Figure 7.8: Probability of observing a given number of subjects with an event (ALT > ULN)
by chance using the population average probability
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Scenario in practice
A common scenario in practice may be observing 1 out of 6 subjects on the experimental
drug with an ALT elevation > ULN, whilst observing no events in the placebo arm, shown
in Table 7.10.
Table 7.10: 2 by 2 analysis
Experimental Control Total
Event 1 0 1
No event 5 2 7
Total 6 2 8
For the experimental subjects suppose we calculate the predicted probabilities of having
an event under placebo, as shown in Table 7.9. We can translate this into an average prob-
ability to see if our observed proportion of events in the experimental arm (1/6=0.17) is
consistent:
Average predicted probability =
0.045 + 0.066 + 0.067 + 0.22 + 0.16 + 0.32
6
(7.5)
= 0.15 (95% CrI: 0.016 to 0.55)
The observed number of events in the experimental arm is consistent with what would be
expected under placebo, i.e. not a cause for concern.
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7.6 Discussion
This is the first known large review of the expected frequency of random safety findings in
placebo-treated healthy volunteers. We developed a model to predict how likely a safety
event is due to occur by chance, conditional on the characteristics of the subject and the
study. The key findings and how this study adds to current knowledge are displayed in
Figure 7.9 and now discussed.
Figure 7.9: Key findings
 Little information is available in the literature on the expected variations in lab-
oratory values and vital signs in a clinical study setting, when subjects receive
placebo. A few reviews have mentioned unexpectedly high rates of ALT eleva-
tions in subjects taking placebo, but were based on small datasets and did not
adjust for individual characteristics.
 Our goal was to provide a tool for clinicians working on FIH studies, to quantify
whether safety signals observed were likely the result of chance or the compound
under investigation.
 We synthesised data from a set of previous studies to provide estimates for the in-
cidence of how likely an event is due to chance, conditional on the characteristics
of the subject and the study.
 These could be used to formulate informative prior distributions through the (fu-
ture development of) Bayesian approaches. This work should help teams identify
safety signals earlier and with greater accuracy.
7.6.1 Overview of key findings
The reference event rates provided for parameters relating to the safety of the liver, cardio-
vascular system, kidney and pancreas will provide valuable insight for clinical teams as-
sessing the safety of investigational compounds in early phase studies. Using the liver en-
zyme ALT as an example, we showed how predictive models can provide a more precise
assessment of the chance occurrence of a safety signal in a subject. We developed a ran-
dom effects logistic model for the probability of a subject developing an ALT > ULN event
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during a study, while taking placebo. This model showed that the most important factor
influencing the chance of a random event is the ALT value at baseline. In our dataset, the
mean probability estimates of a healthy volunteer to develop an ALT > ULN event under
placebo is 6.2%. For a typical subject with average baseline characteristics (baseline ALT
value of 21.5 U/L), this probability is 2.4%. If the baseline ALT doubles to 40 U/L, this
probability increases to 19%. This illustrates that caution should be taken when interpret-
ing ALT elevations in cases where the baseline value is higher than usual. Sponsors may
elect to recruit only subjects with a predicted probability of a random elevation that is
lower than 10% in FIH studies, since for those subjects, it will be easier to attribute any
emerging liver safety signal to the investigational drug. If an individual has a low model-
predicted probability under placebo but has the event, then the higher the chance that the
drug under investigation is causing the issue.
7.6.2 Limitations
There are a few limitations with this work. The first one is the choice of modelling the ALT
> ULN on a binary scale. We first tried to model ALT on a continuous scale, as this should
theoretically make more efficient use of the data than dichotomising. This can be seen as
a limitation although our final model did fit the data well. However, as documented in
Section 7.4.1, modelling ALT as a continuous outcome did not fit the observed data well.
Furthermore, our primary interest, was the probability of a safety event (of ALT>ULN)
which is viewed as a binary variable in clinical practice.
Another limitation is that some of the events described in the text as ‘random elevations’
may be partially explained by factors that were not captured in the database. Differences
in whether subjects were kept under controlled conditions (domiciled) and subject man-
agement between studies may explain some of these differences, and unmeasured medical
history or other study specific design features (such as food intake, etc.) may explain oth-
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ers. For example, while our database did not capture this information, we know that most
subjects in the dataset were domiciled at least for the first 3-5 days of the study and had
normal access to food three times a day. Data collection in FIH studies is likely not optimal
for this type of exercise. Each company may have different standards for first-in-human
protocols and the numbers observed in studies sponsored by other companies than No-
vartis may look slightly different for this reason. Most FIH studies have samples collected
in the first 3 to 5 days under domiciled conditions. Subjects under domiciled conditions
are much less likely to have access to alcohol or drugs and as a result are less likely to
have liver enzyme elevations due to that. As such it is possible these are true random
fluctuations and random elevations outside this period could be incidences of alcohol or
drug abuse. It is intuitive to assume subjects under domiciled conditions will have a lower
incidence rate because of having less access to alcohol. If not, it is possible that elevations
are driven by other internal biochemistry rather than the external factors, such as the en-
vironment. However, it is not routinely recorded whether an observation is under these
conditions and so it is not possible to compare the incidence rate of elevations.
7.6.3 Previous studies looking at safety data in early phase trials
Previous attempts at quantifying the expected incidence of ALT elevations in healthy vol-
unteers taking placebo [184] have reported a higher ALT > ULN event rate of 20.4%. They
found that 19/93 subjects (20.4%) had at least one ALT value > 1 x ULN and 7/93 (7.5%)
had at least one value >2 x ULN. They found the incidence was extremely rare in the first
week of hospitalization and increased over time during the second week. ALT levels re-
turned to normal after a few days of hospital discharge. The inclusion criteria included
males aged 18-40 who were deemed healthy with no significant diseases after a physi-
cal examination however subjects with a high baseline were still enrolled in the studies.
Between 2 and 7 samples were taken during the 14 days. Therefore, the difference is inci-
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dence is probably due to the small dataset used and the inclusion of less healthy subjects
with higher baseline ALT levels. This highlights further the importance of controlling for
baseline when making these predictions.
Kobayashi et al found a lower prevalence of 12.5% (13/104) in 104 health male volunteers
in their phase 1 study compared to Rosenzweig et al but their review included studies
with treatment duration of only 7 days. Similar to our pooled FIH studies, they found
average ALT levels were higher at baseline in the group with elevated levels (13 subjects)
compared to the group with non-elevated levels (91 subjects).
Informative priors have been used in phase 2 trials which have small populations like rare
diseases and paediatrics, populations which are difficult to recruit [192]. Here, historical
controls have been used to supplement the number of controls needed in the new trial and
reduce the sample size needed. However, the focus is on aggregate level data summarised
at the study level (rather than individual patient data) and using power priors [193].
7.6.4 Implications for routine safety data in practice and further research recommen-
dations
We showed that a predictive model can be used to create ‘virtual placebo twins’, i.e. sub-
jects with the same baseline characteristics, but who would have received placebo: for
every subject experiencing an event under an investigational drug, the model will predict
the likelihood of his/her ‘virtual placebo twin’ experiencing the same event. The lower
this model-predicted probability, the higher the chance that the drug under investigation
is causing the issue. By using the large amounts of placebo data collected in healthy vol-
unteers over decades of clinical investigations, companies can contribute to increasing
the quality of safety decision making in early phase clinical trials. We can quantify, with
higher precision, the expected frequency of random safety signals in FIH studies and sep-
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arate real signals from the noise.
In early phase studies, decisions are taken in the context of all available data (includ-
ing pre-clinical evidence, pharmacokinetic data, etc.) and this tool is not intended to lead
teams to ignore this complexity of information; rather, it should be viewed as a way to
consider one piece of the complex array of data (namely, the rates of laboratory abnormal-
ities) in a more objective and quantitative way.
Variability in the distribution of study effects does add a considerable amount of uncer-
tainty to the predictions, however, it would be incorrect to ignore this when making pre-
dictions [191]. We have compared predictions from our model to observed events in a
new study to see how likely they would have occurred. Future work could also investi-
gate whether a particular study is more similar to the new study. In this case, a shrunken
estimate from a similar study, in terms of its inclusion criteria, could be used to form
a prior distribution. It may also not be clinically relevant to average across the random
effects distribution. Instead, researchers could look at baseline risk in each study. Further-
more, in our scenario in practice, using Table 7.10 our simple approach does not account
for the matching of predictions and observations. Further work should be conducted to
explore how best to do this and then second how to make use of the two patients in the
placebo arm.
A new policy should be put into practice to regularly update the database to get to the
’true’ population. Such a model exercise could be repeated regularly e.g. annually to in-
clude more newly generated data. For implementation, R Shiny apps could be developed
to translate these findings into user-friendly tools for clinical teams. In particular, to pro-
duce model-based predictions with new covariate values based on the active-cohort in
a new FIH study. This will aid interpretation of emerging results in the ongoing study.
Future work should include looking at the difference of incidence under domiciled and
non-domiciled conditions. Further work should also include modelling other safety pa-
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rameters, such as AST.
Finally, this work could be extended to patient populations (in particular for rare pop-
ulations [194], for example paediatric studies [195, 196]). Hampson et al [196] have also
found that there is a lack of data in paediatrics and potential for use of informative priors.
This would come with additional complications, since patient studies often do not share
similar designs and inclusion criteria, unlike FIH studies of healthy volunteers. Neverthe-
less, we think the outcome of this exercise could help distinguishing effects related to the
drug under study from the underlying disease, in populations where the effect of placebo
has been poorly studied. In addition, this work could also be extended by using historical
control data from patient studies in the same or similar disease area to inform a new pa-
tient study. For example, when information is available on the expected event rate in the
control population but the control group in the new study may not be powered to detect
rare or adverse events. As seen in the literature (Section 1.4), external data could be used
to inform the trialist of the expected population rate of particular outcomes in the control
population, rather than the placebo population here. Furthermore, where IPD are acces-
sible, for example, collated data within a trials unit, trialists may refine the population
estimate by deriving individual expected predictions of an event using our model based
approach. The trialist would then be better equipped to interpret the observed adverse
event rate.
7.6.5 Conclusions
Liver toxicity is a widespread problem in drug development. An elevated ALT level is
specific to liver toxicity which usually results in the development of a compound being
stopped. However, what is unclear is why an elevated ALT has occurred. Since ALT ele-
vations can occur in the general population it is not always a sign that the active drug is
toxic. Therefore, in FIH studies of healthy volunteers, it is imperative to know whether an
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elevated ALT level is caused by the active drug or if it is likely to be caused by chance. One
way to answer this question is to find the expected incidence rate in the healthy volunteer
population taking placebo.
Little information is available in the literature on the expected variations in laboratory val-
ues and vital signs in a clinical study setting, when subjects receive placebo. A few reviews
have mentioned unexpectedly high rates of ALT elevations in subjects taking placebo but
were based on small datasets and did not adjust for individual characteristics. Our goal
was to provide a tool for clinicians working on FIH studies, to quantify whether safety sig-
nals observed were likely the result of chance or the compound under investigation. As
such this study provides reference incidence rates under placebo for commonly measured
safety parameters.
We have developed models to appropriately synthesise relevant previous data to pro-
vide predictions. By modelling existing placebo data, we can make predictions about the
chance occurrence of safety signals for individuals, rather than using the population av-
erage. We built a predictive model for ALT elevations which can be used to quantify pre-
cisely how likely an event is due to chance, conditionally on the characteristics of the
subject and the study. These predictions could be used informally (compare observed
events vs predictions from model) or more formally through (the future development of)
Bayesian approaches. This work should help teams identify safety signals earlier and with
greater accuracy. For pharmaceutical companies in particular, this data is already easily
accessible and allows this array of data to be viewed in a more objective and quantitative
way, and ultimately increase the quality of safety decision making in FIH studies.
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8 Discussion
This thesis has explored areas in which external evidence syntheses can be used to in-
form the design and analysis of a new clinical trial, with specific attention to our three
case studies of using external evidence to inform: (i) the likely amount of bias in an esti-
mated treatment effect (using information from meta-epidemiological evidence), (ii) the
likely treatment effect, for use in sample size calculations (using information from a meta-
analysis), and (iii) the likely control group event rate when the sample size is small and
events are rare (using individual patient information from a synthesis of FIH placebo arm
studies) to potentially increase precision in analysis of FIH studies. We have compared
these to the traditional approaches to determine potential advantages, key differences,
and limitations. This chapter summarises the key findings and implications from the the-
sis and discusses areas for further research.
8.1 Key findings
The incorporation of external evidence syntheses to inform the design and analysis of a
new RCT has long been discussed; mainly due to the intuition that we can learn from
something that has been done in a similar setting [7, 197]. Traditionally, trials are under-
taken in isolation and analysed within a frequentist framework, that is, trial results do not
usually explicitly incorporate prior information about the potential effectiveness of two
treatments (or any other parameters). In regard to using existing evidence, this is done
[78, 198], but more descriptively rather than through Bayesian analyses [71].
In Chapter 2, our 2015 survey (’INVEST’) investigated how trialists were using evidence
synthesis in trials. We found they were using evidence synthesis informally in multiple
ways to make inferences about the design and analysis of a trial. For example, using a
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systematic review to justify the intervention comparison, determine the most appropriate
outcome or duration of follow-up or inform the size of the intervention that the trial is
powered to detect. We also found trialists would like to be making more use of existing
data but were not, due to time pressures and concerns over the relevance of such informa-
tion to their trial.
Finding: The results of our INVEST survey, in Chapter 2, highlighted that
trial teams responding to the survey at the ICTMC generally reported they
are using evidence synthesis in trial design and analysis more than we
might have expected, but less than they might like to.
Given the high proportions of participants reporting the use of external evidence in trial
analysis, we felt that some participants may have interpreted our question about this dif-
ferently from how we had intended: potentially referring to updating a meta-analysis
rather than explicitly incorporating information from the meta-analysis in a Bayesian
framework.
Therefore, a qualitative study was undertaken in Chapter 3 to explore precisely how tri-
alists were using existing external data when analysing trials, and whether there were
areas in which such evidence could be advantageous over current methods, through semi-
structured one to one interviews. Our findings were consistent with our INVEST survey,
in that, trialists were using evidence synthesis in several ways; and time pressures and
concerns over the relevance of previous data to their own trial were barriers to the use of
evidence synthesis in practice. However, we found trialists rarely (never in our sample)
incorporated external evidence with data from their own trial through Bayesian analyses.
Finding: Our qualitative study in Chapter 3 confirmed trialists do use ex-
isting evidence a lot to inform different aspects of their trial but only ever
informally, and trialists rarely (never in our sample) explicitly combined this
previous evidence statistically with data from their own trial.
We additionally found that barriers to explicitly incorporating external evidence synthe-
ses into trials were (i) personal feelings: a lack of confidence in Bayesian methods; (ii)
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practical challenges such as accessing data with no infrastructure, subsequent anonymi-
sation issues and an unfamiliarity with Bayesian software and (iii) concerns about a lack
of acceptance due to the perceived negative views of Bayesian methods.
Finding: We found that although trialists want to make more use of existing
data, their biggest concern regarding formally incorporating existing data
in a Bayesian framework was their trust and relevance in/of external data;
and how that could potentially impact their own trial. We also found that
trialists did not feel confident in Bayesian methods and there were practical
issues (hard to access data, anonymisation issues, Bayesian software).
Since RCTs can have methodological limitations [21, 63], a trialist may want to adjust the
treatment effect estimate in a new study for potential bias to assess the sensitivity of their
findings. A Bayesian approach can easily be used to adjust a treatment effect estimate
suspected to be biased, by forming a prior distribution for the bias. In Chapters 4 and 5,
we have developed meta-epidemiological models which can be used to inform this prior
distribution on the bias parameter. Previous meta-epidemiological studies have, to our
knowledge, only looked at the impact of double-blinding. However, this is an ambiguous
term which does not describe precisely what party is blinded to the intervention. There-
fore, in Chapter 4, a new meta-epidemiological study was conducted, the first to separate
performance and detection bias. We found no evidence of an average difference in esti-
mated treatment effect between randomised clinical trials with blinded and non-blinded
patients, between trials with blinded and non-blinded healthcare providers, and between
trials with blinded and non-blinded outcome assessors, which was surprising. We also
extended current statistical methodology to (i) combine binary and continuous outcomes
and (ii) use meta-analysis covariates in order to produce stratified or tailored analyses by
those groups.
In Chapter 5, we extended current meta-epidemiological methods further, which had so
far only used a binary study characteristic, looking at the average difference in treatment
effect estimates between high versus low RoB trials. The unclear RoB trials are usually
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grouped with the high RoB trials, or separate analyses of high vs low and unclear vs low
RoB contrasts are conducted. However, a trialist will likely know whether their trial was at
a high or low RoB, meaning the outputs from an analysis in which high and unclear RoB
trials are grouped together would not be relevant and separate analyses often reduce the
sample size. We therefore developed a bivariate model and a probability model to include
all the data and assess how likely an unclear RoB trial was to be indeed high risk. How-
ever, we saw no gain in precision for the average bias estimates in this case study, given
the extra computational time. In the probability model we found the estimate of high vs
low RoB was slightly more precisely estimated than when only the informative high vs
low RoB trials was analysed univariately. We extended the probability model further by
using the sample size to predict how likely an unclear risk trial would be high risk.
Finding: We developed novel meta-epidemiological methods to address the
issue of dichotomising study characteristics in to high and low RoB classi-
fications. This would allow future researchers to use the extended versions
of the Welton et al models.
Previous work also hypothesised that smaller studies were more likely to estimate larger
treatment effects than bigger studies. Rhodes et al found evidence that trials with sample
sizes less than 100 tended to estimate larger treatment effects on average than trials with
sample sizes greater than 100 [140]. We extended the current Welton et al model to treat
sample size as a continuous characteristic rather than dichotomising it. We have provided
the analogous model with a continuous study characteristic to the Welton et al binary
study characteristic model which allows for the estimated treatment effect to vary with,
for example, sample size. Results from the model can be used to predict what value a
new study needs to have of this variable to provide an unbiased estimate of the treatment
effect. To look at the association between treatment effects and sample size, and treating
sample size as continuous, we found the best fitting model modelled the intervention




In our qualitative study we found trialists were wary about bias adjustment. Most were
not aware of any methods for bias adjustment whilst some did not even think about it.
Qualitative finding: Trialists were hesitant about bias adjustment. Most
were not aware of any methods for bias adjustment and were wary of the
relevance of other trials to their own.
In Chapter 6, existing methods were compared for using a meta-analysis to inform a sam-
ple size or power calculation. These methods vary in terms of their assumptions and
whether the focus of inference is the new trial or an updated meta-analysis. We found
that when an existing meta-analysis has moderate heterogeneity, a new trial had prac-
tically no ability to impact upon the estimated mean in a random effects meta-analysis.
When powering the new trial to update the existing meta-analysis it is likely a much
larger sample size will be needed. This was the same for the ‘expected’ and ‘conditional’
frameworks. In our case study, calculations based on the conditional power of a Bayesian
analysis of the new trial, using an informative prior distribution, gave lower power than
classical power calculations. This was likely driven by the relationship between the MCID
and the prior distribution based on the meta-analysis: if the prior distribution is closer to
the null compared to the MCID, then the power of a Bayesian analysis of the new trial,
incorporating the prior, may be less than classical power. In this case study, it is likely that
there will be little gain (reduction in required sample size), from using the meta-analysis
as a prior distribution for a new trial. The conditional power of the new trial can be seen
as a natural extension of interim analyses [13] with design considerations the same as
when conducting a conventional power calculation and may be more applicable than the
expected power approach.
Finding: We provided a comparison of methods which explicitly incorpo-
rate information from an existing meta-analysis into power or sample size
calculations, allowing a trialist to see what size a new trial needs to be to
impact the current evidence base.
In our qualitative study, we found that the concept of using an existing meta-analysis to
276
power a new trial based on its ability to impact an existing meta-analysis was unfamiliar
to all participants. Having briefly explained to participants that it is possible to power a
new trial in this way, the majority of participants saw it as an advantage and many thought
it was a very attractive idea and could make the trial more efficient.
Qualitative finding: Although trialists do not think about how their trial
results will impact a future meta-analysis, many recognised it was the po-
tential meta-analysis that would change practice.
In Chapter 7, we proposed pooling information from previous trials to assess ’normal’
rates of adverse events, in situations where the sample size is small, or events are rare.
We used pooled placebo data from Novartis sponsored FIH studies to obtain individual
subject predictions of how likely a safety event would occur, based on participant demo-
graphic and study characteristics. A multilevel logistic regression model was fit and then
used to predict how likely an adverse event, in any given patient, was to occur by chance
in a new FIH study. This approach had not previously been used in this context and was
shown to help the decision-making process.
Finding: Our proposed method to synthesise control arm data from multi-
ple studies allows predictions of how likely an adverse event would occur
by chance.
In our qualitative study we found trialists felt a key area where external evidence could
be useful was when it was difficult to compare adverse event rates (in particular when the
number of events are small) between two groups. Participants also described how they
relied on the clinician to pick up any safety concerns, which some viewed as not ideal.
Qualitative finding: Trialists felt they could be making more use of exist-
ing data to inform adverse event rates rather than relying on clinicians to
determine if there are any potential safety concerns.
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8.2 Implications/recommendations
Throughout this thesis, an important consideration was how likely these methods would
be used in practice and therefore questions regarding this were asked throughout our
qualitative study. We asked trialists what the key things were that needed to change for
these methods to be used in practice, with specific attention to our three case studies. In the
remainder of this final chapter we build upon our key findings, with specific applications
for their use in practice. We then make suggestions for potential future research to address
the remaining questions unanswered in the thesis.
Extensions of meta-epidemiological models can increase the scope of their use to inform
bias parameters
Given that a key finding was that people were wary about bias adjustment, an implication
is that models and research in meta-epidemiological methods should work towards tai-
lored estimates. Whilst bias adjustment has been proposed in a meta-analysis context [55],
trialists can in principle adjust for biases in the same way in an RCT context. In Chapter
4, we demonstrated how covariates (e.g. level of subjectivity) can be included in meta-
epidemiological research to provide such tailored estimates, which are potentially more
acceptable to trialists.
Similarly, by separating the impact that unclear and high RoB trials have in meta-epidemiological
models in the bivariate and probability models, this allows the interpretation of such mod-
els to be more applicable to trialists for bias adjustment. When trialists are concerned their
trial is at a high RoB, they can use the outputs from these extended versions of the Welton
et al model to correct and down weight the results of trials at high RoB of a new RCT.
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Implication: Using our extensions to the Welton et al model, researchers
could assess how their conclusions change when they down weight their
trial’s results based on meta-epidemiological evidence.
Trialists could consider how a meta-analysis can be used to inform power or sample size
calculation, dependent upon their perspective
When designing a new trial, determining the sample size needed is a crucial part of the
design stage. It is at this point the trials team have already gathered their external evidence
as part of the case to justify a gap in the evidence base or help determine which outcomes
have previously been used. Lau et al [6] have suggested this can be used to make addi-
tional inferences in power, or similarly, sample size calculations. Given that a key finding
in our qualitative study was that people do not usually think of the impact their trial has
on the overall evidence base, but are potentially interested, trialists should consider some
of the methods available, as described in Chapter 6.
Each of the methods compared makes different assumptions and, as discussed in Section
6.6.2, the choice of method should depend on how the study results may be used and
interpreted: (i) in isolation, (ii) in terms of its impact upon an updated meta-analysis, or
(iii) in terms of its impact upon a cost effectiveness analysis.
Implication: When a relevant meta-analysis exists, the impact of a new trial
could be assessed, even as a sensitivity analysis. The trialist will need to as-
sess the relevance of information in the meta-analysis to the trial of interest
and decide upon primary use of the new trial.
In cases where a relevant meta-analysis has been used to justify a new trial, conditional
and expected power calculations could be used alongside a traditional power calculation,
as part of a sensitivity analysis. We therefore suggest that education or a greater awareness
is needed to highlight that this is one path which allows changes to be made to existing
policies and treatments adopted, and can be, at the very least, considered in the design
stage of a new RCT.
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The largest barriers to the use of incorporating external evidence identified by both our
qualitative study and the INVEST survey were time constraints and the need to use spe-
cialist Bayesian software, such as WinBUGS. The work conducted in Chapter 6 was based
on normal approximations and therefore closed form solutions which are implementable
by hand and consequently easy to code in standard statistical software.
External evidence could be used to make evidence-based predictions of adverse events
Methods were explored in Chapter 7 for the analysis of FIH studies, which are small in
sample size and therefore underpowered to detect rare events, meaning the response rate
in the control arm is inadequate. It can therefore be difficult for a trialist to statistically
compare two groups and make any quantitative inferences. In turn, this means that clin-
icians are heavily relied upon for potential rates of adverse events in particular popula-
tions. This is consistent with our qualitative study: many of the trialists interviewed stated
that there was often no quantitative evidence behind adverse event rates, and whether an
observed rate was ’normal’ was assessed fairly subjectively, with quite often the Chief
Investigator making the final decision.
In Chapter 7, it was shown how a synthesis of placebo arm data from multiple studies can
be used to make predictions on how likely an individual with particular characteristics
(model-based covariates) would have an adverse event by chance in the placebo arm and
this was compared with their observed event rate in the experimental arm. If their model
based prediction was low but the patient did have the event, this would raise safety con-
cerns to the clinical team. Therefore, given that trialists felt they could be making more
use of external data, this method may generally be more acceptable for use in practice.
Although there have been calls for a global database and emerging guidance to help en-
able data sharing, it is likely this is still some time away. To bridge this gap, trials units
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could collate databases of their own trials. It is likely that most trials units specialise in
certain disease areas, such as cardiac trials, and so other trials ran by the same trials unit
may have similar populations to the control arm of their new trial. We suggest using in-
house databases of individual patient data and filtering by similar populations i.e. those
with similar baseline demographics to see what the rates of these expected events have
been and see if this matches with what the clinician might expect. An extension to this
would also be to use individual patient characteristics to predict how likely each person
was to experience an event based on the information in the database, as demonstrated in
Chapter 7.
Implication: To make more use of existing data to inform adverse event
rates, individual trials units could set up a platform or database for their
own trials which could be used to make inferences about adverse event rates
for new trials. These trials are likely to be more similar in terms of their
inclusion criteria to the new trial.
8.3 External evidence in a routine clinical trial setting: does it have a
place?
"To consult the statistician after an experiment is finished is often merely to
ask him to conduct a post mortem examination. He can perhaps say what the
experiment died of."
Ronald Fisher 1890-1962
From our INVEST survey and qualitative study we have seen that Bayesian methods are
rarely used in clinical trials. We also know evidence synthesis methods are more likely
to be conducted to inform aspects of the design, rather than in the analysis stage. For
example, in our INVEST survey and qualitative study, we found that a systematic review
or meta-analysis is often used by trialists in numerous ways to inform aspects of trial
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design. Trialists also felt they could be making more use of evidence synthesis methods
but because of time pressures and relevance of external data to their trial were not. In this
thesis we have shown three areas in which trialists could consider explicitly incorporating
external evidence.
The potential advantages of using informative prior distributions need to be counter bal-
anced by whether the clinical trials community will ever accept the formal incorporation
of, what is likely to be, someone else’s data. Even if the prior information is based on pre-
vious ’similar’ trials there are still different ways in which this information could be used
to form a prior distribution, depending on various assumptions regarding the relationship
between the previous trials and the new trial. The relevance of the prior data will need to
be carefully assessed by individuals who are closely related to the research question of
the new trial. There are two disadvantages to a Bayesian analysis of a trial. First, it is gen-
erally more complex than a classical analysis due to (usually) specialist software being
required. Second, informative priors are subjective: there are multiple ways in which the
same external information could be used to define an informative prior distribution for a
parameter. As seen in our qualitative study, this is a source of concern to trialists.
The methods described for FIH studies in Chapter 7 could in principle be applied to Phase
III trials, but we suggest that formal incorporation of external information on adverse
event rates would generally be considered less acceptable in these trials. However, ex-
ternal information could be used in two less formal ways. First, as seen in the literature
(Section 1.4), external data could be used to inform the trialist of the expected population
rate of particular outcomes in the control population. Second, where IPD are accessible, for
example, collated data within a trials unit, trialists may refine the population estimate by
deriving individual expected predictions of an event (using a model approach as shown




This thesis offers contributions to the Bayesian analysis of clinical trials and consequently
the use of informative priors. However, there are several aspects that remain unaddressed
and these are presented in Figure 8.1.
Given a key finding in our qualitative study was a general lack of confidence in and neg-
ative perception of Bayesian methods, this is something which will need to be addressed
in future work. This may include more case studies exploring the ways in which incorpo-
ration of external data might be advantageous, together with clear methodological guide-
lines. Additionally, training courses in Bayesian methods, focusing on potential uses in
trials, could promote use and increase confidence. The remaining barriers and additional
future work regarding statistical methodology are discussed below.
Our MetaBLIND study in Chapter 4, which separates the impact of not blinding patients,
healthcare providers and outcome assessors, gave surprising but inconclusive results. As
discussed in Section 4.6.2, a potential reason for this is the sample of trials analysed. Fur-
ther work could try and replicate this result in other samples [199, 200].
In Chapter 5, we briefly discussed the possible ways of forming a prior distribution on the
bias parameter based on the outputs from meta-epidemiological models (Section 5.2.4).
Future work should be conducted to explore the imapct of bias-adjustment based on these
priors to trials in practice. We also recognise that methodological guidelines are needed
to increase the uptake of bias adjustment in trials. This could include a tutorial paper in a
general medical journal on bias adjustment and the role of meta-epidemiological methods.
In Chapter 6, we compared methods to see what size a new trial needs to be when infer-
ence is based on the new clinical trial, the updated random effects mean or on the updated
cost-effectiveness model. Given we only looked at one case study, properties of these var-
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ious methods should be investigated through more case studies or a simulation study.
In Chapter 7, we first modelled external data about adverse event rates in the placebo
population of FIH studies. Second, due to the small sample sizes in FIH studies (making
it difficult for a clinician to determine if a new drug was harmful), we used the model
to predict how likely an individual in a new study would have an event. Future work
should consider how best to analyse a new FIH study, formally accounting for this ex-
ternal evidence. This could include matching an individual’s prediction to their observed
data.
Figure 8.1: Key future research needs.
 Our MetaBLIND study had potentially lower power than we anticipated, as we
had to disregard lots of meta-analyses which were non-informative. A future
meta-epidemiology study investigating the impact of separate types of blinding
should be conducted, in order to replicate our findings.
 Based on our findings in the INVEST survey and the qualitative study, further
guidance is required on bias adjustment. This could include a general medical
journal on bias adjustment and the role of meta-epidemiological methods in this.
 Given we only looked at one case study, properties of the various methods that
use information from a meta-analysis in sample size calculations should be in-
vestigated.
 Further work is required to explore how best to incorporate external evidence on
adverse event rates in trials, given the limited number of controls, including how
to match individual model based predictions with event data.
8.5 Final conclusions
In conclusion, there are many arguments both for and against the use of Bayesian methods
and more specifically informative priors, based on the current evidence base, in the design
and analysis of clinical trials. The constant push to make more use of existing data by
methodologists versus the practical issues and hesitation of doing so in a clinical trials
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setting has long been debated. Almost everyone agrees that existing evidence should be
used, in some way, to inform the design and analysis of a clinical trial. This can range
from using it to justify a gap in the evidence base (such as using a systematic review
to show there is an unanswered clinical question) or using it to inform parameters in
the sample size calculations such as the expected control group event rate. However, at
present trialists rarely explicitly, statistically combine this previous evidence with their
actual trial.
The work in this thesis has explored in depth the concerns about and barriers to the use of
Bayesian methods in practice, by interviewing the trialists who have the ability to imple-
ment such methods in practice in order to better understand their views. We found that
although trialists want to make more use of existing data, their biggest concern regarding
formally incorporating existing data in a Bayesian framework was their trust in and per-
ceived lack of relevance of external data; and how that could potentially impact their own
trial.
In this thesis we explored how existing data could be synthesised and translated into
prior information to inform aspects of the design or analysis of a new clinical trial. Trials
are subject to biases, despite best efforts. We have shown how information from meta-
epidemiological evidence can be used to quantify the likely amount of bias in the treat-
ment effect of a trial, allowing the analyst to assess the sensitivity of the findings. Incor-
porating information from an existing meta-analysis into sample size calculations could
lead to appropriately reduced sample sizes in some situations, but this depends on how
the trial evidence will be used in practice. In cases where the number of patients or events
in the control arm is small, individual patient adverse event rate data can be synthesised
to help the clinical team quantify the expected event rate in the control group.
Trials are a huge burden to society; costing a huge amount of private and public money,
as well as the time and resources by medical researchers and patients [183]. There must
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be a focus on making the incorporation of evidence implementable in a trial setting by
methodologists who advocate such methods. Unless the necessary guidance is provided
or there is a requirement by funders, it is likely the prevalence of use of informative priors
will remain low in practice. Despite the challenges regarding applying Bayesian methods
in trials, this thesis has shown that it is possible for trialists to make inferences based on all
available evidence, or to assess how their conclusions might change if they incorporated
relevant external evidence.
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A Documents and Tables
Table A.1: Differences between the topic guide for statisticians and clinicians.
Topic guide question for statisticians Topic guide question for clinicians
Can you describe the types of methods you
are using to analyse trials?
What is your role in terms of your input
into the analysis of the trial results?
What are your thoughts on the use of
Bayesian methods to analyse a clinical
trial?
What is it you understand by the use
of Bayesian methods to analyse a clinical
trial?
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Figure A.1: The INVEST survey.
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The INVEST project 
INVESTIGATING THE USE OF EVIDENCE  





This survey aims to investigate the current use of evidence synthesis by clinical trialists, and reasons why it might 
not be used in practice. 
 




Conducting a literature review (systematic or otherwise) and summarising the findings. 
Systematic 
review 
A review to collate all evidence that fits pre-specified eligibility criteria in order to address a 
specific research question. 
Meta-analysis  Statistically combining results from two or more studies addressing the same research question. 
Network meta-
analysis 
An extension of meta-analysis to allow the simultaneous comparison of the effectiveness of 
multiple interventions through the use of direct and indirect evidence. 
Decision model 
A model to allow the synthesis of all available sources of evidence into a single coherent and 




An analytical modelling framework (usually based on a decision model) used to assess whether 
there is value in conducting a new trial, and to identify the optimal design for such a trial. 
 
1. What is your job/role? Tick all that apply. 
□ Clinician □ Clinical co-ordinator □ Data management □ Information specialist 
□ Qualitative researcher □ Trial management □ Epidemiologist □ Research nurse 
□ Health economist □ Statistician □ Programmer □ Student* 
□ Other, please specify:  
*If you are a student please tick your specialty as well. 
 
2. Have you been involved in design, setting up or running trials in your job/role? Tick all that apply. 
□ Not at all  □ In a clinical trials unit □ In industry □ In a different setting, please specify:  
 
3. How long have you spent working in the area of clinical trials? 
□ Not at all □ 0 - 2 years □ 3 – 5 years □ 6 - 10 years □ 11 – 20 years □ Over 20 years 
 
4. Which of the following aspects of clinical trials have you been involved in? Tick all that apply. 
□ Trial design □ Trial conduct □ Statistical analysis 
□ Undertaking a systematic review of trials □ None of these 
 
Answer questions 5 and 6 only if you have been involved in clinical trial design, otherwise go to question 7. 
 
5. Thinking about clinical trials in which you have been involved over the last 10 years, which of the 
following types of evidence synthesis (along the top) have informed particular aspects of trial design 















None of  
these 
Whether a trial is 
needed □ □ □ □ □ □ □ 
Choice of population □ □ □ □ □ □ □ 
Choice of 
interventions □ □ □ □ □ □ □ 
Choice of outcomes 
and follow-up time □ □ □ □ □ □ □ 
Sample size  □ □ □ □ □ □ □ 
Please complete this survey at  
bit.ly/investsurvey 
(a) Page 1 of 2
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6. If you indicated any use of evidence synthesis in question 5, then how were these undertaken?  
















evidence syntheses □ □ □ □ □ □ 
Conducted by the 
clinical trial team □ □ □ □ □ □ 
 
7. Which of the following types of evidence synthesis do you think should be used to inform particular 















None of  
these 
Whether a trial is 
needed □ □ □ □ □ □ □ 
Choice of population □ □ □ □ □ □ □ 
Choice of 
interventions □ □ □ □ □ □ □ 
Choice of outcomes 
and follow-up time □ □ □ □ □ □ □ 
Sample size  □ □ □ □ □ □ □ 
 
8. Answer only if you have been involved in clinical trials. Please rank the TOP 3 of the following potential 
reasons why evidence syntheses have not been used to inform clinical trials in which you have been 
involved, 1 being the biggest reason, 3 being the third biggest reason. 
Time constraints  
Expertise not available  
Financial constraints  
Inefficient – a lot of time and resources for little return  
Believed to be the first trial in the area  
Previous trials were different from the new trial  
Funders did not require it  
Objections to using evidence syntheses (from you or colleagues)  
Other (please specify) ……………………………………………………..  
 
9. Evidence synthesis might also be used to inform aspects of trial analysis. Please indicate if a) evidence 
synthesis was used in clinical trials analysis in which you have been involved over the last 10 years, to 
inform the following aspects and b) you think it should be used. 
 
a) This was used b) This should be used I don’t 
understand Yes No N/A* Yes No Don’t know 
External information about the treatment effect 
(including a meta-analysis) □ □ □ □ □ □ □ 
External information related to potential biases 
arising from trial conduct (e.g. blinding infeasible) □ □ □ □ □ □ □ 
External information about other quantities involved 
in the analysis (e.g. correlations or baseline event 
rates) 
□ □ □ □ □ □ □ 
* N/A=not applicable (as I have not been a part of trial analysis) 





Thank you for taking the time to complete this questionnaire. 
Please hand this in to a member of the INVEST team during the conference, complete it online at bit.ly/investsurvey, 
or post  to Gemma Clayton, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS. Initial results will be emailed shortly 








(b) Page 2 of 2
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Figure A.2: Consent form.
Consent form date of issue: 04/04/2017  
Consent form version number: [VERSION NUMBER] 
  Page 1 of 1 
 
Participant Identification Number XXX 
CONSENT FORM 
 
Study title: Conceptual issues of analysing clinical trials in the context of the wider evidence 
base: qualitative study 
 
Name of Researcher: Gemma Clayton 
Please initial all boxes  
1. I confirm that I have read and understand the participant information sheet dated 
[DATE] (version number [VERSION NUMBER]) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that the interview will be audio recorded and transcribed by the interviewer. 
I understand that some verbatim quotation from the interview may be used in reports or 
publications, but that this will be anonymised. 
 
4. I agree for interview data to be retained and used by the University of Bristol’s 
Population Health Sciences for research and teaching purposes now and in the future, 
where they can use my anonymised quotes in reports and publications (optional). 
 




            
Name of Participant  Date    Signature 
                                
            
Name of Person  Date    Signature  
taking consent.  
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Figure A.3: Participant information sheet.
Date:     [DATE] 
Version number: [VERSION NUMBER] 
   
 
Page 1 of 2 
 
 
PARTICIPANT INFORMATION SHEET 
 
Study title: Conceptual issues of analysing clinical trials in the context of the wider evidence 
base: qualitative study 
 
I am a PhD student looking at whether (and if so, how) existing evidence should be used to inform the 
analysis of a clinical trial. I am based at the department of Population Health Sciences at the 
University of Bristol. My PhD supervisors are Professor Julian Higgins and Dr Hayley Jones. We 
would like to invite you to take part in our research study. Before you decide we would like you to 
understand why the research is being done and what it would involve for you. Talk to others about the 
study if you wish.  Ask us if there is anything that is not clear.  
 
What is the purpose of the study?  
The purpose of the study is to explore trialists' views about and experiences of analysing clinical trials 
in the context of the wider evidence base. 
 
Why have I been invited?  
We are asking up to 25 trialists who have some level of responsibility for or control over which methods 
are used to analyse a clinical trial to take part in an interview. This could be trialists who are either (i) 
conducting analysis of trials in practice (ii) planning such analysis and/or (iii) responsible for people 
doing these things. For example, the trial statistician; a methods lead who may advise the trial 
statistician or a researcher applying for a grant who has to briefly state which methods will be applied 
in the application. 
 
Do I have to take part?  
It is up to you to decide to join the study. We will describe the study and go through this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw 
at any time, without giving a reason. 
 
What will happen to me if I take part and what will I have to do?  
You will be asked to consent to participate in an audio-recorded in-depth interview about your views 
and experiences of methods used to analyse a clinical trial. The interviewer will ask questions about 
the types of trials you’ve worked on and the methods used to analyse them. With particular emphasis 
on the use of existing data to inform parameters and putting them in the context of the wider evidence 
base. The interview will be arranged at a time and place convenient to you and will last around 60 
minutes. All interviews will be audio-recorded and transcribed by the interviewer, Gemma Clayton.  
 
What are the possible disadvantages and risks of taking part? 
We see no particular disadvantages or risks, other than the amount of time we ask of you. Please be 
assured that we are not ‘testing’ your knowledge or wanting to be critical of how you have analysed 
trials in the past. There are often many methods which are suitable. If you do experience any difficulties 
with taking part, please feel free to discuss this with one of us so that we can try to resolve the matter. 
Furthermore, as the time taken for the interviews could be considered a burden, you are able to finish 
the interview at any time. 
  
What are the possible benefits of taking part?  
We cannot promise the study will help you but the information we get from this study will help us to 
understand how current methodology is chosen so that we can make possible recommendations 
regarding the analysis of clinical trials in the context of the wider evidence base. 
 
What will happen if I don’t want to carry on with the study?  
(a) Page 1 of 2
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Figure A.3: Participant information sheet (cont.)
Date:     [DATE] 
Version number: [VERSION NUMBER] 
   
 
Page 2 of 2 
 
You can withdraw from the study at any time without giving a reason. The data that you provided would 
continue to be used unless you specify otherwise. 
 
Will my taking part in this study be kept confidential?  
All information collected about you during the course of this research will be kept strictly confidential. 
Recorded data will be stored secured at the University of Bristol. Only the research team will have 
access to the recordings. If we do use any of your recordings, all the quotes will be anonymised so that 
you cannot be recognised from any of the information we present. You will not be identified in any way 
whatsoever, in any report or publication. If you would like to be kept informed of any publications from 
this work please let the researcher know. 
 
Who is organising and funding the research?  
The research is funded as part of Gemma Clayton’s 3 year Medical Research Council PhD studentship. 
 
Who has reviewed the study? 
This study has been extensively reviewed by the study team and Faculty of Health Sciences Research 
Ethics Committee. 
 
Further information and contact details  
If you want to discuss any part of the study including any questions about your participation, please 
contact one of the following: 
 
PhD student/researcher: 
Gemma Clayton (University of Bristol): 
Population Health Sciences 




Professor Julian Higgins (University of Bristol): 
Population Health Sciences 
Bristol Medical School 
Email: julian.higgins@bristol.ac.uk 
Dr Hayley Jones (University of Bristol): 
Population Health Sciences 
Bristol Medical School 
Email: hayley.jones@bristol.ac.uk 
 
If you would like to speak to someone independent from the study team, or wish to make a complaint, 
please e-mail research-governance@bristol.ac.uk. 
 
 Many thanks for reading this information sheet 
 
(b) Page 2 of 2
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Figure A.4: Example of topic guide
  
Topic guide: Conceptual issues of analysing clinical trials in the context of the wider evidence base 
 
Date: XX 




• PIS (broadly), Aim (purpose), voluntary, stop at any time, can’t answer any questions just move on, 
completely confidential. 
• Any questions - Consent form - Start recording! 
• Demographics - Participant Identification Number 
Job role Group Years in profession Types of trials Type of unit Affiliation 
           
 
 Question Probes 
1 
Can you tell me about your 
background and your role? 
How long have you worked there?  
Have you worked anywhere else? 
2 
What role do you think 
previous evidence has in a 
trial? 
Before a trial has started – concepts 
Design 
What is your role in that? 
3 
Can you describe the types of 
methods you are using to 
analyse trials? 
How do you choose which methods to use? 
How would this vary by the type of trial? 
Are they using relatively simple analyses (such as simple linear 
regression models, t-tests) or more complex analyses (such as 
instrumental variables)? 
4 
What is it you think of when I 
say what role does previous 
evidence having during the 
analysis stage of trials? 
Examples of where previous evidence has been used in the analysis 
stage of a trial? 
Do these examples vary by type of trial, type of outcome 
 
Where do you think this previous evidence should come from? 
Do you think previous evidence should be systematically collected 
e.g MA? 
5 
What are your thoughts on the 
use of Bayesian methods to 
analyse a clinical trial? 
 
Do you have any experience of using Bayesian methods to analyse a 
clinical trial? 
Do you know of any colleagues who may have used Bayesian 
methods in the analysis stage? 
 
Can you tell me what you understand about prior distributions? 
Can you tell me what you understand by the term informative prior 
distributions? 
What is it you understand by non-informative or sceptical priors? 
Can you tell me what you think about a subjective prior? 
 
Can you see any advantages or disadvantages to using Bayesian 
methods to analysis a clinical trial? 
6 
What do you think about the 
use of informative prior 
distributions to inform 
Do you have ANY experience of using informative priors? 
Do you know of any colleagues who may have used informative 
priors? 
(a) Page 1 of 2
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Figure A.4: Example of topic guide (cont.)
  
Topic guide: Conceptual issues of analysing clinical trials in the context of the wider evidence base 
 
Date: XX 
Version number: v1.X 
 
parameters (such as the 
treatment effect) in the analysis 
stage? 
See information sheet for further 




Do you see any advantages of using informative priors in the analysis 
stage? 
Do you see any disadvantages of using informative priors in the 
analysis stage? 
What do you think about resource waste? 
Power a new trial based on the impact it can have on a meta-
analysis? 
What do you think about using an objective prior (based on a 
synthesis of previous evidence)? 
7 Bias adjustment 
At the end of a trial are you always confident you can believe the 
results or do you think they may be at a risk of bias or many biases? 
E.g. if you couldn’t blind the patients.  
So if we know that not blinding patients caused a 15% exaggeration 
in treatment effects in trials similar to yours would you adjust for it? 
How many trials do you do with adequate allocation  
concealment etc – do you think in examples where it may not be 
possible to do some of these things that the trial was less likely to get 
funded? 
8 
Are there any parameters 
during the analysis which are 
poorly estimated or need more 
power? 
What types of parameters are usually poorly estimated? 
Do you know why they are poorly estimated? 
What do you do when parameters are poorly estimated? 
How do you report parameters which are poorly estimated? 
Did you find a solution to improve estimation? 
Do you think previous evidence could have helped? 
Would you use previous evidence if it helped estimation? 
Would you use informative priors on adverse events, when event 
rates are usually low? 
 
9 
Would you use informative 
priors on parameters in the 
analysis of a trial? 
Do you know of any situations where using informative priors could 
be useful? 
Do you know of any situations where using informative priors may not 
be applicable? 
How are new methods implemented? 
Would permission have to be sought to use a new method? 
In these situations (treatment effect, other parameters, bias 




• Checks understanding of any outstanding points 
• Thank them for their time 
• Answer further questions, Ask who else we can speak to – contacts?  
(b) Page 2 of 2
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1.0 1.1 After the first two interviews, we added the question “What role
do you think previous evidence has in a trial?”
1.1 1.2 Added the question: “What do you think about explicitly using
prior information to inform a sample size calculation?” following
recent work regarding the use of previous evidence in sample
size calculations during the design of a new trial.
Secondly, a potential use of existing evidence that came up was
on missing data, so this was added as a prompt.
1.2 1.3 Access to the data and where you should get this from is an
emerging theme which has come from discussing how these
methods would be implemented in practice. As such the fol-
lowing question has been added: “How would you access data
needed [prompt: would such data need to be collated by you or
another colleague?]”
Similarly, some participants have suggested it may be harder to
publish Bayesian work and therefore the following question has
been added: “How do you think publishing a Bayesian analysis
with previous evidence will be received? [prompt: do you think
it is more or less likely to get published]”
Some participants mentioned that for this to be used more in
practice it would have to become a requirement by funders
and added to guidelines such as CONSORT. The following was
added “What would make these methods be used in practice?”
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Table A.3: COREQ checklist.
No Item Guide questions/ description Comment
Domain 1: Research team and reflexivity
Personal characteristics
1 Interviewer/facilitator








What was their occupation at the time of
the study?
PhD Student in Trials Methodology




What experience or training did the re-
searcher have?
GC has 2 years’ experience working as a
trial statistician at a clinical trials unit. GC
has also been qualitative workshops and
short courses. GC is also worked with an
experienced qualitative researcher DE.
Relationship with participants
Continued on next page
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Table A.3 – continued from previous page




Was a relationship established prior to
study commencement?
Yes. Since GC has worked in clinical tri-
als for 2 years prior to starting the PhD
she was able to invite several people to




What did the participants know about the
researcher? e.g. personal goals, reasons
for doing the research
GC introduced herself, explained the pur-
pose of the research and provided an in-
formation leaflet about the study. GC did
not go into detail about her PhD until af-
ter the interview so that her views were




What characteristics were reported about
the interviewer/facilitator? e.g. Bias, as-
sumptions, reasons and interests in the
research topic
GC stated that all the answers given
could be positive or negative regarding
the use of previous evidence in trials.
Domain 2: Study design
Theoretical framework
Continued on next page
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Table A.3 – continued from previous page




What methodological orientation was
stated to underpin the study? e.g.
grounded theory, discourse analysis,
ethnography, phenomenology, content
analysis
Data were analysed thematically using
techniques of constant comparison de-




How were participants selected? e.g. pur-
posive, convenience, consecutive, snow-
ball
Purposeful and snowball.
11 Method of approach
How were participants approached? e.g.
face-to-face, telephone, mail, email
GC contacted researchers by email
12 Sample size
How many participants were in the
study?
13 statisticians and 3 clinical academics
13 Non-participation
How many people refused to participate
or dropped out? Reasons?
Of the people asked to participate, one
person who was asked and said they
would take part, then could not find time.
Setting
Continued on next page
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Table A.3 – continued from previous page
No Item Guide questions/description Comment
14
Setting of data collec-
tion
Where was the data collected? e.g. home,
clinic, workplace





Was anyone else present besides the par-
ticipants and researchers?
No
16 Description of sample
What are the important characteristics of
the sample? e.g. demographic data, date
Participants’ full details are provided in
Table 1, and key information is provided
in the methods section
Data collection
Continued on next page
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Table A.3 – continued from previous page
No Item Guide questions/description Comment
17 Interview guide
Were questions, prompts, guides pro-
vided by the authors? Was it pilot tested?
Topic guides were developed (based on
the study aims and relevant literature
along with DE) to ensure that discussions
covered the same basic issues but with
sufficient flexibility to allow new issues of
importance to the informants to emerge.
A pilot interview was conducted, how-
ever as all questions were deemed rele-
vant, this was used as participant data.
As analysis progressed, the topic guide
adapted to enable exploration of emerg-
ing themes and a log of amendments
was recorded. A separate topic guide was
used for clinicians which included simi-
lar question but rephrased.
18 Repeat interviews
Were repeat interviews carried out? If
yes, how many?
No repeat interviews were carried out
Continued on next page
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Table A.3 – continued from previous page




Did the research use audio or visual
recording to collect the data?
Interviews were audio-recorded.
20 Field notes
Were field notes made during and/or af-
ter the interview?
GC kept a few notes about each inter-
view detailing the overall tone and the
key points.
21 Duration What was the duration of the interviews?
Interviews lasted an average of 54 min-
utes (range = 37 - 79 minutes).
22 Data saturation Was data saturation discussed?
Data collection continued until GC and
DE were confident that saturation had
been reached.
23 Transcripts returned
Were transcripts returned to participants
for comment and/or correction?
Transcripts were not returned to partici-
pants for comments or corrections
Domain 3: Analysis and findings
Data analysis
Continued on next page
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Table A.3 – continued from previous page
No Item Guide questions/description Comment
24 Number of data coders How many data coders coded the data?
GC initially coded the data, and emerg-
ing themes were discussed with DE, with
reference to the raw data and coding
frame. Double coding between GC and
HJ was used for three transcriptions in to-
tal, with reference to the raw data. In that
time, we were happy that concerns in in-
terpretation of coding frame was reached.
25
Description of the cod-
ing tree
Did authors provide a description of the
coding tree?
A description of the coding tree is not
provided in the article
26 Derivation of themes
Were themes identified in advance or de-
rived from the data?
Themes were derived from the data
27 Software
What software, if applicable, was used to
manage the data?
NVivo (version 11) was used to analyse
the data
28 Participant checking
Did participants provide feedback on the
findings?
Results were not sent out for response
validation
Reporting
Continued on next page
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Table A.3 – continued from previous page
No Item Guide questions/description Comment
29 Quotations presented
Were participant quotations presented to
illustrate the themes / findings? Was
each quotation identified? e.g. participant
number
The interpretation of each theme is sup-
ported by illustrative quotes. Each quote
is identified by a participant code
30
Data and findings con-
sistent
Was there consistency between the data
presented and the findings?
There is consistency between the data
presented and the findings (see Table3.2)
31 Clarity of major themes
Were major themes clearly presented in
the findings?
The themes are clearly presented in the
findings
32 Clarity of minor themes
Is there a description of diverse cases or
discussion of minor themes?
Description of diverse cases and where
minor themes occurred between partici-
pant groups are discussed
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Table A.4: Characteristics of included trials.
(All) N=1153 (Ia) N=132 (Ib) N=95 (IIa) N=173 (IIb) N=91 (III) N=397
n % n % n % n % n % n %
Blinding status
Patients blind
Definitely no 66 5.7 16 12.1 5 5.3 6 3.5 3 3.3 24 6
Definitely yes 170 14.7 15 11.4 24 25.3 40 23.1 29 31.9 38 9.6
Probably no 589 51.1 73 55.3 32 33.7 73 42.2 18 19.8 250 63
Probably yes 274 23.8 18 13.6 33 34.7 46 26.6 41 45.1 69 17.4
Unclear 54 4.7 10 7.6 1 1.1 8 4.6 0 0 16 4
Healthcare providers blinded
Definitely no 94 8.2 20 15.2 8 8.4 8 4.6 8 8.8 32 8.1
Definitely yes 100 8.7 6 4.5 11 11.6 40 23.1 14 15.4 22 5.5
Probably no 591 51.3 78 59.1 37 38.9 64 37 21 23.1 248 62.5
Probably yes 312 27.1 21 15.9 37 38.9 53 30.6 47 51.6 79 19.9
Unclear 56 4.9 7 5.3 2 2.1 8 4.6 1 1.1 16 4
Outcome assessors blinded
Definitely no 21 1.8 0 0 0 0 0 0 0 0 18 4.5
Continued on next page
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Table A.4 – continued from previous page
n % n % n % n % n % n %
Definitely yes 202 17.5 0 0 76 80 0 0 54 59.3 128 32.2
Probably no 290 25.2 0 0 0 0 0 0 0 0 160 40.3
Probably yes 181 15.7 0 0 19 20 0 0 19 20.9 71 17.9
Unclear 38 3.3 0 0 0 0 0 0 0 0 20 5
N/A 421 36.5 132 100 0 0 173 100 18 19.8 0 0
Double-blind explicitly mentioned
Yes 402 34.9 28 21.2 49 51.6 81 46.8 64 70.3 100 25.2
No 750 65 103 78 46 48.4 92 53.2 27 29.7 297 74.8
Unclear 1 0.1 1 0.8 0 0 0 0 0 0 0 0
All groups described as blinded/ double-blinded/ triple-blinded
Yes 412 35.7 29 22 49 51.6 87 50.3 65 71.4 102 25.7
No 740 64.2 102 77.3 46 48.4 86 49.7 26 28.6 295 74.3
Unclear 1 0.1 1 0.8 0 0 0 0 0 0 0 0
Risk of bias
Concealment of allocation
High risk 127 11.1 15 11.5 19 20 9 5.2 11 12.1 67 16.9
Continued on next page
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Table A.4 – continued from previous page
n % n % n % n % n % n %
Low risk 510 44.4 69 52.7 46 48.4 110 64 57 62.6 151 38.1
Unclear 512 44.6 47 35.9 30 31.6 53 30.8 23 25.3 178 44.9
Incomplete outcome data
High risk 177 15.8 6 4.5 9 11.1 12 6.9 8 9.1 69 18.3
Low risk 771 68.7 103 78 59 72.8 143 82.7 69 78.4 228 60.3
Unclear 175 15.6 23 17.4 13 16 18 10.4 11 12.5 81 21.4
Drug trial* 753 65.3 48 36.4 77 81.1 127 73.4 81 89 205 51.6
Funding
Profit organisations 251 21.8 16 12.1 29 30.5 40 23.1 36 39.6 61 15.4
Non- profit
organisations
364 31.6 63 47.7 36 37.9 48 27.7 23 25.3 144 36.3
Both 108 9.4 10 7.6 5 5.3 13 7.5 10 11 36 9.1




20 1.7 2 1.5 0 0 0 0 0 0 12 3
Continued on next page
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Table A.4 – continued from previous page
n % n % n % n % n % n %
Cross-over 7 0.6 0 0 0 0 0 0 0 0 4 1
Cross-over trial used as
parallel group trial in
meta-analysis
9 0.8 3 2.3 3 3.2 0 0 0 0 7 1.8
Parallel 1112 96.4 125 94.7 92 96.8 173 100 91 100 374 94.2
Split body 0 0 0 0 0 0 0 0 0 0 0 0
Unclear 5 0.4 2 1.5 0 0 0 0 0 0 0 0335
Figure A.5: RORs from individual meta-analyses and from analyses combined across all
meta-analyses. Results for individual meta-analyses are frequentist estimates with confi-
dence intervals, based on comparing the summary odds ratio from studies with the study
characteristic of interest with the summary odds ratio from studies without the character-
istic. The overall estimates of RORs are results based on the Bayesian hierarchical model
described in Section 4.3.1. CD numbers are identifiers of individual Cochrane reviews,
from the Cochrane Database of Systematic Reviews.














































































































(a) (Ia) The effect of blinding patients in trials with patient-reported outcomes
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Figure A.5: (cont.)


























































































(b) (Ib) The effect of blinding patients in trials with blinded observer-reported outcomes
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Figure A.5: (cont.)












































































































































































































































































































































































































































































































































































(e) (III) The effect of blinding outcome assessors (i.e. observers) in trials with subjective outcomes
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Blinded Blinded 399 (34.6) 26 (19.7) 48 (50.5) 84 (48.6) 61 (67.0) 99 (24.9)
Blinded Non-blinded 45 (3.9) 7 (5.3) 9 (9.5) 2 (1.2) 9 (9.9) 8 (2.0)
Non-blinded Blinded 13 (1.1) 1 (0.8) 0 (0) 9 (5.2) 0 (0) 2 (0.5)
















Blinded Blinded 264 (35.9) 0 (0) 57 (60.0) 0 (0) 52 (71.2) 103 (25.9)
Blinded Non-blinded 10 (1.4) 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.0)
Non-blinded Blinded 120 (16.3) 0 (0) 38 (40.0) 0 (0) 21 (28.8) 96 (24.2)











Continued on next page
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Blinded Yes 261 (22.7) 23 (17.4) 38 (40.0) 68 (39.3) 52 (57.1) 56 (14.1)
Blinded No 183 (15.9) 10 (7.6) 19 (20.0) 18 (10.4) 18 (19.8) 51 (12.8)
Non-blinded Yes 249 (21.7) 46 (34.8) 8 (8.4) 42 (24.3) 5 (5.5) 95 (23.9)

















Blinded Complete 338 (30.1) 28 (21.2) 44 (46.3) 74 (42.8) 56 (61.5) 78 (19.6)
Blinded Incomplete 100 (8.9) 5 (3.8) 13 (13.7) 12 (6.9) 14 (15.4) 29 (7.3)
Non-blinded Complete 433 (38.6) 75 (56.8) 15 (15.8) 69 (39.9) 13 (14.3) 150 (37.8)
Non-blinded Incomplete 252 (22.4) 24 (18.2) 23 (24.2) 18 (10.4) 8 (8.8) 140 (35.3)
Continued on next page
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Blinded Blinded 248 (33.7) 0 (0) 48 (50.5) 0 (0) 48 (65.8) 100 (25.2)
Blinded Non-blinded 1 (0.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.3)
Non-blinded Blinded 136 (18.5) 0 (0) 47 (49.5) 0 (0) 25 (34.2) 99 (24.9)















Blinded Yes 243 (21.1) 16 (12.1) 33 (34.7) 74 (42.8) 45 (49.5) 54 (13.6)
Blinded No 168 (14.6) 11 (8.3) 15 (15.8) 19 (11.0) 16 (17.6) 47 (11.8)
Non-blinded Yes 267 (23.2) 53 (40.2) 13 (13.7) 36 (20.8) 12 (13.2) 97 (24.4)
Continued on next page
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Blinded Complete 319 (28.4) 23 (17.4) 40 (42.1) 81 (46.8) 49 (53.8) 77 (19.4)
Blinded Incomplete 88 (7.8) 4 (3.0) 8 (8.4) 12 (6.9) 12 (13.2) 24 (6.0)
Non-blinded Complete 452 (40.2) 80 (60.6) 19 (20.0) 62 (35.8) 20 (22.0) 151 (38.0)

















Blinded Yes 200 (27.2) 0 (0) 46 (48.4) 0 (0) 41 (56.2) 99 (24.9)
Blinded No 184 (25.1) 0 (0) 49 (51.6) 0 (0) 32 (43.8) 100 (25.2)
Continued on next page
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Non-blinded Yes 94 (12.8) 0 (0) 0 (0) 0 (0) 0 (0) 52 (13.1)













Blinded Complete 267 (37.7) 0 (0) 59 (62.1) 0 (0) 55 (75.3) 126 (31.7)
Blinded Incomplete 103 (14.5) 0 (0) 36 (37.9) 0 (0) 18 (24.7) 73 (18.4)
Non-blinded Complete 190 (26.8) 0 (0) 0 (0) 0 (0) 0 (0) 102 (25.7)













WinBUGS code: Combining binary and continuous outcomes
model {
for (i in 1:Nb) {
rc[i] ~ dbin(pc[i],nc[i]) # likelihood for binary outcomes
rt[i] ~ dbin(pt[i],nt[i])
logit(pc[i]) <- mu[i] # model for binary outcomes (logit link)
logit(pt[i]) <- mu[i] + delta[i] + beta[i]*C[i]
mu[i] ~ dnorm(0,.0001)
}
for (i in Nb+1:Nc+Nb) {
var[i] <- pow(se[i],2) # calculate variances
prec.smd[i] <- 1/var[i] # set precisions
# likelihood for continuous outcomes on log odds ratio scale
lnor[i] ~ dnorm(nu[i],prec.smd[i])
# model for continuous outcomes (identity link)
nu[i] <- delta[i] + beta[i]*C[i]
}
for (i in 1:Nc+Nb) {
# between study, within MA, variation in bias
beta[i]~dnorm(b[ma[i]],p.k2[ma[i]])I(-10,10)




for (m in 1:N_ma) {
# priors for true fixed (unrelated) treatment effects
d[m] ~ dnorm(0,.0001)












for (m in 1:N_kappa_ok){
p.k2[kappa_ok[m]]<-p.k
}








#predictive distn for mean bias in new meta-analysis
b.new~dnorm(b0,p.phi)






WinBUGS code: Stratifying the average magnitude of bias at the meta-
analysis level
model {




logit(pt[i]) <- mu[i] + delta[i] + beta[i]*C[i]
mu[i] ~ dnorm(0,.0001)
}
for (i in Nb+1:Nc+Nb) {
var[i] <- pow(se[i],2) # calculate variances
348
prec.smd[i] <- 1/var[i] # set precisions
lnor[i] ~ dnorm(nu[i],prec.smd[i]) # likelihood
nu[i] <- delta[i] + beta[i]*C[i] # model
}





















for (m in 1:N_kappa_ok){
p.k2[kappa_ok[m]]<-p.k
}







#predictive distn for mean bias in new meta-analysis
b.new~dnorm(b0,p.phi)






WinBUGS code: Product normal model
model {
































for (m in 1:N_kappa_ih_ok){
p.k22[kappa_ih_ok[m]]<-p.kre
}










for (m in 1:N_kappa_iu_ok){
p.k21[kappa_iu_ok[m]]<-p.k1
}































WinBUGS code: Probability model
model {











for (m in 1:N_ma) {
# priors for true fixed (unrelated) treatment effects
d[m] ~ dnorm(0,.0001)





sd.tau[m] <- pow(p.tau[m], -0.5)
354
}







for (m in 1:N_kappa_ih_ok){
p.k2[kappa_ih_ok[m]]<-p.k1
}











CDnumber[] ma[] s[] ih[] iu[] rt[] rt[] nt[] rc[] nc[]
8603 1 1 0 1 11 11 102 13 104
8603 1 2 0 1 7 7 163 5 84
8603 1 3 0 1 9 9 156 6 156
8603 1 4 0 0 30 30 538 27 539
355
8603 1 5 0 1 5 5 124 2 16
8603 1 6 0 1 3 3 119 2 79
8603 1 7 0 1 9 9 190 2 82
8603 1 8 0 1 0 0 40 1 41
8603 1 9 0 1 2 2 25 2 25
8603 1 10 0 1 2 2 178 1 171
8603 1 11 0 1 18 18 155 12 148
8603 1 12 0 0 2 2 43 1 42
7228 2 13 1 0 3 3 62 4 65
WinBUGS code: Probability model with sample size
model {






logit(p[i]) <- m*(x[i] - mean(x[]))+ c
logit(pc[i]) <- mu[i]














for (m in 1:N_ma) {
d[m] ~ dnorm(0,.0001)
# priors for true fixed (unrelated) treatment effects
b[m] ~ dnorm(b0,p.phi)




sd.tau[m] <- pow(p.tau[m], -0.5)
}
b0 ~ dnorm(0,.0001)





















CDnumber[] ma[] s[] ih[] iu[] rt[] rt[] nt[] rc[] nc[] highrisk[]
8603 1 1 0 1 11 11 102 13 104 NA
8603 1 2 0 1 7 7 163 5 84 NA
8603 1 3 0 1 9 9 156 6 156 NA
8603 1 4 0 0 30 30 538 27 539 0
8603 1 5 0 1 5 5 124 2 16 NA
8603 1 6 0 1 3 3 119 2 79 NA
8603 1 7 0 1 9 9 190 2 82 NA
8603 1 8 0 1 0 0 40 1 41 NA
8603 1 9 0 1 2 2 25 2 25 NA
8603 1 10 0 1 2 2 178 1 171 NA
8603 1 11 0 1 18 18 155 12 148 NA
8603 1 12 0 0 2 2 43 1 42 0
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WinBUGS code: Meta-epidemiological model wth continuous study char-
acteristic
model {








new.var[i]<-pow(tau[ma[i]], 2) + kappa.sq*(c[i])
new.p[i]<-1/new.var[i]
mu[i] ~ dnorm(0,.0001)
rhat.c[i] <-pc[i]*nc[i] #calculate residual deviance
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rhat.t[i]<-pt[i]*nt[i]
dev.t[i] <- 2 * (rt[i] * (log(rt[i])-log(rhat.t[i])) +
(nt[i]-rt[i]) * (log(nt[i]-rt[i]) - log(nt[i]-rhat.t[i])))
dev.c[i] <- 2 * (rc[i] * (log(rc[i])-log(rhat.c[i])) +
(nc[i]-rc[i]) * (log(nc[i]-rc[i]) - log(nc[i]-rhat.c[i])))
}
resdev <-sum(dev.t[])+sum(dev.c[])
for (m in 1:N_ma) {
d[m] ~ dnorm(0,.0001)
b[m] ~ dnorm(b0,p.phi)
log.tau[m] ~ dnorm(mean.lt, prec.lt)I(-5,5)
log(tau[m]) <- log.tau[m]
p.d[m] <- pow(tau[m], -2)
}
b0 ~ dnorm(0,.0001)
mean.lt ~ dnorm(0, 0.0001)
sd.lt ~ dunif(0, 2)
prec.lt <- pow(sd.lt, -2)
sd.k ~ dunif(0, 5)
p.k<- pow(sd.k, -2)
kappa.sq<-sd.k*sd.k
p.phi1~dgamma(.001,.001)
phi <- pow(p.phi,-0.5)
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p.phi<-p.phi1/(1-patom.phi)
patom.phi~dbeta(1,1)
dum1<-s[1]
log.tau2~dnorm(mean.lt, prec.lt)
B0<-exp(b0)
}
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